Macrocyclic picolinamides as fungicides

ABSTRACT

This disclosure relates to macrocyclic picolinamides of Formula (I) and their use as fungicides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Phase Patent Application based on International Application No. PCT/US2015/028407 filed Apr. 30, 2015, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/989,149 filed May 6, 2014, which is expressly incorporated by reference herein.

BACKGROUND & SUMMARY

Fungicides are compounds, of natural or synthetic origin, which act to protect and/or cure plants against damage caused by agriculturally relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less.

The present disclosure relates to macrocyclic picolinamides and their use as fungicides. The compounds of the present disclosure may offer protection against ascomycetes, basidiomycetes, deuteromycetes and oomycetes.

One embodiment of the present disclosure may include compounds of Formula I:

-   -   wherein     -   X is hydrogen or C(O)R₃;     -   Y is hydrogen, C(O)R₃, or Q;     -   Q is

R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, and aryl, each optionally substituted with 0, 1 or multiple R₆;

R₃ is alkoxy or benzyloxy, each optionally substituted with 0, 1, or multiple R₆;

R₄ is hydrogen, —C(O)R₅, or —CH₂OC(O)R₅;

R₅ is alkyl, alkoxy, or aryl, each optionally substituted with 0, 1, or multiple R₆;

R₆ is hydrogen, alkyl, aryl, halo, acyloxy, alkenyl, alkoxy, heteroaryl, heterocyclyl, or thioalkyl, each optionally substituted with 0, 1, or multiple R₇; and

R₇ is hydrogen, alkyl, aryl, or halo.

Another embodiment of the present disclosure may include a fungicidal composition for the control or prevention of fungal attack comprising the compounds described above and a phytologically acceptable carrier material.

Yet another embodiment of the present disclosure may include a method for the control or prevention of fungal attack on a plant, the method including the steps of applying a fungicidally effective amount of one or more of the compounds described above to at least one of the fungus, the plant, and an area adjacent to the plant.

It will be understood by those skilled in the art that the following terms may include generic “R”-groups within their definitions, e.g., “the term alkoxy refers to an —OR substituent”. It is also understood that within the definitions for the following terms, these “R” groups are included for illustration purposes and should not be construed as limiting or being limited by substitutions about Formula I.

The term “alkyl” refers to a branched, unbranched, or saturated cyclic carbon chain, including, but not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

The term “alkenyl” refers to a branched, unbranched or cyclic carbon chain containing one or more double bonds including, but not limited to, ethenyl, propenyl, butenyl, isopropenyl, isobutenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.

The term “alkynyl” refers to a branched or unbranched carbon chain containing one or more triple bonds including, but not limited to, propynyl, butynyl, and the like.

The terms “aryl” and “Ar” refer to any aromatic ring, mono- or bi-cyclic, containing 0 heteroatoms.

The term “heterocycle” refers to any aromatic or non-aromatic ring, mono- or bi-cyclic, containing one or more heteroatoms

The term “alkoxy” refers to an —OR substituent.

The term “acyloxy” refers to an —OC(O)R substituent.

The term “cyano” refers to a —C≡N substituent.

The term “hydroxyl” refers to an —OH substituent.

The term “amino” refers to a —N(R)₂ substituent.

The term “arylalkoxy” refers to —O(CH₂)_(n)Ar where n is an integer selected from the list 1, 2, 3, 4, 5, or 6.

The term “haloalkoxy” refers to an —OR—X substituent, wherein X is Cl, F, Br, or I, or any combination thereof.

The term “haloalkyl” refers to an alkyl, which is substituted with Cl, F, I, or Br or any combination thereof.

The term “halogen” or “halo” refers to one or more halogen atoms, defined as F, Cl, Br, and I.

The term “nitro” refers to a —NO₂ substituent.

The term thioalkyl refers to an —SR substituent.

Throughout the disclosure, reference to the compounds of Formula I is read as also including diastereomers, enantiomers, and mixtures thereof. In another embodiment, Formula (I) is read as also including salts or hydrates thereof. Exemplary salts include, but are not limited to: hydrochloride, hydrobromide, and hydroiodide.

It is also understood by those skilled in the art that additional substitution is allowable, unless otherwise noted, as long as the rules of chemical bonding and strain energy are satisfied and the product still exhibits fungicidal activity.

Another embodiment of the present disclosure is a use of a compound of Formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots.

Additionally, another embodiment of the present disclosure is a composition useful for protecting a plant against attack by a phytopathogenic organism and/or treatment of a plant infested by a phytopathogenic organism comprising a compound of Formula I and a phytologically acceptable carrier material.

DETAILED DESCRIPTION

The compounds of the present disclosure may be applied by any of a variety of known techniques, either as the compounds or as formulations comprising the compounds. For example, the compounds may be applied to the roots or foliage of plants for the control of various fungi, without damaging the commercial value of the plants. The materials may be applied in the form of any of the generally used formulation types, for example, as solutions, dusts, wettable powders, flowable concentrate, or emulsifiable concentrates.

Preferably, the compounds of the present disclosure are applied in the form of a formulation, comprising one or more of the compounds of Formula I with a phytologically acceptable carrier. Concentrated formulations may be dispersed in water, or other liquids, for application, or formulations may be dust-like or granular, which may then be applied without further treatment. The formulations can be prepared according to procedures that are conventional in the agricultural chemical art.

The present disclosure contemplates all vehicles by which one or more of the compounds may be formulated for delivery and use as a fungicide. Typically, formulations are applied as aqueous suspensions or emulsions. Such suspensions or emulsions may be produced from water-soluble, water-suspendable, or emulsifiable formulations which are solids, usually known as wettable powders; or liquids, usually known as emulsifiable concentrates, aqueous suspensions, or suspension concentrates. As will be readily appreciated, any material to which these compounds may be added may be used, provided it yields the desired utility without significant interference with the activity of these compounds as antifungal agents.

Wettable powders, which may be compacted to form water-dispersible granules, comprise an intimate mixture of one or more of the compounds of Formula I, an inert carrier and surfactants. The concentration of the compound in the wettable powder may be from about 10 percent to about 90 percent by weight based on the total weight of the wettable powder, more preferably about 25 weight percent to about 75 weight percent. In the preparation of wettable powder formulations, the compounds may be compounded with any finely divided solid, such as prophyllite, talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite clays, diatomaceous earths, purified silicates or the like. In such operations, the finely divided carrier and surfactants are typically blended with the compound(s) and milled.

Emulsifiable concentrates of the compounds of Formula I may comprise a convenient concentration, such as from about 1 weight percent to about 50 weight percent of the compound, in a suitable liquid, based on the total weight of the concentrate. The compounds may be dissolved in an inert carrier, which is either a water-miscible solvent or a mixture of water-immiscible organic solvents, and emulsifiers. The concentrates may be diluted with water and oil to form spray mixtures in the form of oil-in-water emulsions. Useful organic solvents include aromatics, especially the high-boiling naphthalenic and olefinic portions of petroleum such as heavy aromatic naphtha. Other organic solvents may also be used, for example, terpenic solvents, including rosin derivatives, aliphatic ketones, such as cyclohexanone, and complex alcohols, such as 2-ethoxyethanol.

Emulsifiers which may be advantageously employed herein may be readily determined by those skilled in the art and include various nonionic, anionic, cationic and amphoteric emulsifiers, or a blend of two or more emulsifiers. Examples of nonionic emulsifiers useful in preparing the emulsifiable concentrates include the polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids with ethylene oxide, propylene oxides such as the ethoxylated alkyl phenols and carboxylic esters solubilized with the polyol or polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include the oil-soluble salts (e.g., calcium) of alkylaryl sulphonic acids, oil-soluble salts or sulfated polyglycol ethers and appropriate salts of phosphated polyglycol ether.

Representative organic liquids which may be employed in preparing the emulsifiable concentrates of the compounds of the present disclosure are the aromatic liquids such as xylene, propyl benzene fractions; or mixed naphthalene fractions, mineral oils, substituted aromatic organic liquids such as dioctyl phthalate; kerosene; dialkyl amides of various fatty acids, particularly the dimethyl amides of fatty glycols and glycol derivatives such as the n-butyl ether, ethyl ether or methyl ether of diethylene glycol, the methyl ether of triethylene glycol, petroleum fractions or hydrocarbons such as mineral oil, aromatic solvents, paraffinic oils, and the like; vegetable oils such as soy bean oil, rape seed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cotton seed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above vegetable oils; and the like. Mixtures of two or more organic liquids may also be employed in the preparation of the emulsifiable concentrate. Organic liquids include xylene, and propyl benzene fractions, with xylene being most preferred in some cases. Surface-active dispersing agents are typically employed in liquid formulations and in an amount of from 0.1 to 20 percent by weight based on the combined weight of the dispersing agent with one or more of the compounds. The formulations can also contain other compatible additives, for example, plant growth regulators and other biologically active compounds used in agriculture.

Aqueous suspensions comprise suspensions of one or more water-insoluble compounds of Formula I, dispersed in an aqueous vehicle at a concentration in the range from about 1 to about 50 weight percent, based on the total weight of the aqueous suspension. Suspensions are prepared by finely grinding one or more of the compounds, and vigorously mixing the ground material into a vehicle comprised of water and surfactants chosen from the same types discussed above. Other components, such as inorganic salts and synthetic or natural gums, may also be added to increase the density and viscosity of the aqueous vehicle.

The compounds of Formula I can also be applied as granular formulations, which are particularly useful for applications to the soil. Granular formulations generally contain from about 0.5 to about 10 weight percent, based on the total weight of the granular formulation of the compound(s), dispersed in an inert carrier which consists entirely or in large part of coarsely divided inert material such as attapulgite, bentonite, diatomite, clay or a similar inexpensive substance. Such formulations are usually prepared by dissolving the compounds in a suitable solvent and applying it to a granular carrier which has been preformed to the appropriate particle size, in the range of from about 0.5 to about 3 mm. A suitable solvent is a solvent in which the compound is substantially or completely soluble. Such formulations may also be prepared by making a dough or paste of the carrier and the compound and solvent, and crushing and drying to obtain the desired granular particle.

Dusts containing the compounds of Formula I may be prepared by intimately mixing one or more of the compounds in powdered form with a suitable dusty agricultural carrier, such as, for example, kaolin clay, ground volcanic rock, and the like. Dusts can suitably contain from about 1 to about 10 weight percent of the compounds, based on the total weight of the dust.

The formulations may additionally contain adjuvant surfactants to enhance deposition, wetting, and penetration of the compounds onto the target crop and organism. These adjuvant surfactants may optionally be employed as a component of the formulation or as a tank mix. The amount of adjuvant surfactant will typically vary from 0.01 to 1.0 percent by volume, based on a spray-volume of water, preferably 0.05 to 0.5 volume percent. Suitable adjuvant surfactants include, but are not limited to ethoxylated nonyl phenols, ethoxylated synthetic or natural alcohols, salts of the esters or sulphosuccinic acids, ethoxylated organosilicones, ethoxylated fatty amines, blends of surfactants with mineral or vegetable oils, crop oil concentrate (mineral oil (85%)+emulsifiers (15%)); nonylphenol ethoxylate; benzylcocoalkyldimethyl quaternary ammonium salt; blend of petroleum hydrocarbon, alkyl esters, organic acid, and anionic surfactant; C₉-C₁₁ alkylpolyglycoside; phosphated alcohol ethoxylate; natural primary alcohol (C₁₂-C₁₆) ethoxylate; di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap; nonylphenol ethoxylate+urea ammonium nitrate; emulsified methylated seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow amine ethoxylate (15 EO); PEG(400) dioleate-99. The formulations may also include oil-in-water emulsions such as those disclosed in U.S. patent application Ser. No. 11/495,228, the disclosure of which is expressly incorporated by reference herein.

The formulations may optionally include combinations that contain other pesticidal compounds. Such additional pesticidal compounds may be fungicides, insecticides, herbicides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds. Accordingly, in such embodiments, the other pesticidal compound is employed as a supplemental toxicant for the same or for a different pesticidal use. The compounds of Formula I and the pesticidal compound in the combination can generally be present in a weight ratio of from 1:100 to 100:1.

The compounds of the present disclosure may also be combined with other fungicides to form fungicidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure are often applied in conjunction with one or more other fungicides to control a wider variety of undesirable diseases. When used in conjunction with other fungicide(s), the presently claimed compounds may be formulated with the other fungicide(s), tank-mixed with the other fungicide(s) or applied sequentially with the other fungicide(s). Such other fungicides may include 2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, ametoctradin, amisulbrom, antimycin, Ampelomyces quisqualis, azaconazole, azoxystrobin, Bacillus subtilis, Bacillus subtilis strain QST713, benalaxyl, benomyl, benthiavalicarb-isopropyl, benzovindiflupyr benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole, bupirimate, calcium polysulfide, captafol, captan, carbendazim, carboxin, carpropamid, carvone, chlazafenone, chloroneb, chlorothalonil, chlozolinate, Coniothyrium minitans, copper hydroxide, copper octanoate, copper oxychloride, copper sulfate, copper sulfate (tribasic), cuprous oxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dazomet, debacarb, diammonium ethylenebis-(dithiocarbamate), dichlofluanid, dichlorophen, diclocymet, diclomezine, dichloran, diethofencarb, difenoconazole, difenzoquation, diflumetorim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap, diphenylamine, dithianon, dodemorph, dodemorph acetate, dodine, dodine free base, edifenphos, enestrobin, enestroburin, epoxiconazole, ethaboxam, ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl, fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, guazatine, guazatine acetates, GY-81, hexachlorobenzene, hexaconazole, hymexazol, imazalil, imazalil sulfate, imibenconazole, iminoctadine, iminoctadine triacetate, iminoctadine tris(albesilate), iodocarb, ipconazole, ipfenpyrazolone, iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam, isotianil, kasugamycin, kasugamycin hydrochloride hydrate, kresoxim-methyl, laminarin, mancopper, mancozeb, mandipropamid, maneb, mefenoxam, mepanipyrim, mepronil, meptyl-dinocap, mercuric chloride, mercuric oxide, mercurous chloride, metalaxyl, metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium, metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate, metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil, nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic acid (fatty acids), orysastrobin, oxadixyl, oxine-copper, oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, pentachlorophenyl laurate, penthiopyrad, phenylmercury acetate, phosphonic acid, phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim, potassium bicarbonate, potassium hydroxyquinoline sulfate, probenazole, prochloraz, procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyroquilon, quinoclamine, quinoxyfen, quintozene, Reynoutria sachalinensis extract, sedaxane, silthiofam, simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium pentachlorophenoxide, spiroxamine, sulfur, SYP-Z048, tar oils, tebuconazole, tebufloquin, tecnazene, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumizole, triforine, triticonazole, validamycin, valifenalate, valiphenal, vinclozolin, zineb, ziram, zoxamide, Candida oleophila, Fusarium oxysporum, Gliocladium spp., Phlebiopsis gigantea, Streptomyces griseoviridis, Trichoderma spp., (RS)—N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide, 1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone hydrate, 1-chloro-2,4-dinitronaphthalene, 1-chloro-2-nitropropane, 2-(2-heptadecyl-2-imidazolin-1-yl)ethanol, 2,3-dihydro-5-phenyl-1,4-dithi-ine 1,1,4,4-tetraoxide, 2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride, 2-methoxyethylmercury silicate, 3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-1-enyl)phenyl thiocyanateme, ampropylfos, anilazine, azithiram, barium polysulfide, Bayer 32394, benodanil, benquinox, bentaluron, benzamacril; benzamacril-isobutyl, benzamorf, binapacryl, bis(methylmercury) sulfate, bis(tributyltin) oxide, buthiobate, cadmium calcium copper zinc chromate sulfate, carbamorph, CECA, chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox, climbazole, copper bis(3-phenylsalicylate), copper zinc chromate, cufraneb, cupric hydrazinium sulfate, cuprobam, cyclafuramid, cypendazole, cyprofuram, decafentin, dichlone, dichlozoline, diclobutrazol, dimethirimol, dinocton, dinosulfon, dinoterbon, dipyrithione, ditalimfos, dodicin, drazoxolon, EBP, ESBP, etaconazole, etem, ethirim, fenaminosulf, fenapanil, fenitropan, fluotrimazole, furcarbanil, furconazole, furconazole-cis, furmecyclox, furophanate, glyodine, griseofulvin, halacrinate, Hercules 3944, hexylthiofos, ICIA0858, isopamphos, isovaledione, mebenil, mecarbinzid, metazoxolon, methfuroxam, methylmercury dicyandiamide, metsulfovax, milneb, mucochloric anhydride, myclozolin, N-3,5-dichlorophenyl-succinimide, N-3-nitrophenylitaconimide, natamycin, N-ethylmercurio-4-toluenesulfonanilide, nickel bis(dimethyldithiocarbamate), OCH, phenylmercury dimethyldithiocarbamate, phenylmercury nitrate, phosdiphen, prothiocarb; prothiocarb hydrochloride, pyracarbolid, pyridinitril, pyroxychlor, pyroxyfur, quinacetol; quinacetol sulfate, quinazamid, quinconazole, rabenzazole, salicylanilide, SSF-109, sultropen, tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate, thioquinox, tioxymid, triamiphos, triarimol, triazbutil, trichlamide, urbacid, zarilamid, and any combinations thereof.

Additionally, the compounds described herein may be combined with other pesticides, including insecticides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more other pesticides to control a wider variety of undesirable pests. When used in conjunction with other pesticides, the presently claimed compounds may be formulated with the other pesticide(s), tank-mixed with the other pesticide(s) or applied sequentially with the other pesticide(s). Typical insecticides include, but are not limited to: 1,2-dichloropropane, abamectin, acephate, acetamiprid, acethion, acetoprole, acrinathrin, acrylonitrile, alanycarb, aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, allyxycarb, alpha-cypermethrin, alpha-ecdysone, alpha-endosulfan, amidithion, aminocarb, amiton, amiton oxalate, amitraz, anabasine, athidathion, azadirachtin, azamethiphos, azinphos-ethyl, azinphos-methyl, azothoate, barium hexafluorosilicate, barthrin, bendiocarb, benfuracarb, bensultap, beta-cyfluthrin, beta-cypermethrin, bifenthrin, bioallethrin, bioethanomethrin, biopermethrin, bistrifluron, borax, boric acid, bromfenvinfos, bromocyclen, bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin, butacarb, butathiofos, butocarboxim, butonate, butoxycarboxim, cadusafos, calcium arsenate, calcium polysulfide, camphechlor, carbanolate, carbaryl, carbofuran, carbon disulfide, carbon tetrachloride, carbophenothion, carbosulfan, cartap, cartap hydrochloride, chlorantraniliprole, chlorbicyclen, chlordane, chlordecone, chlordimeform, chlordimeform hydrochloride, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos, chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide, cinerin I, cinerin II, cinerins, cismethrin, cloethocarb, closantel, clothianidin, copper acetoarsenite, copper arsenate, copper naphthenate, copper oleate, coumaphos, coumithoate, crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin, cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cyromazine, cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O, demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl, demeton-S-methylsulphon, diafenthiuron, dialifos, diatomaceous earth, diazinon, dicapthon, dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil, dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan, dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex, dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan, dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos, d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC, empenthrin, endosulfan, endothion, endrin, EPN, epofenonane, eprinomectin, esdepallethrine, esfenvalerate, etaphos, ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl formate, ethyl-DDD, ethylene dibromide, ethylene dichloride, ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos, fenazaflor, fenchlorphos, fenethacarb, fenfluthrin, fenitrothion, fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin, fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil, flonicamid, flubendiamide, flucofuron, flucycloxuron, flucythrinate, flufenerim, flufenoxuron, flufenprox, fluvalinate, fonofos, formetanate, formetanate hydrochloride, formothion, formparanate, formparanate hydrochloride, fosmethilan, fospirate, fosthietan, furathiocarb, furethrin, gamma-cyhalothrin, gamma-HCH, halfenprox, halofenozide, HCH, HEOD, heptachlor, heptenophos, heterophos, hexaflumuron, HHDN, hydramethylnon, hydrogen cyanide, hydroprene, hyquincarb, imidacloprid, imiprothrin, indoxacarb, iodomethane, IPSP, isazofos, isobenzan, isocarbophos, isodrin, isofenphos, isofenphos-methyl, isoprocarb, isoprothiolane, isothioate, isoxathion, ivermectin, jasmolin I, jasmolin II, jodfenphos, juvenile hormone I, juvenile hormone II, juvenile hormone III, kelevan, kinoprene, lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, lindane, lirimfos, lufenuron, lythidathion, malathion, malonoben, mazidox, mecarbam, mecarphon, menazon, mephosfolan, mercurous chloride, mesulfenfos, metaflumizone, methacrifos, methamidophos, methidathion, methiocarb, methocrotophos, methomyl, methoprene, methoxychlor, methoxyfenozide, methyl bromide, methyl isothiocyanate, methylchloroform, methylene chloride, metofluthrin, metolcarb, metoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin oxime, mipafox, mirex, molosultap, monocrotophos, monomehypo, monosultap, morphothion, moxidectin, naftalofos, naled, naphthalene, nicotine, nifluridide, nitenpyram, nithiazine, nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl, oxydemeton-methyl, oxydeprofos, oxydisulfoton, para-dichlorobenzene, parathion, parathion-methyl, penfluron, pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate, phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon, phosphine, phoxim, phoxim-methyl, pirimetaphos, pirimicarb, pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium thiocyanate, pp′-DDT, prallethrin, precocene I, precocene II, precocene III, primidophos, profenofos, profluralin, promacyl, promecarb, propaphos, propetamphos, propoxur, prothidathion, prothiofos, prothoate, protrifenbute, pyraclofos, pyrafluprole, pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins, pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon, pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia, quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin, rotenone, ryania, sabadilla, schradan, selamectin, silafluofen, silica gel, sodium arsenite, sodium fluoride, sodium hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram, spinosad, spiromesifen, spirotetramat, sulcofuron, sulcofuron-sodium, sulfluramid, sulfotep, sulfoxaflor, sulfuryl fluoride, sulprofos, tau-fluvalinate, tazimcarb, TDE, tebufenozide, tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos, TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos, tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid, thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam oxalate, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-disodium, thiosultap-monosodium, thuringiensin, tolfenpyrad, tralomethrin, transfluthrin, transpermethrin, triarathene, triazamate, triazophos, trichlorfon, trichlormetaphos-3, trichloronat, trifenofos, triflumuron, trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, zolaprofos, and any combinations thereof.

Additionally, the compounds described herein may be combined with herbicides that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more herbicides to control a wide variety of undesirable plants. When used in conjunction with herbicides, the presently claimed compounds may be formulated with the herbicide(s), tank-mixed with the herbicide(s) or applied sequentially with the herbicide(s). Typical herbicides include, but are not limited to: 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB; 3,4-DB; 2,4-DEB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB; acetochlor, acifluorfen, aclonifen, acrolein, alachlor, allidochlor, alloxydim, allyl alcohol, alorac, ametridione, ametryn, amibuzin, amicarbazone, amidosulfuron, aminocyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole, ammonium sulfamate, anilofos, anisuron, asulam, atraton, atrazine, azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid, benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron, bensulide, bentazone, benzadox, benzfendizone, benzipram, benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron, bicyclopyrone, bifenox, bilanafos, bispyribac, borax, bromacil, bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon, butachlor, butafenacil, butamifos, butenachlor, buthidazole, buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid, cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor, carbasulam, carbetamide, carboxazole chlorprocarb, carfentrazone, CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop, chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, chloridazon, chlorimuron, chlornitrofen, chloropon, chlorotoluron, chloroxuron, chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim, cliodinate, clodinafop, clofop, clomazone, clomeprop, cloprop, cloproxydim, clopyralid, cloransulam, CMA, copper sulfate, CPMF, CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate, cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyperquat, cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet, delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil, dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop, diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron, difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam, dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul, dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endothal, epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron, ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxysulfuron, etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop, fenoxaprop, fenoxaprop-P, fenoxasulfone, fenteracol, fenthiaprop, fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M, flazasulfuron, florasulam, fluazifop, fluazifop-P, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, flufenican, flufenpyr, flumetsulam, flumezin, flumiclorac, flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen, fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil, flupropanate, flupyrsulfuron, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron, fosamine, furyloxyfen, glufosinate, glufosinate-P, glyphosate, halauxifen, halosafen, halosulfuron, haloxydine, haloxyfop, haloxyfop-P, hexachloroacetone, hexaflurate, hexazinone, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane, iodosulfuron, ioxynil, ipazine, ipfencarbazone, iprymidam, isocarbamid, isocil, isomethiozin, isonoruron, isopolinate, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen, lenacil, linuron, MAA, MAMA, MCPA, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, medinoterb, mefenacet, mefluidide, mesoprazine, mesosulfuron, mesotrione, metam, metamifop, metamitron, metazachlor, metazosulfuron, metflurazon, methabenzthiazuron, methalpropalin, methazole, methiobencarb, methiozolin, methiuron, methometon, methoprotryne, methyl bromide, methyl isothiocyanate, methyldymron, metobenzuron, metobromuron, metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, molinate, monalide, monisouron, monochloroacetic acid, monolinuron, monuron, morfamquat, MSMA, naproanilide, napropamide, naptalam, neburon, nicosulfuron, nipyraclofen, nitralin, nitrofen, nitrofluorfen, norflurazon, noruron, OCH, orbencarb, ortho-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxasulfuron, oxaziclomefone, oxyfluorfen, parafluron, paraquat, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham, phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram, picolinafen, pinoxaden, piperophos, potassium arsenite, potassium azide, potassium cyanate, pretilachlor, primisulfuron, procyazine, prodiamine, profluazol, profluralin, profoxydim, proglinazine, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfalin, prosulfocarb, prosulfuron, proxan, prynachlor, pydanon, pyraclonil, pyraflufen, pyrasulfotole, pyrazolynate, pyrazosulfuron, pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate, pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quinonamid, quizalofop, quizalofop-P, rhodethanil, rimsulfuron, saflufenacil, S-metolachlor, sebuthylazine, secbumeton, sethoxydim, siduron, simazine, simeton, simetryn, SMA, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone, sulfometuron, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine, terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr, thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron, thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tricamba, triclopyr, tridiphane, trietazine, trifloxysulfuron, triflusulfuron, trifop, trifopsime, trihydroxytriazine, trimeturon, tripropindan, tritac, tritosulfuron, vernolate, and xylachlor.

Another embodiment of the present disclosure is a method for the control or prevention of fungal attack. This method comprises applying to the soil, plant, roots, foliage, or locus of the fungus, or to a locus in which the infestation is to be prevented (for example applying to cereal or grape plants), a fungicidally effective amount of one or more of the compounds of Formula I. The compounds are suitable for treatment of various plants at fungicidal levels, while exhibiting low phytotoxicity. The compounds may be useful both in a protectant and/or an eradicant fashion.

The compounds have been found to have significant fungicidal effect particularly for agricultural use. Many of the compounds are particularly effective for use with agricultural crops and horticultural plants.

It will be understood by those skilled in the art that the efficacy of the compound for the foregoing fungi establishes the general utility of the compounds as fungicides.

The compounds have broad ranges of activity against fungal pathogens. Exemplary pathogens may include, but are not limited to, causing agent of wheat leaf blotch (Mycosphaerella graminicola; anamorph: Septoria tritici), wheat brown rust (Puccinia triticina), wheat stripe rust (Puccinia strhformis), scab of apple (Venturia inaequalis), powdery mildew of grapevine (Uncinula necator), barley scald (Rhynchosporium secalis), blast of rice (Magnaporthe grisea), rust of soybean (Phakopsora pachyrhizi), glume blotch of wheat (Leptosphaeria nodorum), powdery mildew of wheat (Blumeria graminis f sp. tritici), powdery mildew of barley (Blumeria graminis f sp. hordei), powdery mildew of cucurbits (Erysiphe cichoracearum), anthracnose of cucurbits (Glomerella lagenarium), leaf spot of beet (Cercospora beticola), early blight of tomato (Alternaria solani), and spot blotch of barley (Cochliobolus sativus). The exact amount of the active material to be applied is dependent not only on the specific active material being applied, but also on the particular action desired, the fungal species to be controlled, and the stage of growth thereof, as well as the part of the plant or other product to be contacted with the compound. Thus, all the compounds, and formulations containing the same, may not be equally effective at similar concentrations or against the same fungal species.

The compounds are effective in use with plants in a disease-inhibiting and phytologically acceptable amount. The term “disease-inhibiting and phytologically acceptable amount” refers to an amount of a compound that kills or inhibits the plant disease for which control is desired, but is not significantly toxic to the plant. This amount will generally be from about 0.1 to about 1000 ppm (parts per million), with 1 to 500 ppm being preferred. The exact concentration of compound required varies with the fungal disease to be controlled, the type of formulation employed, the method of application, the particular plant species, climate conditions, and the like. A suitable application rate is typically in the range from about 0.10 to about 4 pounds/acre (about 0.01 to 0.45 grams per square meter, g/m²).

Any range or desired value given herein may be extended or altered without losing the effects sought, as is apparent to the skilled person for an understanding of the teachings herein.

The compounds of Formula I may be made using well-known chemical procedures. Intermediates not specifically mentioned in this disclosure are either commercially available, may be made by routes disclosed in the chemical literature, or may be readily synthesized from commercial starting materials utilizing standard procedures.

General Schemes

The following schemes illustrate approaches to generating picolinamide compounds of Formula (I). The following descriptions and examples are provided for illustrative purposes and should not be construed as limiting in terms of substituents or substitution patterns.

Compounds of Formula 1.3, where R₁ and R₂ are as originally defined, can be prepared according to the methods outlined in Scheme 1, steps a-c. Compounds of Formula 1.1, where R₁ is as originally defined, can be obtained by reaction of (S)-5-methylfuran-2(5H)-one, a compound of Formula 1.0 (prepared as in Kobayashi et al. Tetrahedron 2003, 59, 9743-9758) with an organolithium reagent, such as R₁Li, or a Grignard reagent, such as R₁MgX, where R₁ is as originally defined and X is bromide or chloride, and copper (I) iodide in a solvent such as tetrahydrofuran (THF) at cryogenic temperatures such as −78° C., as shown in a. Compounds of Formula 1.2, where R₁ and R₂ are as originally defined, can be obtained by treating compounds of Formula 1.1, where R₁ is as originally defined, with lithium diisopropylamide (LDA), which was generated in situ from n-butyllithium (n-BuLi) and diisopropylamine (i-Pr₂NH) at −20° C., followed by reacting with alkyl or benzyl bromide or alkyl or benzyl chloride, such as R₂Br, where R₂ is as originally defined, in a solvent such as THF from −78° C. to ambient temperature, as shown in b. Compounds of Formula 1.3, where R₁ and R₂ are as originally defined, can be prepared from compounds of Formula 1.2, where R₁ and R₂ are as originally defined, by treating with a reducing agent such as lithium aluminum hydride (LiAlH₄, LAH), in a solvent such as THF from 0° C. to ambient temperature, as depicted in c.

Compounds of Formula 2.3, where R₁ and R₂ are as originally defined, can be prepared as shown in Scheme 2, steps a-d. Diols of Formula 1.3, where R₁ and R₂ are as originally defined, can be protected as bis-trimethylsilyl (TMS) ethers to give compounds of Formula 2.0, where R₁ and R₂ are as originally defined, by reacting with a base such as triethylamine (Et₃N) and silylating reagent, such as chloro trimethylsilane (TMSCl), in an aprotic solvent, such as dichloromethane (DCM), at ambient temperature, as shown in a. Compounds of Formula 2.1, where R₁ and R₂ are as originally defined, can be obtained by reacting compounds of Formula 2.0, where R₁ and R₂ are as originally defined, with an oxidant, such as a solution of chromium trioxide (CrO₃) and pyridine, in a solvent such as DCM at low temperatures such as from −25° C. to −10° C., as shown in b. Compounds of Formula 2.2, where R₁ and R₂ are as originally defined, can be prepared by addition of compounds of Formula 2.1, where R₁ and R₂ are as originally defined, into a mixture of n-BuLi and bromo(methyl)-triphenylphosphorane (Ph₃PBrCH₃), in a solvent such as THF at cryogenic temperatures such as −78° C., and slowly warming to ambient temperature, as shown in c. Compounds of Formula 2.3, where R₁ and R₂ are as originally defined, can be obtained from compounds of Formula 2.2, where R₁ and R₂ are as originally defined, by reacting with a base such as Et₃N, a catalyst such as N,N-dimethylpyridin-4-amine (DMAP), and acetylating reagent such as acetyl chloride (AcCl), in a solvent such as DCM at ambient temperature, as shown in d.

Compounds of Formula 3.3, where R₁ and R₂ are as originally defined, can be prepared as outlined in Scheme 3, steps a-c. Compounds of Formula 3.1 can be prepared by treating compounds of Formula 2.3, where R₁ and R₂ are as originally defined, with an alkylborane reagent, such as 9-borabicyclo[3.3.1]nonane (9-BBN), in a solvent such as THF, at a temperature between ambient temperature and about 50° C., followed by treatment with an alkaline aqueous solution, such as aqueous potassium phosphate (K₃PO₄), a brominated olefin, such as a compound of Formula 3.0 (prepared as in Singh et al. Org. Lett. 2003, 17, 3155-3158), and a palladium catalyst, such as [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [PdCl₂(dppf)] at ambient room temperature to about 55° C., as shown in step a. Compounds of the Formula 3.2, where R₁ and R₂ are as originally defined, can be prepared from enamides, generalized by Formula 3.1, where R₁ and R₂ are as originally defined, using an asymmetric hydrogenation reaction employing a catalyst such as (+)-1,2-bis((2S,5S)-2,5-diethylphospholano)benzene(1,5-cyclooctadiene) rhodium(I) trifluoromethanesulfonate ((S,S)-Et-DuPHOS-Rh) under a hydrogen gas (H₂) atmosphere at a pressure between 40 and 200 pounds per square inch (psi) in a solvent such as methanol (MeOH) as shown in step b. Compounds of Formula 3.3, where R₁ and R₂ are as originally defined, can be prepared from compounds of Formula 3.2, where R₁ and R₂ are as originally defined and the carboxylic acid is protected as either the methyl (Me) or benzyl (Bn) ester, by treating with a hydroxide base, such as lithium hydroxide monohydrate (LiOH.H₂O), in an aqueous MeOH solvent mixture, as shown in step c.

Compounds of Formula 4.0, where R₁ and R₂ are as originally defined, can be prepared according to the methods outlined in Scheme 4. Compounds of Formula 4.0, can be obtained from compounds of Formula 3.3, where R₁ and R₂ are as originally defined, by the addition of a solution of compounds of Formula 3.3 in a halogenated solvent such as DCM or an aromatic solvent such as toluene to a mixture of a base, such as DMAP, and a mixed anhydride, such as 2-methyl-6-nitrobenzoic anhydride (MNBA), in either a halogenated solvent such as DCM or an aromatic solvent such as toluene at a temperature between about 21° C. and about 60° C. over a period of 4-12 hours (h), as shown in step a.

Compounds of Formula 5.1 can be prepared through the methods shown in Scheme 5, steps a-b. Compounds of Formula 5.0, where R₁ and R₂ are as originally defined and X and Y are hydrogen, can be obtained from compounds of Formula 4.0, where R₁ and R₂ are as originally defined, by treating with an acid, such as a 4.0 Molar (M) hydrogen chloride (HCl) solution in dioxane, in a solvent such as DCM, as shown in a. The resulting hydrochloride salt may be neutralized prior to use to give the free amine or neutralized in situ in step b. Compounds of Formula 5.1, where R₁ and R₂ are as originally defined, can be prepared from compounds of Formula 5.0, where R₁ and R₂ are as originally defined, by treatment with 3-hydroxy-4-methoxypicolinic acid in the presence of a base, such as 4-methylmorpholine, and a peptide coupling reagent, such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) or benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), in an aprotic solvent such as DCM, as shown in b.

Compounds of Formula 6.0, where R₁, R₂ and R₄ are as originally defined, can be prepared by the method shown in Scheme 6. Compounds of Formula 6.0, where R₁ and R₂ are as originally defined, can be prepared from compounds of Formula 5.1, where R₁ and R₂ are as originally defined, by treatment with the appropriate alkyl halide with or without a reagent such as sodium iodide (NaI) and an alkali carbonate base such as sodium carbonate (Na₂CO₃) or potassium carbonate (K₂CO₃) in a solvent such as acetone or by treatment with an acyl halide in the presence of an amine base, such as pyridine, Et₃N, DMAP, or mixtures thereof in an aprotic solvent such as DCM, as shown in step a.

EXAMPLES Example 1 Step 1 Preparation of (4R,5S)-4-butyl-5-methyldihydrofuran-2(3H)-one

To a suspension of copper(I) iodide (6.08 grams (g), 31.9 millimole (mmol)) in 35 milliliters (mL) of diethyl ether (Et₂O) at −78° C. was added n-BuLi (2.5 Molar (M) in hexanes, 25.6 mL, 64.0 mmol) dropwise. After stirring between −30 and −20° C. for 30 minutes (min), the reaction mixture became a homogenous, dark brown solution. The solution was cooled to −78° C. and (S)-5-methylfuran-2(5H)-one (2.09 g, 21.3 mmol) in Et₂O (8 mL) was added slowly. The reaction was stirred at −78° C. for 2 hours (h), at which time thin layer chromatography (TLC) analysis showed the reaction to be complete. The reaction was quenched with saturated aqueous ammonium chloride (NH₄Cl) and filtered through Celite® to remove the inorganic salts. The filtrate was extracted with Et₂O (3×), and the combined organic extracts were dried over sodium sulfate (Na₂SO₄), filtered, concentrated, and purified by flash chromatography (silica gel (SiO₂), 0→30% ethyl acetate (EtOAc) in hexanes) to provide the title compound (2.92 g, 88%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 4.21 (dq, J=7.6, 6.2 Hz, 1H), 2.68 (dd, J=17.4, 8.2 Hz, 1H), 2.22 (dd, J=17.4, 9.7 Hz, 1H), 2.14-2.00 (m, 1H), 1.62-1.49 (m, 1H), 1.40 (d, J=6.2 Hz, 3H), 1.38-1.26 (m, 5H), 0.91 (t, J=7.0 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 176.51, 82.16, 43.27, 35.44, 32.11, 29.76, 22.55, 19.80, 13.82; [α]_(D)=−44.2° (a=−0.177, c=0.4, CDCl₃).

Example 1 Step 2 (3R,4R,5S)-3-benzyl-4-butyl-5-methyldihydrofuran-2(3H)-one

To a solution of diisopropylamine (958 microliters (μL), 6.84 mmol) in THF (11 mL) at −78° C. was added n-BuLi (2.5 M in hexanes, 2.74 mL, 6.85 mmol). The reaction was stirred at 0° C. for 15 min, cooled to −78° C., and treated with (4R,5S)-4-butyl-5-methyldihydrofuran-2(3H)-one (890 milligrams (mg), 5.70 mmol). The reaction was stirred at −78° C. for 30 min, treated with benzyl bromide (1016 μL, 8.55 mmol), and the resulting solution was slowly warmed to room temperature overnight. The reaction was quenched with saturated aqueous NH₄Cl and extracted with Et₂O (3×). The combined organic extracts were concentrated and the residue was purified by flash chromatography (SiO₂, 0→5% EtOAc in hexanes) to provide the title compound (950 mg, 67.7%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.10 (m, 5H), 4.12 (dq, J=8.2, 6.2 Hz, 1H), 3.12 (dd, J=14.0, 5.4 Hz, 1H), 2.98 (dd, J=14.0, 6.6 Hz, 1H), 2.63 (ddd, J=10.1, 6.6, 5.4 Hz, 1H), 1.81-1.73 (m, 1H), 1.33-1.26 (m, 2H), 1.26 (d, J=6.2 Hz, 3H), 1.22-1.12 (m, 4H), 0.85-0.79 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) 178.11, 138.11, 129.37, 128.54, 126.69, 80.24, 67.96, 48.07, 46.82, 35.64, 31.70, 28.96, 25.61, 22.77, 20.72, 13.80.

Example 1 Step 3 Preparation of (2R,3R,4S)-2-benzyl-3-butylpentane-1,4-diol

To a solution of (3R,4R,5S)-3-benzyl-4-butyl-5-methyldihydrofuran-2(3H)-one (700 mg, 2.84 mmol) in THF (14 mL) at 0° C. was added LAH (1 M in THF, 3.4 mL, 3.4 mmol) and the reaction was slowly warmed to room temperature overnight. TLC analysis showed complete consumption of the starting material (SM) along with the formation of a more polar spot (2:1 hexanes/EtOAc, R_(f)=0.2-0.3). The reaction was quenched by the careful addition of water (0.2 mL), 10% aqueous sodium hydroxide (NaOH, 0.4 mL), and additional water (0.6 mL). Solid Na₂SO₄ was added and the mixture was filtered to remove salts. The filter cake was washed with EtOAc and the combined organics were concentrated and the residue was purified by flash chromatography (SiO₂, 0→30% EtOAc in hexanes) to provide the title compound (660 mg, 93%) as a colorless, thick oil which solidified upon drying under vacuum: ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.10 (m, 5H), 3.88-3.79 (m, 1H), 3.69 (dt, J=11.1, 3.0 Hz, 1H), 3.49 (dt, J=11.1, 5.5 Hz, 1H), 3.40 (d, J=4.3 Hz, 1H), 3.35-3.23 (m, 1H), 2.82 (dd, J=13.6, 5.8 Hz, 1H), 2.74 (dd, J=13.6, 9.4 Hz, 1H), 2.03-1.94 (m, 1H), 1.53-1.41 (m, 1H), 1.36-1.22 (m, 6H), 1.26 (d, J=6.3 Hz, 3H), 0.88-0.84 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 141.72, 129.17, 128.30, 125.81, 70.00, 61.40, 46.88, 44.46, 37.01, 30.52, 29.84, 23.01, 22.52, 14.07; ESIMS m/z 501.4 ([2M+Na]⁺).

Example 2 Steps 1a-1c Preparation of (2S,3R)-3-((S)-1-phenylbut-3-en-2-yl)heptan-2-ol

Step 1a Preparation of (4S,5R,6R)-6-benzyl-5-butyl-2,2,4,9,9-pentamethyl-3,8-dioxa-2,9-disiladecane

To a solution of (2R,3R,4S)-2-benzyl-3-butylpentane-1,4-diol (470 mg, 1.88 mmol) and Et₃N (1308 μL, 9.39 mmol) in DCM (10 mL) at room temperature was added chlorotrimethylsilane (596 μL, 4.69 mmol). The reaction was stirred at room temperature for 1 hr, diluted with hexane (20 mL), and the resulting salts were removed by filtration through Celite®. The cake was washed with 20:1 hexanes/EtOAc and the organics were concentrated to provide a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.29-7.14 (m, 5H), 4.05 (qd, J=6.3, 3.7 Hz, 1H), 3.42 (dd, J=10.1, 4.4 Hz, 1H), 3.35 (dd, J=10.1, 7.6 Hz, 1H), 3.03 (dd, J=13.5, 3.4 Hz, 1H), 2.23 (dd, J=13.4, 10.7 Hz, 1H), 2.14-1.96 (m, 1H), 1.54 (d, J=4.0 Hz, 1H), 1.41-0.21 (m, 6H), 1.19 (d, J=6.3 Hz, 3H), 1.02-0.79 (m, 3H), 0.01 (s, 9H), 0.00 (s, 9H).

Step 1b Preparation of (2R,3R)-2-benzyl-3-((S)-1-((trimethylsilyl)oxy)-ethyl)heptanal

To a suspension of CrO₃ (563 mg, 5.63 mmol) in DCM (15 mL) at room temperature was added pyridine (907 μL, 11.26 mmol), and the solution was stirred at room temperature for 30 min, cooled to −25° C., treated with a solution of (4S,5R,6R)-6-benzyl-5-butyl-2,2,4,9,9-pentamethyl-3,8-dioxa-2,9-disiladecane (742 mg, 1.88 mmol) in DCM (5 mL), and stirred between −25 and −10° C. for 2 h. The resulting solution was filtered through a plug of SiO₂ to remove inorganic salts and the plug was washed with 10:1 hexanes/EtOAc. The resulting colorless solution was concentrated to give a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 9.55 (d, J=1.5 Hz, 1H), 7.19-7.03 (m, 5H), 3.80 (p, J=6.1 Hz, 1H), 2.91-2.74 (m, 3H), 1.71 (qd, J=6.0, 3.4 Hz, 1H), 1.38-1.17 (m, 6H), 1.13 (d, J=6.2 Hz, 3H), 0.78 (t, J=7.0 Hz, 3H), 0.00 (s, 9H).

Step 1c Preparation of (2S,3R)-3-((S)-1-phenylbut-3-en-2-yl)heptan-2-ol

To a suspension of Ph₃PBrCH₃ (1.68 g, 4.69 mmol) in THF (8 mL) at 0° C. was added n-BuLi (2.5 M in hexane, 1.8 mL, 4.51 mmol) dropwise. The reaction mixture turned from a cloudy, white mixture to a homogeneous, yellow solution. The solution was stirred for 30 min at 0° C., cooled to −78° C., and treated with (2R,3R)-2-benzyl-3-((S)-1-((trimethylsilyl)oxy)ethyl)heptanal (602 mg, 1.88 mmol) in THF (2 mL). The reaction mixture was slowly warmed to room temperature overnight, quenched with water, and the pH was adjusted to 1 by the addition of 1 Normal (N) aqueous hydrogen chloride (HCl). The acidic solution was stirred for 10 min, extracted with Et₂O (3×), and the combined organic phases were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by flash chromatography (SiO₂, 0→10% EtOAc in hexanes) to provide the title compound (247 mg, 53% over 3 steps) as a colorless oil: IR (neat) 3389, 3063, 2929, 1454 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.10 (m, 5H), 5.78 (ddd, J=17.2, 10.3, 8.5 Hz, 1H), 4.98-4.77 (m, 2H), 3.90 (pd, J=6.2, 4.8 Hz, 1H), 2.95 (dd, J=13.4, 5.0 Hz, 1H), 2.63 (dd, J=13.4, 9.3 Hz, 1H), 2.51 (tt, J=9.2, 4.8 Hz, 1H), 1.50-1.40 (m, 1H), 1.40-1.23 (m, 6H), 1.20 (d, J=6.3 Hz, 3H), 0.94-0.85 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 141.24, 140.70, 129.26, 128.07, 125.69, 115.57, 69.34, 48.89, 47.09, 38.57, 31.07, 27.64, 23.11, 21.07, 14.07.

Example 2 Step 2 Preparation of (2S,3R)-3-((S)-1-phenylbut-3-en-2-yl)heptan-2-yl acetate

To a solution of (2S,3R)-3-((S)-1-phenylbut-3-en-2-yl)heptan-2-ol (247 mg, 1.00 mmol) in DCM (5 mL) at room temperature were added Et₃N (391 μL, 2.80 mmol), acetic anhydride (177 μL, 1.869 mmol) and DMAP (22.84 mg, 0.187 mmol). The reaction was stirred at room temperature for 2 h, quenched with saturated aqueous sodium bicarbonate (NaHCO₃), extracted with DCM (3×), and the combined organic phases were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by flash chromatography (SiO₂, 0→10% EtOAc in hexanes) to provide the title compound (256 mg, 95%) as a colorless oil: IR (neat) 3027, 2931, 1733, 1240 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.08 (m, 5H), 5.66 (ddd, J=17.1, 10.3, 8.7 Hz, 1H), 5.10-5.01 (m, 1H), 4.94 (ddd, J=10.3, 1.8, 0.6 Hz, 1H), 4.77 (ddd, J=17.1, 1.9, 1.0 Hz, 1H), 2.93 (dd, J=13.5, 4.8 Hz, 1H), 2.56 (dd, J=13.4, 9.6 Hz, 1H), 2.47-2.36 (m, 1H), 2.05 (s, 3H), 1.68-1.58 (m, 1H), 1.45-1.22 (m, 6H), 1.20 (d, J=6.4 Hz, 3H), 0.95-0.84 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.41, 140.98, 139.68, 129.22, 128.04, 125.72, 115.99, 72.04, 47.21, 45.80, 38.44, 30.83, 27.32, 22.92, 21.54, 17.18, 14.01.

Example 3 Step 1 Preparation of (6R,7R,Z)-methyl 7-((S)-1-acetoxyethyl)-6-benzyl-2-((tert-butoxycarbonyl)amino)undec-2-enoate

To a solution of (2S,3R)-3-((S)-1-phenylbut-3-en-2-yl)heptan-2-yl acetate (252 mg, 0.874 mmol) in THF (2.3 mL) was added 9-BBN (0.5 M in THF, 2272 μL, 1.136 mmol), and the reaction was stirred at room temperature for 30 min, warmed to 50° C., and stirred at 50° C. for 2 h. The reaction mixture was cooled to room temperature, treated with K₃PO₄ (582 μL, 1.75 mmol) followed by a solution of (4-methyl 3-bromo-2-((tert-butoxycarbonyl)amino)acrylate (269 mg, 0.961 mmol) in N,N-dimethylformamide (DMF; 4369 μL), and PdCl₂(dppf) (32.0 mg, 0.044 mmol). The reaction mixture was heated to 55° C. and stirred overnight. The reaction was quenched by the addition of saturated aqueous NaHCO₃ solution (10 mL), extracted with Et₂O (3×), and the combined organic phases were dried over Na₂SO₄ filtered, and concentrated. The residue was purified by flash chromatography (SiO₂, 0→15% EtOAc in hexanes) to give the title compound (310 mg, 72.5%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.09 (m, 5H), 6.37 (t, J=7.2 Hz, 1H), 5.95 (s, 1H), 5.10 (p, J=6.3 Hz, 1H), 3.74 (s, 3H), 2.88 (dd, J=13.5, 4.5 Hz, 1H), 2.30 (dd, J=13.5, 9.8 Hz, 1H), 2.25-2.10 (m, 1H), 2.09-1.99 (m, 1H), 2.06 (s, 3H), 1.88-1.82 (m, 1H), 1.59-1.51 (m, 1H), 1.45 (s, 9H), 1.43-1.21 (m, 8H), 1.26 (d, J=6.3 Hz, 3H), 0.97-0.81 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.55, 165.30, 153.17, 141.66, 136.33, 129.10, 128.29, 125.79, 80.41, 71.93, 52.23, 43.77, 40.24, 37.37, 31.16, 29.48, 28.17, 26.43, 23.03, 21.40, 18.56, 14.01; ESIMS m/z 512.3 ([M+Na]′).

Example 3 Step 2 Preparation of (2S,6R,7R)-methyl 7-((S)-1-acetoxyethyl)-6-benzyl-2-((tert-butoxycarbonyl)amino)undecanoate

A solution of (6R,7R,Z)-methyl 7-((S)-1-acetoxyethyl)-6-benzyl-2-((tert-butoxycarbonyl)amino)undec-2-enoate (364 mg, 0.743 mmol) in anhydrous MeOH (15 mL) was sparged with nitrogen gas (N₂) for 10 min in a stainless steel reactor and then treated with (S,S)-Et-DuPHOS-Rh (5.37 mg, 7.43 μmol). The reactor was sealed, purged twice with 200 psi of hydrogen gas (H₂), pressurized to 200 psi with H₂, and the mixture was stirred at room temperature overnight. The reaction was concentrated and purified by flash chromatography (SiO₂, 0→30% EtOAc in hexanes) to provide the title compound (324 mg, 87%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.05 (m, 5H), 5.08 (p, J=6.3 Hz, 1H), 4.92 (d, J=8.5 Hz, 1H), 4.22 (q, J=7.2 Hz, 1H), 3.70 (s, 3H), 2.86 (dd, J=13.5, 4.6 Hz, 1H), 2.27 (dd, J=13.5, 9.7 Hz, 1H), 2.06 (s, 3H), 1.83 (dd, J=9.9, 5.5 Hz, 1H), 1.75-1.61 (m, 1H), 1.53-1.45 (m, 2H), 1.43 (s, 9H), 1.37-1.10 (m, 13H), 0.89 (td, J=5.6, 4.9, 2.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 173.30, 170.57, 155.29, 141.87, 129.10, 128.25, 125.72, 79.81, 71.92, 53.35, 52.17, 43.80, 40.10, 37.45, 32.80, 31.17, 30.52, 28.31, 26.36, 23.30, 22.99, 21.45, 18.59, 14.02; ESIMS m/z 514.3 ([M+Na]⁺).

Example 3 Step 3 Preparation of (2S,6R,7R)-6-benzyl-2-((tert-butoxycarbonyl)amino)-7-((S)-1-hydroxyethyl)undecanoic acid

To a solution of (2S,6R,7R)-methyl 7-((S)-1-acetoxyethyl)-6-benzyl-2-((tert-butoxycarbonyl)amino)undecanoate (314 mg, 0.639 mmol) in MeOH (4 mL) and water (2 mL) at room temperature was added LiOH.H₂O (161 mg, 3.83 mmol). The reaction was stirred at room temperature overnight and the solution was diluted with EtOAc, washed with 1 N HCl, the phases separated, and the aqueous phase extracted with additional EtOAc (3×). The combined organic phases were washed with saturated aqueous NaHCO₃, dried over Na₂SO₄, filtered, and concentrated to furnish the title compound (277 mg, 100%) as a white foam: ESIMS m/z 458.3 ([M+Na]⁺).

Example 4 Preparation of tert-butyl((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)carbamate (Compound 127)

A solution of (2S,6R,7R)-6-benzyl-2-((tert-butoxycarbonyl)amino)-7-((S)-1-hydroxyethyl)undecanoic acid (298 mg, 0.684 mmol) in DCM (20 mL) was added over a 3 h period via a syringe pump to a solution of MNBA (377 mg, 1.095 mmol) and DMAP (501 mg, 4.10 mmol) in DCM (117 mL) at room temperature. The reaction mixture was stirred at room temperature overnight, concentrated, and the residue was purified by flash chromatography (SiO₂, 0→10% EtOAc in hexanes) to provide the title compound (202 mg, 70.7%) as a colorless oil, which slowly solidified to a white solid upon drying under vacuum: See Table 2 for characterization data.

Example 5 Steps 1 and 2 Preparation of N-((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (Compounds 99 and 71

Step 1

To a solution of tert-butyl((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)carbamate (194 mg, 0.465 mmol) in DCM (2.5 mL) at room temperature was added HCl (4 M in dioxane, 1.2 mL, 4.8 mmol) and the reaction mixture was stirred at room temperature for 3 h. The solvent was evaporated in vacuo to provide (3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-aminium chloride (99, 142 mg, 86%) as a white solid: See Table 2 for characterization data.

Step 2

To a solution of the amine hydrochloride from step 1 (142 mg, 0.401 mmol) in DCM (4 mL) were added 3-hydroxy-4-methoxypicolinic acid (74.6 mg, 0.441 mmol) and PyBOP (230 mg, 0.441 mmol). To the resulting suspension was added N-ethyl-N-isopropylpropan-2-amine (231 μL, 1.32 mmol) and after 1 h, the reaction was concentrated and the residue was purified by flash chromatography (SiO₂, 0→100% EtOAc in hexanes) to provide the title compound (71, 158 mg, 84%) as a colorless, thick oil: See Table 2 for characterization data.

Example 6 Preparation of ((2-(((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl)oxy)methyl acetate (Compound 2)

To a solution of N-((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (78 mg, 0.166 mmol) in acetone (3 mL) were added bromomethyl acetate (24.48 μL, 0.250 mmol) and K₂CO₃ (46.0 mg, 0.333 mmol), and the solution was heated to 50° C. and stirred for 2 h. The solution was cooled to room temperature and concentrated, and the residue was purified by flash chromatography (SiO₂, 0→100% EtOAc in hexanes) to provide the title compound (71 mg, 79%) as a colorless oil: See Table 2 for characterization data.

Example 7 Preparation of 2-(((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl acetate (Compound 1)

To a solution of N-((3S,7R,8R,9S)-7-benzyl-8-butyl-9-methyl-2-oxooxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (70 mg, 0.149 mmol), DMAP (3.65 mg, 0.030 mmol) and Et₃N (41.6 μL, 0.299 mmol) in DCM (3 mL) was added acetyl chloride (15.9 μL, 0.224 mmol) at room temperature, and the reaction color gradually turned to orange. After stirring at room temperature for 2 h, the reaction mixture was purified by flash chromatography (SiO₂, 0→80% EtOAc in hexanes) to provide the title compound (71 mg, 93%) as a colorless oil: See Table 2 for characterization data.

Example 8 Preparation of ((2-(((3S,7R,8R,9S)-7,8-dibenzyl-9-methyl-2-oxooxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl)oxy)methyl isobutyrate (Compound 7)

To a solution of N-((3S,7R,8R,9S)-7,8-dibenzyl-9-methyl-2-oxooxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (77 mg, 0.153 mmol) in acetone (3 mL) were added chloromethyl isobutyrate (31.4 mg, 0.230 mmol), NaI (4.6 mg, 0.031 mmol) and Na₂CO₃ (32.5 mg, 0.306 mmol), and the solution was heated to 50° C. and stirred for overnight. The solution was cooled to room temperature and concentrated, and the residue was purified by flash chromatography (SiO₂, 0→100% EtOAc in hexanes) to provide the title compound (79 mg, 86%) as a colorless oil: See Table 2 for characterization data.

Example 9 Preparation of ((2-(((3S,7R,8R,9S)-7,8-dibenzyl-9-methyl-2-oxooxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl)oxy)methyl 2-ethoxyacetate (Compound 8)

To a solution of N-((3S,7R,8R,9S)-7,8-dibenzyl-9-methyl-2-oxooxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (77 mg, 0.153 mmol) in acetone (3 mL) were added chloromethyl 2-ethoxyacetate (37.4 mg, 0.245 mmol), NaI (4.6 mg, 0.031 mmol) and Na₂CO₃ (32.5 mg, 0.306 mmol), and the solution was heated to 50° C. and stirred for overnight. The solution was cooled to room temperature and concentrated, and the residue was purified by flash chromatography (SiO₂, 0→100% EtOAc in hexanes) to provide the title compound (74 mg, 78%) as a colorless oil: See Table 2 for characterization data.

Example 10 Preparation of 4-methoxy-2-(((3S,7S,8R,9S)-9-methyl-2-oxo-7-(3-phenylpropyl)-8-(4-(trifluoromethoxy)benzyl)oxonan-3-yl)carbamoyl)pyridin-3-yl isobutyrate (Compound 58)

To a solution of 3-hydroxy-4-methoxy-N-((3S,7S,8R,9S)-9-methyl-2-oxo-7-(3-phenylpropyl)-8-(4-(trifluoromethoxy)benzyl)oxonan-3-yl)picolinamide (70.2 mg, 0.114 mmol), DMAP (3.6 mg, 0.029 mmol), and Et₃N (32 μL, 0.230 mmol) in dichloromethane (1 mL) was added isobutyryl chloride (18 μL, 0.172 mmol) at room temperature. After stirring at room temperature for 3.5 h, the reaction mixture was purified by flash chromatography (SiO₂, 240% acetone in hexanes) to provide the title compound (78 mg, 100%) as a colorless oil: See Table 2 for characterization data.

Example A: Evaluation of Fungicidal Activity: Leaf Blotch of Wheat (Mycosphaerella graminicola; Anamorph: Septoria tritici; Bayer code SEPTTR)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 110 ppm Triton X-100. The fungicide solutions were applied onto wheat seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling. All fungicides were evaluated using the aforementioned method for their activity vs. all target diseases, unless stated otherwise. Wheat leaf blotch and brown rust activity were also evaluated using track spray applications, in which case the fungicides were formulated as EC formulations, containing 0.1% Trycol 5941 in the spray solutions.

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Septoria tritici either prior to or after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. When disease symptoms were fully expressed on the 1^(st) leaves of untreated plants, infection levels were assessed on a scale of 0 to 100 percent disease severity. Percent disease control was calculated using the ratio of disease severity on treated plants relative to untreated plants.

Example B: Evaluation of Fungicidal Activity: Wheat Brown Rust (Puccinia triticina; Synonym: Puccinia recondita f sp. tritici; Bayer code PUCCRT)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Puccinia triticina either prior to or after fungicide treatments. After inoculation the plants were kept in a dark dew room at 22° C. with 100% relative humidity overnight to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 24° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.

Example C: Evaluation of Fungicidal Activity: Wheat Glume Blotch (Leptosphaeria nodorum; Bayer code LEPTNO)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Leptosphaeria nodorum 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.

Example D: Evaluation of Fungicidal Activity: Apple Scab (Venturia inaequalis; Bayer code VENTIN)

Apple seedlings (variety McIntosh) were grown in soil-less Metro mix, with one plant per pot. Seedlings with two expanding young leaves at the top (older leaves at bottom of the plants were trimmed) were used in the test. Plants were inoculated with a spore suspension of Venturia inaequalis 24 hr after fungicide treatment and kept in a 22° C. dew chamber with 100% relative humidity for 48 hr, and then moved to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example E: Evaluation of Fungicidal Activity: Grape Powdery Mildew (Uncinula necator; Bayer code UNCINE)

Grape seedlings (variety Carignane) were grown in soil-less Metro mix, with one plant per pot, and used in the test when approximately one month old. Plants were inoculated 24 hr after fungicide treatment by shaking spores from infected leaves over test plants. Plants were maintained in a greenhouse set at 20° C. until disease was fully developed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example F: Evaluation of Fungicidal Activity: Powdery Mildew of Cucumber (Erysiphe cichoracearum; Bayer code ERYSCI)

Cucumber seedlings (variety Bush Pickle) were grown in soil-less Metro mix, with one plant per pot, and used in the test when 12 to 14 days old. Plants were inoculated with a spore suspension 24 hr following fungicide treatments. After inoculation the plants remained in the greenhouse set at 20° C. until disease was fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example G: Evaluation of Fungicidal Activity: Leaf Spot of Sugar Beets (Cercospora beticola; Bayer code CERCBE)

Sugar beet plants (variety HH88) were grown in soil-less Metro mix and trimmed regularly to maintain a uniform plant size prior to test. Plants were inoculated with a spore suspension 24 hr after fungicide treatments. Inoculated plants were kept in a dew chamber at 22° C. for 48 hr then incubated in a greenhouse set at 24° C. under a clear plastic hood with bottom ventilation until disease symptoms were fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example H: Evaluation of Fungicidal Activity: Asian Soybean Rust (Phakopsora pachyrhizi; Bayer code PHAKPA)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 0.011% Tween 20. The fungicide solutions were applied onto soybean seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling.

Soybean plants (variety Williams 82) were grown in soil-less Metro mix, with one plant per pot. Two weeks old seedlings were used for testing. Plants were inoculated either 3 days prior to or 1 day after fungicide treatments. Plants were incubated for 24 h in a dark dew room at 22° C. and 100% relative humidity then transferred to a growth room at 23° C. for disease to develop. Disease severity was assessed on the sprayed leaves.

Example I: Evaluation of Fungicidal Activity: Barley Powdery Mildew (Blumeria graminis fsp. hordei; Synonym: Erysiphe graminis fsp. hordei; Bayer code ERYSGH)

Barley seedlings (variety Harrington) were propagated in soil-less Metro mix, with each pot having 8 to 12 plants, and used in the test when first leaf was fully emerged. Test plants were inoculated by dusting with infected stock plants 24 hr after fungicide treatments. After inoculation the plants were kept in a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example J: Evaluation of Fungicidal Activity: Barley Scald (Rhyncosporium secalis; Bayer code RHYNSE)

Barley seedlings (variety Harrington) were propagated in soil-less Metro mix, with each pot having 8 to 12 plants, and used in the test when first leaf was fully emerged. Test plants were inoculated by an aqueous spore suspension of Rhyncosporium secalis 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 20° C. with 100% relative humidity for 48 hr. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example K: Evaluation of Fungicidal Activity: Tomato Early Blight (Alternaria solani; Bayer code ALTESO)

Tomato plants (variety Outdoor Girl) were propagated in soil-less Metro mix, with each pot having one plant, and used when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Alternaria solani 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.). to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example L: Evaluation of Fungicidal Activity: Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotrichum lagenarium; Bayer code COLLLA)

Cucumber seedlings (variety Bush Pickle) were propagated in soil-less Metro mix, with each pot having one plant, and used in the test when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Colletotrichum lagenarium 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 22° C. with 100% relative humidity for 48 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room set at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

TABLE 1 Compound Structure and Appearance Prepared According *Cmpd. to No. Structure Example Appearance 1

Example 7 Colorless Oil 2

Example 6 Colorless Oil 3

Example 6 Colorless Gel 4

Example 7 Colorless Oil 5

Example 7 Colorless Oil 6

Example 6 Colorless Foam 7

Example 8 Colorless Foam 8

Example 9 Colorless Oil 9

Example 7 Colorless Oil 10

Example 6 Colorless Oil 11

Example 8 Colorless Oil 12

Example 6 Colorless Oil 13

Example 7 Colorless Oil 14

Example 6 White Solid 15

Example 6 Colorless Solid 16

Example 9 Colorless Thick Oil 17

Example 8 Colorless Solid 18

Example 7 Pale Yellow Oil 19

Example 6 Colorless Solid 20

Example 9 Colorless Oil 21

Example 7 Yellow Oil 22

Example 7 Colorless Oil 23

Example 6 Colorless Oil 24

Example 8 Colorless Oil 25

Example 7 Colorless Oil 26

Example 6 Colorless Oil 27

Example 8 Colorless Oil 28

Example 7 Colorless Oil 29

Example 6 Colorless Oil 30

Example 8 Colorless Oil 31

Example 9 Colorless Oil 32

Example 6 White Foam 33

Example 7 Light Yellow Oil 34

Example 6 Colorless Oil 35

Example 9 Colorless Oil 36

Example 7 Yellow Oil 37

Example 6 Colorless Oil 38

Example 7 Yellow Oil 39

Example 6 White Foam 40

Example 7 Light Orange Foam 41

Example 8 White Foam 42

Example 6 Colorless Oil 43

Example 7 Light Orange Foam 44

Example 8 Colorless Oil 45

Example 7 Colorless Oil 46

Example 7 Colorless Oil 47

Example 6 Colorless Oil 48

Example 6 Colorless Oil 49

Example 10 Colorless Oil 50

Example 8 Colorless Oil 51

Example 9 Colorless Oil 52

Example 6 White Foam 53

Example 7 Light Orange Foam 54

Example 6 Light Yellow Oil 55

Example 7 Orange Foam 56

Example 7 Colorless Oil 57

Example 7 Colorless Oil 58

Example 10 Colorless Oil 59

Example 6 Colorless Oil 60

Example 7 Colorless Oil 61

Example 6 Colorless Oil 62

Example 7 Colorless Oil 63

Example 6 Colorless Oil 64

Example 8 Colorless Oil 65

Example 6 Colorless Foam 66

Example 9 Colorless Foam 67

Example 7 Pale Yellow Foam 68

Example 6 Colorless Foam 69

Example 9 Colorless Foam 70

Example 6 Colorless Foam 71

Example 5, Step 2 Colorless Oil 72

Example 5, Step 2 White Foam 73

Example 5, Step 2 White Foam 74

Example 5, Step 2 White Foam 75

Example 5, Step 2 Colorless Foam 76

Example 5, Step 2 Colorless Oil 77

Example 5, Step 2 White Solid 78

Example 5, Step 2 Colorless Solid 79

Example 5, Step 2 Colorless Solid 80

Example 5, Step 2 White Foam 81

Example 5, Step 2 Colorless Oil 82

Example 5, Step 2 Colorless Solid 83

Example 5, Step 2 Colorless Solid 84

Example 5, Step 2 Colorless Oil 85

Example 5, Step 2 White Foam 86

Example 5, Step 2 White Foam 87

Example 5, Step 2 White Powder 88

Example 5, Step 2 Colorless Oil 89

Example 5, Step 2 Colorless Oil 90

Example 5, Step 2 White Foam 91

Example 5, Step 2 White Foam 92

Example 5, Step 2 White Foam 93

Example 5, Step 2 White Solid 94

Example 5, Step 2 White Foam 95

Example 5, Step 2 White Foam 96

Example 5, Step 2 Colorless Solid 97

Example 5, Step 2 Colorless Solid 98

Example 5, Step 2 Thick Colorless Oil 99

Example 5, Step 1 White Solid 100

Example 5, Step 1 White Solid 101

Example 5, Step 1 White Foam 102

Example 5, Step 1 White Foam 103

Example 5, Step 1 White Solid 104

Example 5, Step 1 White Solid 105

Example 5, Step 1 White Solid 106

Example 5, Step 1 White Foam 107

Example 5, Step 1 Colorless Oil 108

Example 5, Step 1 White Solid 109

Example 5, Step 1 White Solid 110

Example 5, Step 1 White Solid 111

Example 5, Step 1 Off-White Solid 112

Example 5, Step 1 Off-White Solid 113

Example 5, Step 1 Yellow Foam 114

Example 5, Step 1 White Solid 115

Example 5, Step 1 White Solid 116

Example 5, Step 1 White Solid 117

Example 5, Step 1 White Solid 118

Example 5, Step 1 White Foam 119

Example 5, Step 1 White Foam 120

Example 5, Step 1 White Solid 121

Example 5, Step 1 White Solid 122

Example 5, Step 1 White Foam 123

Example 5, Step 1 White Solid 124

Example 5, Step 1 White Solid 125

Example 5, Step 1 White Solid 126

Example 5, Step 1 White Solid 127

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 128

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 129

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 130

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 131

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 132

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 133

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 134

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 135

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Foam 136

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 137

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 138

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 139

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 140

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 White Solid 141

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 142

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 143

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 144

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 145

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 146

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 147

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 148

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 149

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Tacky White Solid 150

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 151

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Oil 152

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Colorless Solid 153

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Sticky Colorless Solid 154

Example 1, Steps 1-3; Example 2, Steps 1a-c, Step 2; Example 3, Steps 1-3; Example 4 Sticky Colorless Solid

TABLE 2 Analytical Data *Cmpd. MP IR NMR No. (° C.) (cm⁻¹) MASS (¹H, ¹³C or ¹⁹F) 1 — — HRMS-FAB ¹H NMR (CDCl₃) 8.60-8.43 (m, 1H), 8.31 (d, J = (m/z) 5.4 Hz, 1H), 7.33-7.11 (m, 5H), 6.98 (d, J = [M + H]⁺ 5.5 Hz, 1H), 4.82 (dq, J = 9.6, 6.3 Hz, 1H), 4.56 calcd for (ddd, J = 11.0, 8.5, 7.3 Hz, 1H), 3.88 (s, 3H), C₂₉H₃₉N₂O₆, 2.91-2.79 (m, 1H), 2.40 (s, 3H), 2.38-2.23 (m, 511.2811; 2H), 1.79 (ddt, J = 11.0, 8.0, 3.2 Hz, 1H), 1.69- found, 1.11 (m, 11H), 1.35 (d, J = 6.3 Hz, 3H); 0.94 (t, J = 511.2805 7.2 Hz, 3H), 0.79 (ddd, J = 13.5, 10.9, 7.1 Hz, 1H) ¹³C NMR (CDCl₃) 172.46, 168.90, 162.39, 159.40, 146.71, 141.53, 141.18, 137.44, 128.73, 128.33, 125.86, 109.75, 75.36, 56.27, 51.15, 45.31, 42.60, 37.88, 33.40, 29.35, 27.82, 27.48, 23.51, 20.76, 19.66, 18.55, 14.04 2 — — HRMS-FAB ¹H NMR (CDCl₃) 8.29 (d, J = 8.5 Hz, 1H), 8.27 (m/z) (d, J = 5.4 Hz, 1H), 7.31-7.12 (m, 5H), 6.93 (d, [M + H]⁺ J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.83 (dq, J = 9.6, calcd for 6.3 Hz, 1H), 4.63-4.53 (m, 1H), 3.90 (s, 3H), C₃₀H₄₁N₂O₇, 2.91-2.80 (m, 1H), 2.41-2.27 (m, 2H), 2.07 (s, 541.2921; 3H), 1.85-1.74 (m, 1H), 1.71-1.13 (m, 11H), found, 1.36 (d, J = 6.3 Hz, 1H), 0.94 (t, J = 7.2 Hz, 3H), 541.2916 0.86-0.74 (m, 1H) ¹³C NMR (CDCl₃) 172.58, 170.27, 162.96, 160.23, 145.76, 143.87, 142.61, 141.19, 128.73, 128.32, 125.86, 109.55, 89.53, 75.35, 56.18, 51.41, 45.32, 42.60, 37.88, 33.23, 29.36, 27.82, 27.48, 23.51, 20.89, 19.68, 18.59, 14.04 3 — — HRMS-FAB ¹H NMR (CDCl₃) 8.36-8.17 (m, 2H), 7.65- (m/z) 7.47 (m, 2H), 7.31-7.17 (m, 2H), 6.94 (d, J = [M + H]⁺ 5.4 Hz, 1H), 5.74 (s, 2H), 4.83 (dq, J = 9.7, 6.3 calcd for Hz, 1H), 4.63-4.53 (m, 1H), 3.90 (s, 3H), 2.95- C₃₁H₄₀F₃N₂O₇, 2.82 (m, 1H), 2.43 (dd, J = 13.8, 11.3 Hz, 1H), 609.2806; 2.33 (dt, J = 13.5, 6.8 Hz, 1H), 2.06 (s, 3H), 1.86- found, 1.76 (m, 1H), 1.71-1.60 (m, 2H), 1.60-1.10 609.2801 (m, 11H), 1.37 (d, J = 6.3 Hz, 1H), 0.94 (t, J = 7.1 Hz, 3H), 0.83 (ddd, J = 15.1, 8.2, 2.8 Hz, 1H) ¹⁹F NMR (CDCl₃) −62.3 4 — — HRMS-FAB ¹H NMR (CDCl₃) 8.55 (d, J = 8.6 Hz, 1H), 8.33 (m/z) (d, J = 5.4 Hz, 1H), 7.36-7.15 (m, 5H), 6.99 (d, [M + H]⁺ J = 5.4 Hz, 1H), 4.87 (dq, J = 9.6, 6.4 Hz, 1H), calcd for 4.54 (ddd, J = 10.9, 8.3, 7.1 Hz, 1H), 3.89 (s, C₃₀H₄₁N₂O₆, 3H), 2.75 (dd, J = 15.4, 3.2 Hz, 1H), 2.56 (dd, J = 525.2963; 15.4, 7.7 Hz, 1H), 2.39 (s, 3H), 2.37-2.29 (m, found, 1H), 1.99-1.88 (m, 1H), 1.84-1.74 (m, 1H), 525.2957 1.66-1.51 (m, 2H), 1.51-1.34 (m, 2H), 1.33- 1.22 (m, 4H), 1.19 (d, J = 6.4 Hz, 3H), 1.06- 0.89 (m, 2H), 0.84 (d, J = 6.6 Hz, 6H) ¹³C NMR (CDCl₃) δ 172.49, 168.91, 162.37, 159.41, 146.71, 141.56, 141.00, 137.44, 128.83, 128.40, 125.97, 109.74, 76.20, 56.27, 51.32, 47.54, 42.28, 37.53, 36.77, 33.38, 29.33, 28.24, 27.87, 23.03, 22.32, 20.75, 18.55 5 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.61-8.39 (m, 1H), 8.31 (d, (m/z) J = 5.4 Hz, 1H), 7.38-7.05 (m, 10H), 6.97 (d, J = [M + H]⁺ 5.5 Hz, 1H), 4.93 (dq, J = 9.7, 6.4 Hz, 1H), calcd for 4.57 (ddd, J = 10.9, 8.4, 7.1 Hz, 1H), 3.87 (s, C₃₂H₃₇N₂O₆, 3H), 2.96 (td, J = 15.6, 3.3 Hz, 2H), 2.72 (dd, J = 545.2653; 15.6, 7.5 Hz, 1H), 2.48-2.39 (m, 1H), 2.39 (s, found, 3H), 2.30 (dt, J = 13.4, 6.8 Hz, 1H), 2.11 (dtd, J = 545.2648 9.8, 7.1, 3.8 Hz, 1H), 1.81-1.38 (m, 4H), 1.27 (d, J = 6.3 Hz, 3H), 1.24-1.10 (m, 1H), 0.90- 0.80 (m, 1H) ¹³C NMR (CDCl₃) δ 172.38, 168.92, 162.41, 159.42, 146.72, 141.52, 140.77, 140.56, 137.46, 128.89, 128.71, 128.57, 128.33, 126.23, 125.94, 109.78, 76.00, 56.29, 51.23, 46.88, 44.26, 37.86, 37.33, 33.41, 27.46, 20.77, 20.73, 18.74 6 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.39-7.04 (m, 10H), [M + H]⁺ 6.93 (d, J = 5.4 Hz, 1H), 5.73 (s, 2H), 4.93 (dq, J = calcd for 9.7, 6.4 Hz, 1H), 4.58 (dt, J = 11.0, 7.5 Hz, C₃₃H₃₉N₂O₇, 1H), 3.89 (s, 3H), 3.08-2.88 (m, 2H), 2.73 (dd, 575.2757; J = 15.6, 7.5 Hz, 1H), 2.43 (dd, J = 13.8, 11.6 Hz, found, 1H), 2.33 (dt, J = 13.5, 6.8 Hz, 1H), 2.12 (tdd, J = 575.2745 10.0, 5.9, 3.0 Hz, 1H), 2.06 (s, 3H), 1.77-1.39 (m, 4H), 1.28 (d, J = 6.4 Hz, 3H), 1.24-1.09 (m, 1H), 0.89-0.81 (m, 1H) ¹³C NMR (CDCl₃) δ 172.49, 170.27, 162.96, 160.23, 145.76, 143.88, 142.59, 140.77, 140.55, 128.89, 128.71, 128.56, 128.32, 126.22, 125.93, 109.56, 89.51, 75.97, 56.18, 51.48, 46.86, 44.25, 37.85, 37.32, 33.24, 27.45, 20.89, 20.74, 18.76 7 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.1 Hz, 1H), (m/z) 8.25 (d, J = 5.4 Hz, 1H), 7.35-7.08 (m, 10H), [M + H]⁺ 6.92 (d, J = 5.4 Hz, 1H), 5.81-5.72 (m, 2H), calcd for 4.94 (dq, J = 9.7, 6.3 Hz, 1H), 4.58 (ddd, J = C₃₅H₄₃N₂O₇, 11.0, 8.1, 7.1 Hz, 1H), 3.87 (s, 3H), 3.06-2.90 603.3070; (m, 2H), 2.72 (dd, J = 15.6, 7.5 Hz, 1H), 2.53 found, (hept, J = 7.0 Hz, 1H), 2.44 (dd, J = 13.8, 11.6 603.3067 Hz, 1H), 2.37-2.28 (m, 1H), 2.17-2.07 (m, 1H), 1.82-1.64 (m, 2H), 1.64-1.52 (m, 1H), 1.46 (tdd, J = 14.9, 8.9, 4.4 Hz, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.25-1.15 (m, 1H), 1.13 (d, J = 7.0 Hz, 6H), 0.90-0.78 (m, 1H) ¹³C NMR (CDCl₃) δ 176.23, 172.48, 162.94, 160.22, 145.62, 144.10, 142.24, 140.77, 140.57, 128.89, 128.71, 128.56, 128.32, 126.22, 125.93, 109.52, 89.87, 75.95, 56.14, 51.47, 46.87, 44.25, 37.85, 37.33, 33.86, 33.24, 27.45, 20.74, 18.77, 18.69 8 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.4 Hz, 1H), 7.35-7.07 (m, 10H), [M + H]⁺ 6.93 (d, J = 5.4 Hz, 1H), 5.81 (s, 2H), 4.93 (dq, J = calcd for 9.7, 6.3 Hz, 1H), 4.57 (ddd, J = 11.0, 8.1, 7.1 C₃₅H₄₃N₂O₈, Hz, 1H), 4.09 (s, 2H), 3.88 (s, 3H), 3.58 (q, J = 619.3019; 7.0 Hz, 2H), 3.03-2.89 (m, 2H), 2.73 (dd, J = found, 15.6, 7.5 Hz, 1H), 2.43 (dd, J = 13.8, 11.6 Hz, 619.3018 1H), 2.37-2.27 (m, 1H), 2.16-2.06 (m, 1H), 1.79-1.38 (m, 4H), 1.28 (d, J = 6.4 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H), 1.19-1.11 (m, 1H), 0.89-0.81 (m, 1H) ¹³C NMR (CDCl₃) δ 172.46, 170.05, 162.91, 160.15, 145.80, 143.85, 142.42, 140.76, 140.55, 128.88, 128.70, 128.56, 128.32, 126.22, 125.93, 109.67, 89.54, 75.99, 67.80, 67.18, 56.22, 51.47, 46.87, 44.23, 37.86, 37.32, 33.24, 27.46, 20.75, 18.76, 15.02 9 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.55 (s, 1H), 8.32 (d, J = 5.9 (m/z) Hz, 1H), 7.32-7.15 (m, 5H), 6.99 (d, J = 5.4 Hz, [M + H]⁺ 1H), 4.96 (dq, J = 8.5, 6.3 Hz, 1H), 4.56 (ddd, J = calcd for 11.1, 8.3, 6.6 Hz, 1H), 3.89 (s, 3H), 2.85 (dd, J = C₃₀H₃₉N₂O₆, 14.4, 3.6 Hz, 1H), 2.61 (dd, J = 14.2, 11.2 Hz, 523.2808; 1H), 2.40 (s, 3H), 2.30-2.19 (m, 1H), 2.12- found, 1.98 (m, 2H), 1.89-1.41 (m, 10H), 1.39 (d, J = 523.2797 6.3 Hz, 3H), 1.37-1.14 (m, 3H), 0.89-0.79 (m, 1H) ¹³C NMR (CDCl₃) δ 172.46, 168.92, 162.37, 159.40, 146.69, 141.54, 141.08, 137.44, 128.64, 128.28, 125.87, 109.74, 74.67, 56.28, 51.72, 48.73, 42.58, 40.11, 39.46, 33.56, 29.50, 28.75, 27.75, 25.22, 24.48, 21.46, 20.77, 19.59 10 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.0 Hz, 1H), (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.32-7.17 (m, 5H), [M + H]⁺ 6.94 (d, J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.96 (dq, J = calcd for 8.7, 6.3 Hz, 1H), 4.58 (ddd, J = 11.2, 8.0, 6.6 C₃₁H₄₁N₂O₇, Hz, 1H), 3.90 (s, 3H), 2.86 (dd, J = 14.2, 3.8 Hz, 553.2914; 1H), 2.62 (dd, J = 14.2, 11.2 Hz, 1H), 2.27 (dt, J = found, 13.4, 6.8 Hz, 1H), 2.13-1.97 (m, 2H), 2.07 (s, 553.2904 3H), 1.85-1.45 (m, 10H), 1.40 (d, J = 6.2 Hz, 3H), 1.39-1.15 (m, 3H), 0.92-0.78 (m, 1H) ¹³C NMR (CDCl₃) δ 172.56, 170.27, 162.95, 160.23, 145.76, 143.86, 142.63, 141.08, 128.64, 128.28, 125.87, 109.55, 89.53, 74.66, 56.18, 51.95, 48.67, 42.56, 40.11, 39.45, 33.37, 29.48, 28.71, 27.76, 25.22, 24.46, 21.45, 20.89, 19.61 11 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.39 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.37-7.13 (m, 5H), [M + H]⁺ 6.93 (d, J = 5.4 Hz, 1H), 5.86-5.67 (m, 2H), calcd for 4.97 (dq, J = 8.5, 6.3 Hz, 1H), 4.57 (ddd, J = C₃₃H₄₅N₂O₇, 11.1, 8.1, 6.6 Hz, 1H), 3.88 (s, 3H), 2.92-2.80 581.3227; (m, 1H), 2.62 (dd, J = 14.2, 11.3 Hz, 1H), 2.60- found, 2.46 (m, 1H), 2.27 (dt, J = 13.4, 6.8 Hz, 1H), 581.3215 2.13-1.98 (m, 2H), 1.83-1.45 (m, 10H), 1.40 (d, J = 6.3 Hz, 3H), 1.38-1.20 (m, 3H), 1.14 (d, J = 7.0 Hz, 6H), 0.91-0.81 (m, 1H) ¹³C NMR (CDCl₃) δ 176.24, 172.56, 162.92, 160.22, 145.63, 144.10, 142.26, 141.09, 128.64, 128.28, 125.87, 109.49, 89.90, 74.64, 56.13, 51.94, 48.66, 42.56, 40.10, 39.45, 33.86, 33.37, 29.48, 28.71, 27.76, 25.22, 24.46, 21.45, 19.62, 18.69 12 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.6 Hz, 1H), (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.27-7.20 (m, 2H), [M + H]⁺ 7.15-7.03 (m, 2H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.74 (s, 2H), 4.75 (dq, J = 9.4, 6.4 Hz, 1H), 4.58 C₃₀H₄₀ClN₂O₇, (ddd, J = 11.0, 8.1, 7.1 Hz, 1H), 3.90 (s, 3H), 575.2524; 2.93-2.77 (m, 1H), 2.42-2.25 (m, 2H), 2.07 (s, found, 3H), 1.77-1.49 (m, 5H), 1.44-1.32 (m, 2H), 575.2523 1.37 (d, J = 6.3 Hz, 3H), 1.24-1.06 (m, 2H), 0.98 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.86-0.77 (m, 1H) ¹³C NMR (CDCl₃) δ 172.53, 170.26, 162.96, 160.22, 145.75, 143.87, 142.55, 139.52, 131.56, 130.01, 128.43, 109.57, 89.50, 76.69, 56.18, 51.39, 45.92, 43.72, 41.55, 36.81, 33.22, 27.56, 27.28, 24.09, 21.96, 20.88, 19.72, 18.53 13 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.5 Hz, 1H), (m/z) 8.31 (d, J = 5.4 Hz, 1H), 7.26-7.20 (m, 2H), [M + H]⁺ 7.13-7.03 (m, 2H), 6.99 (d, J = 5.5 Hz, 1H), calcd for 4.74 (dq, J = 9.2, 6.3 Hz, 1H), 4.56 (ddd, J = C₂₉H₃₈ClN₂O₆, 10.9, 8.4, 7.1 Hz, 1H), 3.88 (s, 3H), 2.92-2.77 545.2418; (m, 1H), 2.40 (s, 3H), 2.35-2.24 (m, 2H), 1.80- found, 1.46 (m, 5H), 1.43-1.28 (m, 2H), 1.36 (d, J = 545.2417 6.5 Hz, 3H), 1.22-1.05 (m, 2H), 0.98 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H), 0.85-0.71 (m, 1H) ¹³C NMR (CDCl₃) δ 172.42, 168.89, 162.39, 159.40, 146.71, 141.48, 139.52, 137.43, 131.57, 130.01, 128.43, 109.77, 76.70, 56.27, 51.13, 45.92, 43.71, 41.54, 36.80, 33.39, 27.56, 27.29, 24.09, 21.97, 20.76, 19.70, 18.49 14 60-64 — ESIMS ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.1 Hz, 1H), m/z 541 8.26 (d, J = 5.4 Hz, 1H), 7.32-7.25 (m, 2H), [M + H]⁺ 7.22-7.13 (m, 3H), 6.93 (d, J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.76 (dq, J = 8.9, 6.3 Hz, 1H), 4.58 (dt, J = 11.0, 7.5 Hz, 1H), 3.90 (s, 3H), 2.89 (d, J = 14.0 Hz, 1H), 2.37-2.27 (m, 2H), 2.11-2.02 (m, 3H), 1.80-1.48 (m, 5H), 1.47-1.33 (m, 5H), 1.24-1.09 (m, 2H), 0.98 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 0.88-0.77 (m, 1H) ¹³C NMR (CDCl₃) δ 172.57, 170.24, 162.92, 160.20, 145.71, 143.86, 142.59, 141.08, 128.67, 128.28, 125.84, 109.49, 89.52, 76.78, 56.14, 51.40, 45.96, 43.73, 41.54, 37.40, 33.29, 27.57, 27.31, 24.10, 21.94, 20.86, 19.72, 18.54 15 89-91 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.6 Hz, 1H), 3383, (m/z) 8.28 (d, J = 5.4 Hz, 1H), 7.35-7.26 (m, 4H), 2940, [M]⁺ 7.24-7.13 (m, 6H), 6.94 (d, J = 5.4 Hz, 1H), 1739, calcd for 5.75 (s, 2H), 4.98-4.88 (m, 1H), 4.65-4.56 (m, 1676, C₃₄H₄₀N₂O₇, 1H), 3.91 (s, 3H), 2.90-2.72 (m, 2H), 2.61- 1504, 588.2836; 2.48 (m, 1H), 2.42-2.28 (m, 2H), 2.07 (s, 3H), 1370, found, 1.96-1.72 (m, 4H), 1.72-1.47 (m, 3H), 1.48 (d, 1203 588.2839 J = 6.3 Hz, 3H), 1.28-1.15 (m, 1H), 0.91-0.77 (m, 1H) 16 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.2 Hz, 1H), 3380, (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.34-7.26 (m, 4H), 2940, [M]⁺ 7.25-7.13 (m, 6H), 6.94 (d, J = 5.4 Hz, 1H), 1738, calcd for 5.83 (s, 2H), 4.98-4.87 (m, 1H), 4.64-4.53 (m, 1677, C₃₆H₄₄N₂O₈, 1H), 4.10 (s, 2H), 3.90 (s, 3H), 3.59 (q, J = 7.0 1504, 632.3098; Hz, 2H), 2.89-2.72 (m, 2H), 2.60-2.48 (m, 1210 found, 1H), 2.42-2.27 (m, 2H), 1.96-1.72 (m, 4H), 632.3097 1.71-1.48 (m, 3H), 1.48 (d, J = 6.3 Hz, 3H), 1.27-1.16 (m, 1H), 1.23 (t, J = 7.0 Hz, 3H), 0.90-0.79 (m, 1H) 17 79-81 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.2 Hz, 1H), 3382, (m/z) 8.27 (d, J = 5.3 Hz, 1H), 7.35-7.26 (m, 4H), 2939, [M]⁺ 7.24-7.12 (m, 6H), 6.93 (d, J = 5.4 Hz, 1H), 1741, calcd for 5.81-5.74 (m, 2H), 4.98-4.88 (m, 1H), 4.65- 1676, C₃₆H₄₄N₂O₇, 4.55 (m, 1H), 3.89 (s, 3H), 2.92-2.70 (m, 2H), 1504, 616.3149; 2.62-2.48 (m, 2H), 2.42-2.28 (m, 2H), 1.96- 1315, found, 1.72 (m, 4H), 1.71-1.47 (m, 3H), 1.48 (d, J = 1210 616.3159 6.3 Hz, 3H), 1.30-1.17 (m, 1H), 1.15 (d, J = 7.0 Hz, 6H), 0.91-0.79 (m, 1H) 18 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.51 (d, J = 6.8 Hz, 1H), 3378, (m/z) 8.33 (d, J = 5.4 Hz, 1H), 7.34-7.26 (m, 4H), 2940, [M]⁺ 7.24-7.12 (m, 6H), 6.99 (d, J = 5.5 Hz, 1H), 1737, calcd for 4.98-4.87 (m, 1H), 4.64-4.53 (m, 1H), 3.90 (s, 1677, C₃₃H₃₈N₂O₆, 3H), 2.89-2.71 (m, 2H), 2.59-2.48 (m, 1H), 1508, 558.2730; 2.40 (s, 3H), 2.40-2.25 (m, 2H), 1.95-1.72 (m, 1369, found, 4H), 1.70-1.48 (m, 3H), 1.46 (d, J = 6.3 Hz, 1200 558.2732 3H), 1.28-1.14 (m, 1H), 0.91-0.77 (m, 1H) 19  98-100 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.4 Hz, 1H), 3380, (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.36-7.30 (m, 2H), 2938, [M]⁺ 7.29-7.19 (m, 5H), 7.03-6.98 (m, 2H), 6.93 (d, 2249, calcd for J = 5.4 Hz, 1H), 5.73 (s, 2H), 4.99-4.87 (m, 1737, C₃₃H₃₇ClN₂O₇, 1H), 4.64-4.53 (m, 1H), 3.90 (s, 3H), 2.95 (dd, 1675, 608.2289; J = 15.6, 3.3 Hz, 1H), 2.91-2.83 (m, 1H), 2.74 1495, found, (dd, J = 15.7, 7.5 Hz, 1H), 2.46-2.28 (m, 2H), 1202 608.2293 2.16-2.05 (m, 1H), 2.06 (s, 3H), 1.79-1.62 (m, 2H), 1.59-1.35 (m, 2H), 1.29 (d, J = 6.4 Hz, 3H), 1.27-1.13 (m, 1H), 0.90-0.79 (m, 1H) 20 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.1 Hz, 1H), 3380, (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.35-7.30 (m, 2H), 2938, [M]⁺ 7.28-7.18 (m, 5H), 7.04-6.98 (m, 2H), 6.93 (d, 2249, calcd for J = 5.4 Hz, 1H), 5.81 (s, 2H), 4.99-4.88 (m, 1736, C₃₅H₄₁ClN₂O₈, 1H), 4.61-4.52 (m, 1H), 4.09 (s, 2H), 3.90 (s, 1675, 652.2551; 3H), 3.58 (q, J = 7.0 Hz, 2H), 2.95 (dd, J = 15.6, 1505, found, 3.3 Hz, 1H), 2.92-2.83 (m, 1H), 2.74 (dd, J = 1207 652.2550 15.6, 7.4 Hz, 1H), 2.46-2.26 (m, 2H), 2.16- 2.05 (m, 1H), 1.79-1.35 (m, 4H), 1.29 (d, J = 6.4 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H), 1.24-1.13 (m, 1H), 0.90-0.78 (m, 1H) 21 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.4 Hz, 1H), 3377, (m/z) 8.33 (d, J = 5.4 Hz, 1H), 7.35-7.29 (m, 2H), 2939, [M]⁺ 7.28-7.19 (m, 5H), 7.03-6.96 (m, 3H), 4.99- 1736, calcd for 4.87 (m, 1H), 4.62-4.51 (m, 1H), 3.90 (s, 3H), 1675, C₃₂H₃₅ClN₂O₆, 2.94 (dd, J = 15.6, 3.3 Hz, 1H), 2.91-2.82 (m, 1508, 578.2184; 1H), 2.73 (dd, J = 15.6, 7.4 Hz, 1H), 2.39 (s, 3H), 1370, found, 2.45-2.34 (m, 1H), 2.35-2.25 (m, 1H), 2.14- 1199 578.2184 2.04 (m, 1H), 1.77-1.35 (m, 4H), 1.28 (d, J = 6.4 Hz, 3H), 1.23-1.12 (m, 1H), 0.89-0.79 (m, 1H) 22 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.4 Hz, 1H), (m/z) 8.32 (d, J = 5.4 Hz, 1H), 7.58-7.48 (m, 2H), [M + H]⁺ 7.36-7.21 (m, 2H), 6.99 (d, J = 5.5 Hz, 1H), calcd for 4.76 (dq, J = 9.1, 6.3 Hz, 1H), 4.57 (ddd, J = C₃₀H₃₈F₃N₂O₆, 11.0, 8.3, 7.1 Hz, 1H), 3.89 (s, 3H), 2.92 (d, J = 579.2682; 13.7 Hz, 1H), 2.43-2.36 (m, 1H), 2.40 (s, 3H), found, 2.30 (dt, J = 13.5, 6.9 Hz, 1H), 1.78-1.48 (m, 579.2669 5H), 1.44-1.30 (m, 2H), 1.37 (d, J = 6.4 Hz, 3H), 1.24-1.07 (m, 2H), 0.99 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.90-0.81 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.77 23 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.1 Hz, 1H), (m/z) 8.27 (d, J = 5.3 Hz, 1H), 7.54 (dd, J = 8.2, 1.0 [M + H]⁺ Hz, 2H), 7.31-7.24 (m, 2H), 6.94 (d, J = 5.4 Hz, calcd for 1H), 5.74 (s, 2H), 4.77 (dq, J = 9.0, 6.3 Hz, 1H), C₃₁H₄₀F₃N₂O₇, 4.66-4.52 (m, 1H), 3.90 (s, 3H), 3.01-2.85 (m, 609.2787; 1H), 2.41 (dd, J = 13.8, 10.9 Hz, 1H), 2.33 (dt, J = found, 13.5, 6.8 Hz, 1H), 2.07 (s, 3H), 1.79-1.53 (m, 609.2774 5H), 1.45-1.33 (m, 2H), 1.38 (d, J = 6.4 Hz, 3H), 1.23-1.08 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.91-0.81 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.28 24 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.4 Hz, 1H), 7.59-7.49 (m, 2H), [M + H]⁺ 7.34-7.23 (m, 2H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.87-5.73 (m, 2H), 4.77 (dq, J = 8.8, 6.3 Hz, C₃₃H₄₄F₃N₂O₇, 1H), 4.59 (ddd, J = 11.0, 8.1, 7.1 Hz, 1H), 3.88 637.3100; (s, 3H), 3.00-2.88 (m, 1H), 2.55 (hept, J = 7.0 found, Hz, 1H), 2.41 (dd, J = 13.8, 10.9 Hz, 1H), 2.37- 637.3089 2.28 (m, 1H), 1.80-1.47 (m, 5H), 1.45-1.17 (m, 4H), 1.14 (d, J = 7.0 Hz, 6H), 0.99 (d, J = 6.5 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H), 0.91-0.82 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.28 25 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.4 Hz, 1H), (m/z) 8.32 (d, J = 5.4 Hz, 1H), 7.55-7.12 (m, 9H), [M + H]⁺ 6.99 (d, J = 5.5 Hz, 1H), 4.94 (dq, J = 9.7, 6.3 calcd for Hz, 1H), 4.57 (ddd, J = 10.9, 8.4, 7.1 Hz, 1H), C₃₃H₃₆F₃N₂O₆, 3.89 (s, 3H), 2.94 (ddd, J = 12.2, 9.7, 3.2 Hz, 613.2525; 2H), 2.76 (dd, J = 15.6, 7.3 Hz, 1H), 2.48 (dd, J = found, 13.9, 11.6 Hz, 1H), 2.39 (s, 3H), 2.31 (dt, J = 613.2517 13.5, 7.0 Hz, 1H), 2.12 (tdd, J = 9.9, 7.2, 3.5 Hz, 1H), 1.83-1.74 (m, 1H), 1.71-1.63 (m, 1H), 1.57-1.47 (m, 1H), 1.43-1.34 (m, 1H), 1.30 (d, J = 6.4 Hz, 3H), 1.23-1.13 (m, 1H), 0.89-0.82 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.29 26 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.1 Hz, 1H), (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.55-7.12 (m, 9H), [M + H]⁺ 6.94 (d, J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.95 (dq, J = calcd for 9.6, 6.3 Hz, 1H), 4.59 (ddd, J = 11.0, 8.1, 7.0 C₃₄H₃₈F₃N₂O₇, Hz, 1H), 3.90 (s, 3H), 3.05-2.86 (m, 2H), 2.77 643.2631; (dd, J = 15.6, 7.3 Hz, 1H), 2.49 (dd, J = 13.8, found, 11.7 Hz, 1H), 2.34 (dt, J = 13.5, 6.6 Hz, 1H), 643.2622 2.17-2.09 (m, 1H), 2.06 (s, 3H), 1.83-1.75 (m, 1H), 1.74-1.66 (m, 1H), 1.60-1.48 (m, 1H), 1.44-1.35 (m, 1H), 1.31 (d, J = 6.4 Hz, 3H), 1.24-1.13 (m, 1H), 0.88-0.83 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.29 27 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.55-7.14 (m, 9H), [M + H]⁺ 6.93 (d, J = 5.4 Hz, 1H), 5.83-5.72 (m, 2H), calcd for 4.95 (dq, J = 9.6, 6.3 Hz, 1H), 4.59 (ddd, J = C₃₆H₄₂F₃N₂O₇, 11.0, 8.2, 7.1 Hz, 1H), 3.88 (s, 3H), 3.04-2.86 671.2944; (m, 2H), 2.77 (dd, J = 15.6, 7.3 Hz, 1H), 2.62- found, 2.44 (m, 2H), 2.33 (dt, J = 13.5, 6.9 Hz, 1H), 671.2936 2.17-2.08 (m, 1H), 1.86-1.75 (m, 1H), 1.74- 1.66 (m, 1H), 1.61-1.48 (m, 1H), 1.46-1.33 (m, 1H), 1.31 (d, J = 6.4 Hz, 3H), 1.28-1.20 (m, 1H), 1.14 (d, J = 7.0 Hz, 6H), 0.89-0.83 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.29 28 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.70-8.49 (m, 1H), 8.32 (d, (m/z) J = 5.4 Hz, 1H), 7.26-7.18 (m, 2H), 7.16-7.07 [M + H]⁺ (m, 2H), 6.99 (d, J = 5.4 Hz, 1H), 4.96 (dq, J = calcd for 8.4, 6.3 Hz, 1H), 4.55 (ddd, J = 11.1, 8.3, 6.6 Hz, C₃₀H₃₈ClN₂O₆, 1H), 3.89 (s, 3H), 2.86-2.72 (m, 1H), 2.59 (dd, 557.2418; J = 14.3, 11.2 Hz, 1H), 2.40 (s, 3H), 2.25 (dt, J = found, 13.5, 6.9 Hz, 1H), 2.11-1.92 (m, 2H), 1.86- 557.2416 1.80 (m, 1H), 1.75-1.49 (m, 8H), 1.38 (d, J = 6.3 Hz, 3H), 1.36-1.15 (m, 4H), 0.90-0.83 (m, 1H) ¹³C NMR (CDCl₃) δ 172.39, 168.90, 162.39, 159.41, 146.71, 141.51, 139.51, 137.44, 131.53, 129.95, 128.40, 109.76, 74.53, 56.28, 51.68, 48.82, 42.59, 40.08, 38.82, 33.52, 29.57, 28.81, 27.63, 25.18, 24.46, 21.48, 20.76, 19.54 29 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.0 Hz, 1H), (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.26-7.22 (m, 2H), [M + H]⁺ 7.16-7.09 (m, 2H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.74 (s, 2H), 4.97 (dq, J = 8.5, 6.3 Hz, 1H), 4.57 C₃₁H₄₀ClN₂O₇, (ddd, J = 11.1, 8.0, 6.6 Hz, 1H), 3.90 (s, 3H), 587.2524; 2.81 (dd, J = 14.3, 3.8 Hz, 1H), 2.61 (dd, J = found, 14.2, 11.2 Hz, 1H), 2.27 (dt, J = 13.4, 6.8 Hz, 587.2518 1H), 2.07 (s, 3H), 2.09-1.93 (m, 2H), 1.86- 1.78 (m, 1H), 1.77-1.50 (m, 8H), 1.39 (d, J = 6.3 Hz, 3H), 1.37-1.15 (m, 4H), 0.88-0.82 (m, 1H) ¹³C NMR (CDCl₃) δ 172.50, 170.26, 162.96, 160.23, 145.76, 143.87, 142.59, 139.52, 131.52, 129.96, 128.40, 109.55, 89.52, 74.53, 56.18, 51.91, 48.76, 42.57, 40.08, 38.81, 33.33, 29.55, 28.76, 27.64, 25.18, 24.44, 21.47, 20.88, 19.57 30 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.39 (d, J = 8.0 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.27-7.19 (m, 2H), [M + H]⁺ 7.16-7.06 (m, 2H), 6.93 (d, J = 5.4 Hz, 1H), calcd for 5.89-5.65 (m, 2H), 4.97 (dq, J = 8.5, 6.3 Hz, C₃₃H₄₄ClN₂O₇, 1H), 4.57 (ddd, J = 11.1, 8.0, 6.5 Hz, 1H), 3.88 615.2837; (s, 3H), 2.81 (dd, J = 14.4, 3.8 Hz, 1H), 2.67- found, 2.48 (m, 2H), 2.36-2.21 (m, 1H), 2.11-1.94 615.2819 (m, 2H), 1.85-1.80 (m, 1H), 1.76-1.53 (m, 8H), 1.39 (d, J = 6.3 Hz, 3H), 1.35-1.23 (m, 4H), 1.14 (d, J = 7.0 Hz, 6H), 0.88-0.82 (m, 1H) ¹³C NMR (CDCl₃) δ 176.23, 172.50, 162.93, 160.22, 145.62, 144.10, 142.24, 139.52, 131.52, 129.95, 128.40, 109.49, 89.88, 74.51, 56.12, 51.91, 48.78, 42.58, 40.08, 38.81, 33.85, 33.34, 29.55, 28.77, 27.64, 25.18, 24.44, 21.48, 19.57, 18.68 31 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.35 (d, J = 8.0 Hz, 1H), (m/z) 8.27 (d, J = 5.3 Hz, 1H), 7.27-7.20 (m, 2H), [M + H]⁺ 7.16-7.08 (m, 2H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.82 (s, 2H), 4.97 (dq, J = 8.5, 6.4 Hz, 1H), 4.56 C₃₃H₄₄ClN₂O₈, (ddd, J = 11.1, 8.0, 6.6 Hz, 1H), 4.10 (s, 2H), 631.2786; 3.90 (s, 3H), 3.59 (q, J = 7.0 Hz, 2H), 2.81 (dd, J = found, 14.2, 3.8 Hz, 1H), 2.61 (dd, J = 14.2, 11.1 Hz, 631.2786 1H), 2.26 (dt, J = 13.4, 6.8 Hz, 1H), 2.11-1.92 (m, 2H), 1.85-1.79 (m, 1H), 1.77-1.52 (m, 8H), 1.39 (d, J = 6.3 Hz, 3H), 1.37-1.14 (m, 4H), 1.23 (t, J = 7.0 Hz, 1H), 0.91-0.81 (m, 1H) ¹³C NMR (CDCl₃) δ 172.47, 170.04, 162.90, 160.15, 145.81, 143.83, 142.42, 139.51, 131.52, 129.95, 128.40, 109.66, 89.54, 74.53, 67.79, 67.17, 56.21, 51.91, 48.79, 42.57, 40.07, 38.82, 33.33, 29.55, 28.78, 27.66, 25.18, 24.44, 21.49, 19.57, 15.01 32 — — ESIMS ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.1 Hz, 1H), m/z 617 8.29 (d, J = 5.4 Hz, 1H), 7.32-7.24 (m, 4H), [M + H]⁺ 7.18 (t, J = 6.7 Hz, 4H), 7.10 (d, J = 8.3 Hz, 2H), 6.94 (d, J = 5.4 Hz, 1H), 5.75 (s, 2H), 4.88 (dt, J = 12.6, 6.3 Hz, 1H), 4.57 (dt, J = 10.8, 7.5 Hz, 1H), 3.91 (s, 3H), 2.62 (ddt, J = 22.4, 15.1, 7.1 Hz, 3H), 2.43 (ddd, J = 13.7, 11.4, 5.9 Hz, 1H), 2.35 (dt, J = 13.6, 6.5 Hz, 1H), 2.07 (s, 3H), 1.90- 1.19 (m, 12H), 1.42 (d, J = 6.3 Hz, 3H) 0.94 (dd, J = 14.9, 7.1 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.68, 170.30, 162.99, 160.25, 145.77, 143.91, 142.64, 142.35, 142.28, 128.46, 128.35, 128.32, 128.19, 125.93, 125.75, 109.55, 89.56, 75.31, 56.19, 51.50, 45.66, 40.11, 35.95, 33.19, 32.40, 32.12, 30.94, 29.16, 28.00, 20.90, 19.76, 18.40 33 — — ESIMS ¹H NMR (CDCl₃) δ 8.55 (d, J = 7.0 Hz, 1H), m/z 587 8.34 (d, J = 5.4 Hz, 1H), 7.30-7.24 (m, 4H), [M + H]⁺ 7.21-7.15 (m, 4H), 7.14-7.06 (m, 2H), 7.00 (d, J = 5.5 Hz, 1H), 4.88 (m, 1H), 4.55 (dt, J = 10.8, 7.4 Hz, 1H), 3.91 (s, 3H), 2.68-2.50 (m, 3H), 2.47-2.40 (m, 1H), 2.40 (s, 3H), 2.35-2.22 (m, 1H), 1.85-1.38 (m, 11H), 1.40 (d, J = 6.3 Hz, 3H), 1.32-1.22 (m, 1H), 0.93 (dd, J = 15.1, 7.2 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.56, 168.93, 162.40, 159.42, 146.71, 142.35, 142.29, 141.56, 137.46, 128.46, 128.35, 128.32, 128.19, 125.93, 125.75, 109.74, 75.31, 56.28, 51.24, 45.65, 40.09, 35.93, 33.37, 32.40, 32.11, 30.93, 29.15, 28.00, 20.77, 19.73, 18.35 34 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.1 Hz, 1H), 3381, (m/z) 8.29 (d, J = 5.4 Hz, 1H), 7.32-7.26 (m, 2H), 2948, [M]⁺ 7.22-7.13 (m, 3H), 6.95 (d, J = 5.4 Hz, 1H), 1737, calcd for 5.75 (s, 2H), 4.95-4.84 (m, 1H), 4.64-4.52 (m, 1676, C₃₂H₄₄N₂O₇, 1H), 3.91 (s, 3H), 2.74-2.61 (m, 1H), 2.53- 1503, 568.3149; 2.42 (m, 1H), 2.42-2.31 (m, 1H), 2.08 (s, 3H), 1369, found, 1.88-1.65 (m, 3H), 1.64-1.33 (m, 6H), 1.43 (d, 1202 568.3158 J = 6.3 Hz, 3H), 1.33-1.02 (m, 4H), 0.98-0.91 (m, 1H), 0.91-0.84 (m, 6H) 35 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.35 (d, J = 8.1 Hz, 1H), 3380, (m/z) 8.29 (d, J = 5.4 Hz, 1H), 7.32-7.26 (m, 2H), 2947, [M]⁺ 7.22-7.13 (m, 3H), 6.95 (d, J = 5.4 Hz, 1H), 1736, calcd for 5.83 (s, 2H), 4.94-4.83 (m, 1H), 4.62-4.51 (m, 1676, C₃₄H₄₈N₂O₈, 1H), 4.10 (s, 2H), 3.91 (s, 3H), 3.60 (q, J = 7.0 1503, 612.3411; Hz, 2H), 2.72-2.62 (m, 1H), 2.53-2.41 (m, 1209 found, 1H), 2.40-2.30 (m, 1H), 1.87-1.64 (m, 3H), 612.3412 1.64-1.33 (m, 6H), 1.43 (d, J = 6.3 Hz, 3H), 1.33-1.02 (m, 4H), 1.23 (t, J = 7.0 Hz, 3H), 0.98-0.91 (m, 1H), 0.92-0.85 (m, 6H) 36 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.54 (d, J = 7.9 Hz, 1H), 3381, (m/z) 8.35 (d, J = 5.5 Hz, 1H), 7.33-7.26 (m, 2H), 2948, [M]⁺ 7.23-7.11 (m, 3H), 7.00 (d, J = 5.6 Hz, 1H), 1771, calcd for 4.94-4.82 (m, 1H), 4.62-4.50 (m, 1H), 3.91 (s, 1736, C₃₁H₄₂N₂O₆, 3H), 2.73-2.60 (m, 1H), 2.52-2.40 (m, 1H), 1676, 538.3043; 2.40 (s, 3H), 2.38-2.28 (m, 1H), 1.86-1.63 (m, 1507, found, 3H), 1.63-1.32 (m, 6H), 1.42 (d, J = 6.3 Hz, 1197 538.3046 3H), 1.31-1.02 (m, 4H), 0.98-0.88 (m, 1H), 0.92-0.82 (m, 6H) 37 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.1 Hz, 1H), 3370, (m/z) 8.28 (d, J = 5.3 Hz, 1H), 7.32-7.25 (m, 2H), 2931, [M]⁺ 7.23-7.16 (m, 3H), 6.94 (d, J = 5.4 Hz, 1H), 1736, calcd for 5.74 (s, 2H), 4.93-4.83 (m, 1H), 4.61-4.51 (m, 1676, C₂₉H₃₈N₂O₇, 1H), 3.90 (s, 3H), 2.77 (dd, J = 15.4, 3.0 Hz, 1H), 1503, 526.2679; 2.55 (dd, J = 15.5, 7.9 Hz, 1H), 2.43-2.32 (m, 1202 found, 1H), 2.06 (s, 3H), 1.99-1.88 (m, 1H), 1.86- 526.2680 1.71 (m, 1H), 1.65-1.51 (m, 2H), 1.49-1.27 (m, 5H), 1.19 (d, J = 6.4 Hz, 3H), 1.19-1.06 (m, 1H), 1.00-0.89 (m, 1H), 0.85 (t, J = 7.0 Hz, 3H) 38 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.55 (d, J = 6.8 Hz, 1H), 3379, (m/z) 8.34 (d, J = 5.4 Hz, 1H), 7.32-7.26 (m, 2H), 2931, [M]⁺ 7.22-7.16 (m, 3H), 6.99 (d, J = 5.5 Hz, 1H), 1771, calcd for 4.93-4.81 (m, 1H), 4.60-4.48 (m, 1H), 3.90 (s, 1735, C₂₈H₃₆N₂O₆, 3H), 2.82-2.72 (m, 1H), 2.55 (dd, J = 15.5, 7.9 1676, 496.2573; Hz, 1H), 2.39 (s, 3H), 2.39-2.29 (m, 1H), 1.98- 1507, found, 1.87 (m, 1H), 1.86-1.71 (m, 1H), 1.64-1.51 1197 496.2578 (m, 2H), 1.48-1.26 (m, 5H), 1.18 (d, J = 6.4 Hz, 3H), 1.19-1.06 (m, 1H), 0.98-0.88 (m, 1H), 0.85 (t, J = 7.0 Hz, 3H) 39 — — ESIMS ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.1 Hz, 1H), m/z 661 8.27 (d, J = 5.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), [M + H]⁺ 7.25-7.16 (m, 4H), 7.02 (apparent triplet (at), J = 8.7 Hz, 2H), 6.94 (d, J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.93 (m, 1H), 4.59 (dt, J = 11.0, 7.4 Hz, 1H), 3.90 (s, 3H), 2.92 (bd, J = 15.2 Hz, 2H), 2.74 (dd, J = 15.6, 7.5 Hz, 1H), 2.50 (dd, J = 13.7, 11.9 Hz, 1H), 2.33 (dt, J = 13.4, 6.8 Hz, 1H), 2.08 (m, 1H), 2.06 (s, 3H), 1.83-1.63 (m, 2H), 1.54 (dq, J = 14.1, 7.2 Hz, 1H), 1.46-1.34 (m, 1H), 1.29 (d, J = 6.4 Hz, 3H), 1.25-1.13 (m, 1H), 0.86 (dd, J = 15.2, 7.2 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.41, 170.27, 162.99, 161.45 (d, J = 241 Hz), 160.24, 145.76, 144.77, 143.90, 142.50, 135.86 (d, J = 3 Hz), 130.55 (d, J = 7 Hz), 128.92, 128.42 (q, J = 3 Hz), 125.31 (q, J = 4 Hz), 124.25 (q, J = 271 Hz), 115.46, (d, J = 22 Hz), 109.58, 89.49, 75.58, 56.18, 51.43, 46.96, 43.87, 37.73, 36.51, 33.10, 27.38, 20.88, 20.72, 18.75 ¹⁹F NMR (CDCl₃) δ −62.33, −116.63 40 — — ESIMS ¹H NMR (CDCl₃) δ 8.51 (d, J = 7.1 Hz, 1H), m/z 631 8.32 (d, J = 5.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), [M + H]⁺ 7.24-7.12 (m, 4H), 7.08-6.91 (m, 3H), 4.99- 4.84 (m, 1H), 4.57 (dt, J = 11.0, 7.3 Hz, 1H), 3.90 (s, 3H), 2.91 (bd, J = 13.1 Hz, 2H), 2.73 (dd, J = 15.6, 7.5 Hz, 1H), 2.49 (dd, J = 13.7, 11.9 Hz, 1H), 2.39 (s, 3H), 2.30 (dt, J = 16.6, 7.8 Hz, 1H), 2.12-2.02 (m, 1H), 1.77 (m, 1H), 1.68-1.60 (m, 1H), 1.52 (dd, J = 13.7, 7.0 Hz, 1H), 1.45- 1.31 (m, 1H), 1.27 (d, J = 6.4 Hz, 3H) 1.18 (q, J = 11.8 Hz, 1H), 0.85 (dd, J = 14.6, 7.2 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.30, 168.91, 162.42, 161.44 (d, J = 244 Hz), 159.43, 146.71, 144.76, 141.45, 137.47, 135.86 (d, J = 3 Hz), 130.14 (d, J = 8 Hz), 128.91, 128.43 (q, J = 32 Hz), 125.32 (q, J = 3 Hz), 124.24 (q, J = 270 Hz), 115.47, (d, J = 21 Hz), 109.94, 75.59, 56.29, 51.16, 46.97, 43.88, 37.73, 36.52, 33.27, 27.39, 20.75, 20.70, 18.72 ¹⁹F NMR (CDCl₃) δ −62.33, −116.63 41 — — ESIMS ¹H NMR (CDCl₃) δ 8.35 (d, J = 8.1 Hz, 1H), m/z 689 8.26 (d, J = 5.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), [M + H]⁺ 7.25-7.13 (m, 4H), 7.02 (t, J = 8.6 Hz, 2H), 6.93 (d, J = 5.4 Hz, 1H), 5.88-5.60 (m, 2H), 4.93 (dd, J = 9.6, 6.4 Hz, 1H), 4.59 (dt, J = 11.0, 7.5 Hz, 1H), 3.88 (s, 3H), 2.92 (d, J = 15.0 Hz, 2H), 2.74 (dd, J = 15.6, 7.5 Hz, 1H), 2.60-2.44 (m, 2H), 2.33 (dt, J = 13.4, 6.8 Hz, 1H), 2.09 (dd, J = 7.3, 3.0 Hz, 1H), 1.86-1.64 (m, 2H), 1.54 (m, 1H), 1.47-1.33 (m, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.20 (m, 1H), 1.13 (d, J = 7.0 Hz, 6H), 0.91- 0.81 (m, 1H) ¹³C NMR (CDCl₃) δ 176.24, 172.41, 162.96, 161.44 (d, J = 242 Hz), 160.23, 145.62, 144.78, 144.13, 142.15, 135.87 (d, J = 3 Hz), 130.14 (d, J = 8 Hz), 128.92, 128.42 (q, J = 3 Hz), 125.30 (q, J = 4 Hz), 124.25 (q, J = 271 Hz), 115.46, (d, J = 21 Hz), 109.53, 89.85, 75.56, 56.13, 51.42, 46.97, 43.88, 37.73, 36.52, 33.86, 33.10, 27.38, 20.72, 18.76, 18.68 ¹⁹F NMR (CDCl₃) δ −62.33, −116.63 42 — — ESIMS ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.0 Hz, 1H), m/z 533 8.28 (d, J = 5.4 Hz, 1H), 6.94 (d, J = 5.4 Hz, 1H), [M + H]⁺ 5.75 (d, J = 1.1 Hz, 2H), 4.95 (p, J = 6.4 Hz, 1H), 4.55 (dt, J = 11.1, 7.3 Hz, 1H), 3.91 (s, 3H), 2.34 (dt, J = 13.5, 6.6 Hz, 1H), 2.07 (s, 3H), 1.97- 1.43 (m, 17H), 1.35 (d, J = 6.4 Hz, 3H), 1.38- 1.03 (m, 4H), 0.89 (dd, J = 6.6, 2.2 Hz, 6H) ¹³C NMR (CDCl₃) δ 172.62, 170.27, 162.94, 160.23, 145.75, 143.87, 142.70, 109.50, 89.57, 74.81, 56.17, 52.05, 49.88, 42.56, 38.42, 37.21, 33.55, 31.43, 30.09, 28.45, 28.38, 27.80, 25.07, 24.34, 22.96, 22.49, 21.48, 20.89, 19.13 43 — — ESIMS ¹H NMR (CDCl₃) δ 8.58 (d, J = 5.6 Hz, 1H), m/z 503 8.33 (d, J = 5.4 Hz, 1H), 6.99 (d, J = 5.5 Hz, 1H), [M + H]⁺ 4.95 (p, J = 6.4 Hz, 1H), 4.54 (m, 1H), 3.90 (s, 3H), 2.40 (s, 3H), 2.31 (dt, J = 13.5, 6.3 Hz, 1H), 1.97 (m, 2H), 1.76 (m, 1H), 1.69-1.44 (m, 14H), 1.36-1.03 (m, 4H), 1.33 (d, J = 6.4 Hz, 3H), 0.88 (dd, J = 6.6, 2.8 Hz, 6H) ¹³C NMR (CDCl₃) δ 172.52, 168.93, 162.36, 159.40, 146.69, 141.61, 137.43, 109.70, 74.80, 56.27, 51.82, 49.96, 42.57, 38.41, 37.22, 33.72, 31.42, 30.11, 28.45, 27.77, 25.07, 24.36, 22.95, 22.48, 21.49, 20.76, 19.08 44 — — ESIMS ¹H NMR (CDCl₃) δ 8.42 (d, J = 8.0 Hz, 1H), m/z 561 8.27 (d, J = 5.4 Hz, 1H), 6.93 (d, J = 5.4 Hz, 1H), [M + H]⁺ 5.86-5.63 (m, 2H), 4.95 (m, 1H), 4.56 (m, 1H), 3.89 (s, 3H), 2.55 (p, J = 7.0 Hz, 1H), 2.34 (dt, J = 13.6, 6.6 Hz, 1H), 2.01-1.42 (m, 17H), 1.37- 1.03 (m, 4H), 1.35 (d, J = 6.4 Hz, 3H), 1.14 (d, J = 7.0 Hz, 6H), 0.89 (dd, J = 6.6, 2.1 Hz, 6H) ¹³C NMR (CDCl₃) δ 176.24, 172.62, 162.91, 160.21, 145.62, 144.10, 142.35, 109.44, 89.94, 74.79, 56.11, 52.05, 49.89, 42.56, 38.43, 37.22, 33.86, 33.55, 31.42, 30.09, 28.45, 28.39, 27.79, 25.07, 24.35, 22.96, 22.50, 21.49, 19.13, 18.69 45 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.50 (d, J = 8.2 Hz, 1H), (m/z) 8.31 (d, J = 5.4 Hz, 1H), 7.35-7.23 (m, 2H), [M + H]⁺ 7.23-7.09 (m, 3H), 6.98 (d, J = 5.5 Hz, 1H), calcd for 4.82 (dq, J = 9.7, 6.3 Hz, 1H), 4.56 (ddd, J = C₃₀H₄₁N₂O₆, 11.0, 8.4, 7.2 Hz, 1H), 3.88 (s, 3H), 2.98-2.76 525.2964; (m, 1H), 2.40 (s, 3H), 2.38-2.22 (m, 2H), 1.85- found, 1.75 (m, 1H), 1.72-1.43 (m, 7H), 1.35 (d, J = 525.2966 6.3 Hz, 3H), 1.33-1.25 (m, 1H), 1.23-1.06 (m, 2H), 0.93 (d, J = 6.6 Hz, 6H), 0.83-0.73 (m, 1H) ¹³C NMR (CDCl₃) δ 172.44, 168.89, 162.40, 159.41, 146.70, 141.54, 141.18, 137.44, 128.73, 128.34, 125.87, 109.75, 75.23, 56.27, 51.16, 45.32, 42.41, 37.93, 34.51, 33.40, 28.87, 27.52, 27.20, 22.75, 22.47, 20.77, 19.66, 18.58 46 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.55 (d, J = 8.5 Hz, 1H), (m/z) 8.33 (d, J = 5.4 Hz, 1H), 7.21-7.08 (m, 2H), [M + H]⁺ 7.06-6.86 (m, 3H), 4.85 (dq, J = 9.6, 6.4 Hz, calcd for 1H), 4.54 (ddd, J = 10.9, 8.3, 7.1 Hz, 1H), 3.89 C₂₈H₃₆FN₂O₆, (s, 3H), 2.80-2.64 (m, 1H), 2.53 (dd, J = 15.5, 515.2557; 7.8 Hz, 1H), 2.39 (s, 3H), 2.38-2.30 (m, 1H), found, 1.93-1.81 (m, 1H), 1.81-1.71 (m, 1H), 1.63- 515.2552 1.51 (m, 2H), 1.48-1.25 (m, 5H), 1.17 (d, J = 6.4 Hz, 3H), 1.15-1.07 (m, 1H), 0.96-0.89 (m, 1H), 0.85 (t, J = 7.1 Hz, 3H) ¹⁹F NMR (CDCl₃) δ −117.36 47 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.4 Hz, 1H), 7.37-7.25 (m, 2H), [M + H]⁺ 7.23-7.12 (m, 3H), 6.93 (d, J = 5.4 Hz, 1H), calcd for 5.74 (s, 2H), 4.82 (dq, J = 9.7, 6.3 Hz, 1H), 4.58 C₃₁H₄₃N₂O₇, (ddd, J = 11.0, 8.2, 7.2 Hz, 1H), 3.89 (s, 3H), 555.3070; 2.90-2.74 (m, 1H), 2.43-2.25 (m, 2H), 2.06 (s, found, 3H), 1.86-1.76 (m, 1H), 1.72-1.44 (m, 7H), 555.3074 1.36 (d, J = 6.3 Hz, 3H), 1.33-1.23 (m, 1H), 1.22-1.08 (m, 2H), 0.93 (d, J = 6.6 Hz, 6H), 0.83-0.75 (m, 1H) ¹³C NMR (CDCl₃) δ 172.55, 170.24, 162.96, 160.22, 145.75, 143.86, 142.61, 141.18, 128.73, 128.33, 125.86, 109.55, 89.51, 75.20, 56.18, 51.41, 45.32, 42.39, 37.93, 34.49, 33.21, 28.86, 27.51, 27.20, 22.74, 22.46, 20.88, 19.67, 18.61 48 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.34 (d, J = 8.0 Hz, 1H), (m/z) 8.28 (d, J = 5.3 Hz, 1H), 7.21-7.09 (m, 2H), [M + H]⁺ 7.06-6.89 (m, 3H), 5.74 (s, 2H), 4.86 (dq, J = calcd for 9.6, 6.4 Hz, 1H), 4.56 (ddd, J = 10.9, 8.1, 7.1 Hz, C₂₉H₃₈FN₂O₇, 1H), 3.90 (s, 3H), 2.81-2.67 (m, 1H), 2.54 (dd, 545.2663; J = 15.5, 7.8 Hz, 1H), 2.37 (dddd, J = 13.4, 7.9, found, 5.7, 2.1 Hz, 1H), 2.06 (s, 3H), 1.95-1.85 (m, 545.2660 1H), 1.84-1.73 (m, 1H), 1.68-1.53 (m, 2H), 1.51-1.27 (m, 5H), 1.19 (d, J = 6.4 Hz, 3H), 1.17-1.10 (m, 1H), 0.96-0.90 (m, 1H), 0.86 (t, J = 7.1 Hz, 3H) ¹⁹F NMR (CDCl₃) δ −117.37 49 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.44 (d, J = 6.4 Hz, 1H), (m/z) 8.30 (d, J = 5.4 Hz, 1H), 7.34-7.23 (m, 2H), [M + H]⁺ 7.21-7.11 (m, 3H), 6.96 (d, J = 5.5 Hz, 1H), calcd for 4.81 (dq, J = 9.7, 6.3 Hz, 1H), 4.57 (ddd, J = C₃₂H₄₅N₂O₆, 10.9, 8.5, 7.2 Hz, 1H), 3.86 (s, 3H), 2.95 (hept, J = 553.3277; 7.0 Hz, 1H), 2.87-2.78 (m, 1H), 2.40-2.24 found, (m, 2H), 1.84-1.76 (m, 1H), 1.69-1.46 (m, 553.3275 7H), 1.36 (d, J = 7.1 Hz, 6H), 1.34 (d, J = 5.5 Hz, 3H), 1.32-1.26 (m, 1H), 1.22-1.08 (m, 2H), 0.93 (d, J = 6.6 Hz, 6H), 0.82-0.73 (m, 1H) ¹³C NMR (CDCl₃) δ 174.68, 172.51, 162.38, 159.37, 146.61, 141.95, 141.19, 137.59, 128.73, 128.33, 125.86, 109.59, 75.16, 56.27, 51.11, 45.33, 42.42, 37.94, 34.50, 33.95, 33.43, 28.87, 27.50, 27.21, 22.75, 22.47, 19.65, 18.84, 18.59 50 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.35 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.32-7.25 (m, 2H), [M + H]⁺ 7.21-7.12 (m, 3H), 6.92 (d, J = 5.4 Hz, 1H), calcd for 5.85-5.64 (m, 2H), 4.82 (dq, J = 9.7, 6.3 Hz, C₃₃H₄₇N₂O₇, 1H), 4.58 (ddd, J = 11.0, 8.1, 7.1 Hz, 1H), 3.88 583.3383; (s, 3H), 3.00-2.79 (m, 1H), 2.54 (hept, J = 7.0 found, Hz, 1H), 2.40-2.26 (m, 2H), 1.81 (ddt, J = 10.8, 583.3379 7.4, 3.6 Hz, 1H), 1.71-1.47 (m, 7H), 1.36 (d, J = 6.3 Hz, 3H), 1.33-1.20 (m, 3H), 1.14 (d, J = 7.0 Hz, 6H), 0.93 (d, J = 6.6 Hz, 6H), 0.84-0.75 (m, 1H) ¹³C NMR (CDCl₃) δ 176.22, 172.55, 162.94, 160.22, 145.61, 144.10, 142.27, 141.19, 128.73, 128.33, 125.86, 109.48, 89.90, 75.19, 56.12, 51.41, 45.33, 42.40, 37.94, 34.50, 33.86, 33.23, 28.86, 27.51, 27.21, 22.74, 22.46, 19.67, 18.68, 18.62 51 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.3 Hz, 1H), 7.34-7.24 (m, 2H), [M + H]⁺ 7.23-7.11 (m, 3H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.82 (s, 2H), 4.82 (dq, J = 9.7, 6.3 Hz, 1H), 4.65- C₃₃H₄₇N₂O₈, 4.49 (m, 1H), 4.09 (s, 2H), 3.89 (s, 3H), 3.59 599.3332; (q, J = 7.0 Hz, 2H), 2.91-2.76 (m, 1H), 2.41- found, 2.24 (m, 2H), 1.81 (ddt, J = 12.1, 7.9, 2.2 Hz, 599.3335 1H), 1.72-1.45 (m, 7H), 1.36 (d, J = 6.2 Hz, 3H), 1.33-1.25 (m, 1H), 1.23 (t, J = 7.0 Hz, 3H), 1.19-1.06 (m, 2H), 0.93 (d, J = 6.6 Hz, 6H), 0.84-0.75 (m, 1H) ¹³C NMR (CDCl₃) δ 172.52, 170.04, 162.91, 160.15, 145.80, 143.82, 142.45, 141.17, 128.72, 128.33, 125.86, 109.66, 89.53, 75.22, 67.79, 67.16, 56.21, 51.39, 45.32, 42.38, 37.93, 34.49, 33.20, 28.86, 27.51, 27.19, 22.74, 22.46, 19.67, 18.60, 15.02 52 — — ESIMS ¹H NMR (CDCl₃) δ 8.32 (d, J = 8.2 Hz, 1H), m/z 561 8.28 (d, J = 5.4 Hz, 1H), 7.36 (at, J = 7.3 Hz, [M + H]⁺ 2H), 7.31-7.15 (m, 5H), 7.12 (dd, J = 8.4, 6.1 Hz, 1H), 6.94 (d, J = 5.4 Hz, 1H), 6.90 (d, J = 6.9 Hz, 2H), 5.75 (s, 2H), 5.21 (m, 1H), 4.67 (dt, J = 10.9, 7.6 Hz, 1H), 3.90 (s, 3H), 2.78 (t, J = 9.9 Hz, 1H), 2.53 (bd, J = 12.6 Hz, 1H), 2.39 (dt, J = 13.1, 6.5 Hz, 1H), 2.26 (m, 1H), 2.16 (bd, J = 10.3 Hz, 1H), 2.07 (s, 3H), 1.75 (m, 1H), 1.61 (m, 2H), 1.29 (q, J = 10.8 Hz, 1H), 1.11 (m, 1H), 0.97 (d, J = 6.4 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.71, 170.28, 163.00, 160.25, 145.76, 143.91, 142.57, 142.22, 140.82, 128.75, 128.60, 128.17, 127.00, 125.78, 109.58, 89.53, 75.36, 56.19, 55.19, 51.41, 46.80, 37.54, 33.35, 27.25, 20.89, 20.62, 18.23 53 — — ESIMS ¹H NMR (CDCl₃) δ 8.53 (d, J = 7.1 Hz, 1H), m/z 531 8.33 (d, J = 5.4 Hz, 1H), 7.36 (at, J = 7.4 Hz, [M + H]⁺ 2H), 7.30-7.14 (m, 5H), 7.11 (at, J = 7.3 Hz, 1H), 6.99 (d, J = 5.5 Hz, 1H), 6.89 (d, J = 8.2 Hz, 2H), 5.20 (m, 1H), 4.65 (dt, J = 10.8, 7.6 Hz, 1H), 3.89 (s, 3H), 2.76 (t, J = 9.9 Hz, 1H), 2.52 (d, J = 13.2 Hz, 1H), 2.40 (s, 3H), 2.37 (m, 1H), 2.26 (m, 1H), 2.14 (m, 1H), 1.74 (m, 1H), 1.60 (m, 2H), 1.26 (q, J = 10.8 Hz, 1H), 1.10 (m, 1H), 0.95 (d, J = 6.4 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.58, 168.92, 162.44, 159.43, 146.72, 142.21, 141.50, 140.82, 137.47, 128.75, 128.59, 128.17, 127.00, 125.78, 109.78, 75.37, 56.29, 55.17, 51.14, 46.80, 37.53, 33.53, 27.25, 20.77, 20.60, 18.19 54 — — ESIMS ¹H NMR (CDCl₃) δ 8.36 (d, J = 8.1 Hz, 1H), m/z 513 8.30 (d, J = 5.4 Hz, 1H), 7.30 (at, J = 7.3 Hz, [M + H]⁺ 2H), 7.22 (at, J = 7.3 Hz, 1H), 7.16-7.10 (m, 2H), 6.95 (d, J = 5.4 Hz, 1H), 5.75 (s, 2H), 5.17 (m, 1H), 4.65 (m, 1H), 3.91 (s, 3H), 2.61 (t, J = 9.9 Hz, 1H), 2.43 (dt, J = 13.3, 6.8 Hz, 1H), 2.08 (s, 3H), 1.94-1.78 (m, 2H), 1.75-1.53 (m, 2H), 1.38 (q, J = 11.8 Hz, 1H), 1.31-0.93 (m, 5H), 0.91 (d, J = 6.4 Hz, 3H), 0.69 (t, J = 7.2 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.84, 170.29, 162.99, 160.25, 145.76, 143.93, 142.63, 129.01, 128.47, 126.65, 109.56, 89.56, 75.61, 56.19, 55.53, 51.50, 43.47, 33.49, 33.34, 27.98, 20.89, 20.54, 20.06, 18.15, 14.01 55 — — ESIMS ¹H NMR (CDCl₃) δ 8.64-8.50 (bs, 1H), 8.35 (d, m/z 483 J = 5.4 Hz, 1H), 7.29 (at, J = 7.3 Hz, 2H), 7.22 [M + H]⁺ (at, J = 7.3 Hz, 1H), 7.12 (m, 2H), 7.01 (d, J = 5.5 Hz, 1H), 5.16 (m, 1H), 4.63 (dt, J = 10.7, 7.6 Hz, 1H), 3.91 (s, 3H), 2.59 (t, J = 9.9 Hz, 1H), 2.39 (m, 1H), 2.40 (s, 3H), 1.95-1.78 (m, 2H), 1.71-1.52 (m, 2H), 1.4-0.93 (m, 6H), 0.90 (d, J = 6.4 Hz, 3H), 0.68 (t, J = 7.2 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.72, 168.94, 162.44, 159.43, 146.73, 142.62, 141.55, 137.47, 129.05, 128.47, 126.65, 109.77, 75.63, 56.29, 55.51, 51.25, 43.46, 33.49, 27.98, 20.77, 20.51, 20.06, 18.10, 14.00 56 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.54 (d, J = 8.2 Hz, 1H), (m/z) 8.33 (d, J = 5.4 Hz, 1H), 7.34-7.23 (m, 2H), [M + H]⁺ 7.23-7.10 (m, 3H), 6.99 (d, J = 5.4 Hz, 1H), calcd for 4.70 (dq, J = 9.5, 6.4 Hz, 1H), 4.52 (ddd, J = C₃₁H₄₃N₂O₆, 10.8, 8.4, 7.2 Hz, 1H), 3.89 (s, 3H), 2.69-2.49 539.3121; (m, 2H), 2.39 (s, 3H), 2.36-2.24 (m, 1H), 1.80- found, 1.68 (m, 2H), 1.65-1.53 (m, 1H), 1.54-1.33 539.3123 (m, 5H), 1.30 (d, J = 6.4 Hz, 3H), 1.27-1.15 (m, 4H), 0.92-0.78 (m, 8H) ¹³C NMR (CDCl₃) δ 172.59, 168.91, 162.37, 159.41, 146.70, 142.42, 141.58, 137.44, 128.39, 128.26, 125.71, 109.73, 77.03, 56.27, 51.26, 44.13, 43.23, 41.40, 35.93, 33.46, 30.43, 29.26, 27.91, 27.39, 24.02, 21.88, 20.76, 19.72, 18.34 57 — — ESIMS ¹H NMR (CDCl₃) δ 8.55 (d, J = 8.3 Hz, 1H), m/z 657 8.33 (d, J = 5.4 Hz, 1H), 7.32-7.23 (m, 2H), [M + H]⁺ 7.21-7.10 (m, 7H), 6.99 (d, J = 5.4 Hz, 1H), 4.86 (dq, J = 9.6, 6.4 Hz, 1H), 4.53 (dt, J = 10.9, 7.6 Hz, 1H), 3.89 (s, 3H), 2.68 (dd, J = 15.5, 3.5 Hz, 1H), 2.62-2.45 (m, 3H), 2.39 (s, 3H), 2.33 (dt, J = 13.5, 6.6 Hz, 1H), 2.06-1.66 (m, 4H), 1.64-0.68 (m, 10H) ¹³C NMR (CDCl₃) δ 172.38, 168.85, 162.34, 159.37, 147.44 (q, J = 1.7 Hz), 146.66, 142.23, 141.46, 139.54, 137.41, 129.97, 128.26, 125.75, 120.87, 125.24-115.10 (m), 109.71, 75.70, 56.22, 51.23, 47.48, 41.75, 36.71, 35.98, 33.29, 31.16, 29.67, 29.25, 27.82, 20.70, 18.47 ¹⁹F NMR (CDCl₃) δ −57.90 58 — — ESIMS ¹H NMR (CDCl₃) δ 8.49 (d, J = 8.4 Hz, 1H), m/z 683 8.32 (d, J = 5.4 Hz, 1H), 7.32-7.24 (m, 2H), [M − H]⁻ 7.22-7.10 (m, 7H), 6.97 (d, J = 5.5 Hz, 1H), 4.86 (dq, J = 9.5, 6.3 Hz, 1H), 4.55 (dt, J = 10.8, 7.5 Hz, 1H), 3.87 (s, 3H), 2.95 (hept, J = 7.0 Hz, 1H), 2.68 (dd, J = 15.5, 3.5 Hz, 1H), 2.63-2.45 (m, 3H), 2.39-2.29 (m, 1H), 2.08-0.67 (m, 20H) ¹³C NMR (CDCl₃) δ 174.64, 172.44, 162.32, 159.33, 147.42 (q, J = 1.6 Hz), 146.55, 142.22, 141.86, 139.55, 137.56, 129.97, 128.25, 125.73, 120.86, 124.60-116.51 (m), 109.54, 75.63, 56.21, 51.17, 47.48, 41.75, 36.69, 35.97, 33.89, 33.30, 31.16, 29.66, 29.25, 27.78, 20.67, 18.76, 18.47 ¹⁹F NMR (CDCl₃) δ −57.89 59 — — ESIMS ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.0 Hz, 1H), m/z 687 8.27 (d, J = 5.3 Hz, 1H), 7.30-7.24 (m, 2H), [M + H]⁺ 7.20-7.10 (m, 7H), 6.94 (d, J = 5.4 Hz, 1H), 5.74 (s, 2H), 4.86 (dq, J = 9.5, 6.3 Hz, 1H), 4.55 (dt, J = 10.8, 7.5 Hz, 1H), 2.68 (dd, J = 15.5, 3.5 Hz, 1H), 2.61-2.46 (m, 3H), 2.40-2.31 (m, 1H), 2.06 (s, 3H), 1.95-1.85 (m, 1H), 1.85- 1.66 (m, 2H), 1.65-0.68 (m, 14H) ¹³C NMR (CDCl₃) δ 172.47, 170.20, 162.90, 160.18, 147.41 (q, J = 1.6 Hz), 145.69, 143.86, 142.50, 142.22, 139.53, 129.96, 128.25, 125.73, 120.86, 124.37-116.45 (m), 109.50, 89.46, 75.67, 56.11, 51.47, 47.46, 41.73, 36.67, 35.97, 33.10, 31.15, 29.65, 29.25, 27.79, 20.81, 20.69 ¹⁹F NMR (CDCl₃) δ −57.90 60 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.69-8.48 (m, 1H), 8.33 (d, (m/z) J = 5.4 Hz, 1H), 7.35-7.23 (m, 2H), 7.23-7.11 [M + H]⁺ (m, 3H), 6.99 (d, J = 5.5 Hz, 1H), 4.89 (dq, J = calcd for 9.7, 6.4 Hz, 1H), 4.55 (ddd, J = 10.9, 8.3, 7.1 Hz, C₂₉H₃₇N₂O₆, 1H), 3.89 (s, 3H), 2.71 (dd, J = 15.6, 3.1 Hz, 1H), 509.2651; 2.58-2.49 (m, 1H), 2.39 (s, 3H), 2.37-2.32 (m, found, 1H), 2.04-1.93 (m, 1H), 1.93-1.85 (m, 1H), 509.2643 1.66-1.58 (m, 2H), 1.57-1.46 (m, 2H), 1.37- 1.28 (m, 1H), 1.19 (d, J = 6.3 Hz, 3H), 1.08- 0.98 (m, 2H), 0.73-0.58 (m, 1H), 0.51-0.39 (m, 1H), 0.39-0.28 (m, 1H), 0.09-0.00 (m, 1H), −0.07-−0.19 (m, 1H) ¹³C NMR (CDCl₃) δ 172.45, 168.91, 162.38, 159.41, 146.71, 141.55, 140.84, 137.44, 128.81, 128.39, 126.00, 109.76, 76.19, 56.28, 51.30, 46.80, 42.69, 37.34, 36.62, 33.51, 28.38, 20.76, 20.72, 18.91, 9.19, 5.66, 3.75 61 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.34 (d, J = 8.0 Hz, 1H), (m/z) 8.28 (d, J = 5.4 Hz, 1H), 7.33-7.24 (m, 2H), [M + H]⁺ 7.23-7.10 (m, 3H), 6.94 (d, J = 5.4 Hz, 1H), calcd for 5.74 (s, 2H), 4.89 (dq, J = 9.7, 6.4 Hz, 1H), 4.57 C₃₀H₃₉N₂O₇, (ddd, J = 10.9, 8.0, 7.1 Hz, 1H), 3.90 (s, 3H), 539.2757; 2.71 (dd, J = 15.5, 3.1 Hz, 1H), 2.53 (dd, J = found, 15.5, 7.8 Hz, 1H), 2.46-2.34 (m, 1H), 2.06 (s, 539.2760 3H), 2.04-1.86 (m, 2H), 1.71-1.57 (m, 2H), 1.59-1.48 (m, 2H), 1.38-1.29 (m, 1H), 1.20 (d, J = 6.3 Hz, 3H), 1.09-0.98 (m, 2H), 0.75-0.57 (m, 1H), 0.52-0.40 (m, 1H), 0.40-0.28 (m, 1H), 0.08-−0.01 (m, 1H), −0.08-−0.19 (m, 1H) ¹³C NMR (CDCl₃) δ 172.56, 170.26, 162.95, 160.23, 145.76, 143.89, 142.63, 140.84, 128.81, 128.38, 125.99, 109.55, 89.54, 76.17, 56.18, 51.56, 46.79, 42.69, 37.33, 36.61, 33.34, 28.37, 20.88, 20.73, 18.95, 9.18, 5.66, 3.74 62 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.4 Hz, 1H), (m/z) 8.31 (d, J = 5.4 Hz, 1H), 7.33-7.15 (m, 5H), [M + H]⁺ 7.12-7.06 (m, 2H), 7.06-6.94 (m, 3H), 4.91 calcd for (dq, J = 9.7, 6.4 Hz, 1H), 4.57 (ddd, J = 11.0, 8.3, C₃₂H₃₆FN₂O₆, 7.1 Hz, 1H), 3.88 (s, 3H), 3.03-2.81 (m, 2H), 563.2557; 2.77-2.65 (m, 1H), 2.39 (s, 3H), 2.34-2.25 (m, found, 1H), 2.05 (tdd, J = 9.8, 7.5, 3.1 Hz, 1H), 1.82- 563.2554 1.70 (m, 1H), 1.70-1.61 (m, 1H), 1.61-1.52 (m, 1H), 1.52-1.41 (m, 1H), 1.33-1.24 (m, 1H), 1.25 (d, J = 6.4 Hz, 3H), 1.22-1.10 (m, 1H), 0.88-0.76 (m, 1H) ¹⁹F NMR (CDCl₃) δ −116.90 63 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.1 Hz, 1H), (m/z) 8.26 (d, J = 5.4 Hz, 1H), 7.32-7.14 (m, 5H), [M + H]⁺ 7.14-7.06 (m, 2H), 7.06-6.97 (m, 2H), 6.93 (d, calcd for J = 5.4 Hz, 1H), 5.73 (s, 2H), 4.92 (dq, J = 9.7, C₃₃H₃₈FN₂O₇, 6.4 Hz, 1H), 4.58 (ddd, J = 11.0, 8.1, 7.0 Hz, 593.2663; 1H), 3.89 (s, 3H), 3.04-2.86 (m, 2H), 2.70 (dd, found, J = 15.6, 7.7 Hz, 1H), 2.44 (dd, J = 13.8, 11.6 Hz, 593.2662 1H), 2.38-2.27 (m, 1H), 2.12-2.02 (m, 1H), 2.06 (s, 3H), 1.82-1.63 (m, 2H), 1.63-1.52 (m, 1H), 1.53-1.39 (m, 1H), 1.27 (d, J = 6.5 Hz, 3H), 1.24-1.14 (m, 1H), 0.96-0.76 (m, 1H) ¹⁹F NMR (CDCl₃) δ −116.92 64 — — HRMS-FAB ¹H NMR (CDCl₃) δ 8.35 (d, J = 8.1 Hz, 1H), (m/z) 8.25 (d, J = 5.3 Hz, 1H), 7.33-7.13 (m, 5H), [M + H]⁺ 7.13-7.06 (m, 2H), 7.06-6.98 (m, 2H), 6.92 (d, calcd for J = 5.4 Hz, 1H), 5.87-5.67 (m, 2H), 4.92 (dq, J = C₃₅H₄₂FN₂O₇, 9.7, 6.4 Hz, 1H), 4.58 (ddd, J = 11.0, 8.1, 7.1 621.2976; Hz, 1H), 3.87 (s, 3H), 3.02-2.87 (m, 2H), 2.70 found, (dd, J = 15.7, 7.6 Hz, 1H), 2.54 (hept, J = 7.0 Hz, 621.2975 1H), 2.44 (dd, J = 13.8, 11.6 Hz, 1H), 2.38-2.27 (m, 1H), 2.07 (tdd, J = 9.8, 7.5, 3.0 Hz, 1H), 1.80- 1.64 (m, 2H), 1.64-1.51 (m, 1H), 1.47 (dddd, J = 18.3, 9.2, 4.5, 2.9 Hz, 1H), 1.26 (d, J = 6.3 Hz, 3H), 1.25-1.16 (m, 1H), 1.13 (d, J = 7.0 Hz, 6H), 0.88-0.79 (m, 1H) ¹⁹F NMR (CDCl₃) δ −116.91 65 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.30 (d, J = 8.2 Hz, 1H), 3391, (m/z) 8.27 (d, J = 5.3 Hz, 1H), 7.55-7.49 (m, 2H), 2940, [M]⁺ 7.32-7.26 (m, 2H), 7.22-7.15 (m, 4H), 6.94 (d, 1741, calcd for J = 5.4 Hz, 1H), 5.74 (s, 2H), 5.00-4.88 (m, 1678, C₃₅H₃₆F₆N₂O₈, 1H), 4.65-4.53 (m, 1H), 3.91 (s, 3H), 3.01- 1508, 726.2376; 2.87 (m, 2H), 2.76 (dd, J = 15.7, 7.6 Hz, 1H), 1326, found, 2.58-2.47 (m, 1H), 2.40-2.29 (m, 1H), 2.16- 1260 726.2383 2.05 (m, 1H), 2.06 (s, 3H), 1.83-1.64 (m, 2H), 1.64-1.48 (m, 1H), 1.47-1.35 (m, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.28-1.15 (m, 1H), 0.94-0.81 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.95, −62.35 66 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.1 Hz, 1H), 3379, (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.54-7.49 (m, 2H), 2940, [M]⁺ 7.31-7.26 (m, 2H), 7.21-7.16 (m, 4H), 6.94 (d, 1738, calcd for J = 5.4 Hz, 1H), 5.82 (s, 2H), 4.99-4.89 (m, 1677, C₃₇H₄₀F₆N₂O₉, 1H), 4.62-4.52 (m, 1H), 4.09 (s, 2H), 3.90 (s, 1508, 770.2638; 3H), 3.58 (q, J = 7.0 Hz, 2H), 3.00-2.88 (m, 1325, found, 2H), 2.76 (dd, J = 15.7, 7.5 Hz, 1H), 2.56-2.47 1259 770.2644 (m, 1H), 2.38-2.28 (m, 1H), 2.17-2.06 (m, 1H), 1.83-1.64 (m, 2H), 1.62-1.48 (m, 1H), 1.48-1.34 (m, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H), 1.24-1.15 (m, 1H), 0.93-0.81 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.95, −62.35 67 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.51 (d, J = 8.3 Hz, 1H), 3379, (m/z) 8.33 (d, J = 5.4 Hz, 1H), 7.54-7.48 (m, 2H), 2941, [M]⁺ 7.32-7.26 (m, 2H), 7.22-7.14 (m, 4H), 6.99 (d, 1772, calcd for J = 5.5 Hz, 1H), 4.99-4.88 (m, 1H), 4.63-4.52 1738, C₃₄H₃₄F₆N₂O₇, (m, 1H), 3.90 (s, 3H), 3.01-2.86 (m, 2H), 2.76 1678, 696.2270; (dd, J = 15.7, 7.6 Hz, 1H), 2.57-2.46 (m, 1H), 1508, found, 2.39 (s, 3H), 2.36-2.26 (m, 1H), 2.15-2.05 (m, 1325, 696.2275 1H), 1.83-1.62 (m, 2H), 1.61-1.47 (m, 1H), 1259 1.47-1.34 (m, 1H), 1.27 (d, J = 5.8 Hz, 3H), 1.26-1.11 (m, 1H), 0.93-0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.94, −62.35 68 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.29 (d, J = 8.7 Hz, 1H), 3379, (m/z) 8.27 (d, J = 5.4 Hz, 1H), 7.32-7.23 (m, 4H), 2940, [M]⁺ 7.22-7.15 (m, 3H), 7.11-7.06 (m, 2H), 6.93 (d, 1738, calcd for J = 5.4 Hz, 1H), 5.73 (s, 2H), 4.99-4.87 (m, 1677, C₃₄H₃₇F₃N₂O₈, 1H), 4.64-4.53 (m, 1H), 3.90 (s, 3H), 3.03- 1507, 658.2502; 2.88 (m, 2H), 2.73 (dd, J = 15.7, 7.7 Hz, 1H), 1258, found, 2.51-2.40 (m, 1H), 2.40-2.27 (m, 1H), 2.14- 1202 658.2501 2.04 (m, 1H), 2.06 (s, 3H), 1.82-1.40 (m, 4H), 1.29-1.14 (m, 4H), 0.91-0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.93 69 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.31 (d, J = 8.1 Hz, 1H), 3382, (m/z) 8.26 (d, J = 5.4 Hz, 1H), 7.32-7.23 (m, 4H), 2939, [M]⁺ 7.23-7.14 (m, 3H), 7.12-7.05 (m, 2H), 6.93 (d, 1737, calcd for J = 5.5 Hz, 1H), 5.82 (s, 2H), 4.99-4.87 (m, 1677, C₃₆H₄₁F₃N₂O₉, 1H), 4.62-4.52 (m, 1H), 4.09 (s, 2H), 3.90 (s, 1507, 702.2764; 3H), 3.58 (q, J = 7.0 Hz, 2H), 3.02-2.88 (m, 1258, found, 2H), 2.73 (dd, J = 15.8, 7.7 Hz, 1H), 2.51-2.41 1206 702.2774 (m, 1H), 2.38-2.27 (m, 1H), 2.16-2.05 (m, 1H), 1.82-1.40 (m, 4H), 1.31-1.15 (m, 4H), 1.22 (t, J = 7.0 Hz, 3H), 0.91-0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.93 70 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 8.33 (d, J = 8.0 Hz, 1H), 3377, (m/z) 8.28 (d, J = 5.4 Hz, 1H), 7.30-7.24 (m, 4H), 2935, [M]⁺ 7.22-7.12 (m, 6H), 6.94 (d, J = 5.4 Hz, 1H), 1736, calcd for 5.74 (s, 2H), 4.93-4.82 (m, 1H), 4.60-4.49 (m, 1676, C₃₅H₄₂N₂O₇, 1H), 3.90 (s, 3H), 2.73 (dd, J = 15.4, 3.3 Hz, 1H), 1497, 602.2992; 2.63-2.44 (m, 3H), 2.42-2.29 (m, 1H), 2.06 (s, 1371, found, 3H), 1.99-1.86 (m, 1H), 1.85-1.64 (m, 2H), 1202 602.2995 1.64-1.24 (m, 7H), 1.21 (d, J = 6.4 Hz, 3H), 1.00-0.88 (m, 1H) 71 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.16 (s, 1H), 8.47 (d, J = (m/z) 8.2 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.35-7.25 [M + H]⁺ (m, 2H), 7.23-7.09 (m, 3H), 6.85 (d, J = 5.2 Hz, calcd for 1H), 4.85 (dq, J = 9.6, 6.3 Hz, 1H), 4.56 (dt, J = C₂₇H₃₇N₂O₅, 11.0, 7.7 Hz, 1H), 3.92 (s, 3H), 2.94-2.78 (m, 469.2702; 1H), 2.41-2.25 (m, 2H), 1.81 (tq, J = 10.6, 3.3 found, Hz, 1H), 1.71-1.14 (m, 11H), 1.37 (d, J = 6.3 469.2701 Hz, 3H), 0.95 (t, J = 7.1 Hz, 3H), 0.85-0.74 (m, 1H) ¹³C NMR (CDCl₃) δ 171.95, 168.64, 155.31, 148.70, 141.09, 140.48, 130.49, 128.71, 128.35, 125.90, 109.43, 75.65, 56.05, 51.09, 45.33, 42.53, 37.89, 33.11, 29.35, 27.82, 27.46, 23.50, 19.70, 18.53, 14.04 72 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.13 (s, 1H), 8.47 (d, J = (m/z) 8.2 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.54 (d, J = [M + H]⁺ 8.0 Hz, 2H), 7.37-7.18 (m, 2H), 6.85 (d, J = 5.2 calcd for Hz, 1H), 4.85 (dq, J = 9.7, 6.3 Hz, 1H), 4.56 C₂₈H₃₆F₃N₂O₅, (ddd, J = 11.0, 8.3, 7.2 Hz, 1H), 3.93 (s, 3H), 537.2576; 2.96-2.81 (m, 1H), 2.43 (dd, J = 13.9, 11.3 Hz, found, 1H), 2.32 (dt, J = 13.5, 7.0 Hz, 1H), 1.90-1.77 537.2588 (m, 1H), 1.75-1.15 (m, 11H), 1.38 (d, J = 6.3 Hz, 1H), 0.95 (t, J = 7.1 Hz, 3H), 0.90-0.77 (m, 1H) ¹³C NMR (CDCl₃) δ 171.86, 168.69, 155.35, 148.74, 145.30, 140.48, 130.48, 128.99, 128.35 (q, J = 32.2 Hz), 125.29 (q, J = 3.8 Hz), 124.30 (q, J = 255 Hz), 109.47, 75.49, 56.03, 51.05, 45.40, 42.47, 37.81, 33.02, 29.38, 27.86, 27.48, 23.44, 19.64, 18.55, 13.96 73 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.15 (d, J = 0.6 Hz, 1H), (m/z) 8.51 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.45-7.11 (m, 5H), 6.86 (dd, J = 5.3, 0.7 Hz, calcd for 1H), 4.90 (dq, J = 9.6, 6.4 Hz, 1H), 4.54 (ddd, J = C₂₈H₃₉N₂O₅, 10.9, 8.2, 7.1 Hz, 1H), 3.93 (s, 3H), 2.76 (dd, J = 483.2859; 15.4, 3.2 Hz, 1H), 2.57 (dd, J = 15.4, 7.8 Hz, found, 1H), 2.42-2.27 (m, 1H), 2.03-1.89 (m, 1H), 483.2847 1.88-1.73 (m, 1H), 1.67-1.54 (m, 2H), 1.53- 1.24 (m, 6H), 1.21 (d, J = 6.4 Hz, 3H), 1.07- 0.91 (m, 2H), 0.85 (d, J = 6.6 Hz, 6H) ¹³C NMR (CDCl₃) δ 171.98, 168.62, 155.32, 148.70, 140.92, 140.49, 130.51, 128.82, 128.42, 126.02, 109.42, 76.48, 56.06, 51.24, 47.53, 42.26, 37.51, 36.76, 33.12, 29.33, 28.25, 27.83, 23.04, 22.32, 20.78, 18.54 74 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.13 (d, J = 0.6 Hz, 1H), (m/z) 8.47 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.41-7.04 (m, 10H), 6.85 (dd, J = 5.3, 0.7 Hz, calcd for 1H), 4.96 (dq, J = 9.7, 6.4 Hz, 1H), 4.56 (ddd, J = C₃₀H₃₅N₂O₅, 11.0, 8.2, 7.1 Hz, 1H), 3.93 (s, 3H), 2.98 (td, J = 503.2546; 14.1, 12.7, 3.0 Hz, 2H), 2.73 (dd, J = 15.6, 7.6 found, Hz, 1H), 2.43 (dd, J = 13.8, 11.6 Hz, 1H), 2.36- 503.2537 2.27 (m, 1H), 2.17-1.98 (m, 1H), 1.84-1.66 (m, 2H), 1.67-1.55 (m, 1H), 1.55-1.40 (m, 1H), 1.29 (d, J = 6.4 Hz, 3H), 1.27-1.18 (m, 1H), 0.91-0.82 (m, 1H) ¹³C NMR (CDCl₃) δ 171.87, 168.63, 155.33, 148.71, 140.68, 140.49, 140.48, 130.49, 128.87, 128.69, 128.58, 128.34, 126.26, 125.97, 109.43, 76.26, 56.06, 51.14, 46.88, 44.18, 37.85, 37.31, 33.15, 27.43, 20.75, 18.70 75 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.16 (s, 1H), 8.51 (d, J = (m/z) 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.38-7.14 [M + H]⁺ (m, 5H), 6.85 (d, J = 5.2 Hz, 1H), 4.99 (dq, J = calcd for 8.5, 6.3 Hz, 1H), 4.55 (ddd, J = 11.2, 8.1, 6.6 Hz, C₂₈H₃₇N₂O₅, 1H), 3.93 (s, 3H), 2.87 (dd, J = 14.3, 3.7 Hz, 1H), 481.2702; 2.61 (dd, J = 14.2, 11.3 Hz, 1H), 2.26 (dt, J = found, 13.2, 6.7 Hz, 1H), 2.16-1.96 (m, 3H), 1.91- 481.2687 1.44 (m, 11H), 1.41 (d, J = 6.4 Hz, 3H), 1.39- 1.20 (m, 2H), 0.92-0.78 (m, 1H) ¹³C NMR (CDCl₃) δ 171.96, 168.62, 155.31, 148.69, 140.99, 140.49, 130.51, 128.63, 128.31, 125.92, 109.42, 74.95, 56.06, 51.62, 48.71, 42.55, 40.07, 39.46, 33.26, 29.47, 28.76, 27.76, 25.22, 24.48, 21.48, 19.57 76 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.13 (s, 1H), 8.47 (d, J = (m/z) 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.32-7.18 [M + H]⁺ (m, 2H), 7.16-7.03 (m, 2H), 6.86 (d, J = 5.2 Hz, calcd for 1H), 4.78 (dq, J = 9.4, 6.4 Hz, 1H), 4.55 (ddd, J = C₂₇H₃₆ClN₂O₅, 11.0, 8.2, 7.1 Hz, 1H), 3.93 (s, 3H), 2.92-2.78 503.2312; (m, 1H), 2.34-2.27 (m, 2H), 1.77-1.47 (m, found, 4H), 1.44-1.32 (m, 2H), 1.38 (d, J = 6.3 Hz, 503.2311 3H), 1.29-1.06 (m, 2H), 0.98 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.90-0.80 (m, 2H) ¹³C NMR (CDCl₃) δ 171.92, 168.64, 155.33, 148.70, 140.50, 139.43, 131.64, 130.47, 130.00, 128.47, 109.43, 76.99, 56.06, 51.07, 45.86, 43.73, 41.53, 36.82, 33.13, 27.58, 27.26, 24.08, 21.96, 19.73, 18.48 77 73-76 — ESIMS ¹H NMR (CDCl₃) δ 12.15 (d, J = 0.6 Hz, 1H), m/z 469 8.46 (d, J = 8.2 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.31-7.26 (m, 2H), 7.22-7.14 (m, 3H), 6.85 (d, J = 5.2 Hz, 1H), 4.78 (dq, J = 8.8, 6.4 Hz, 1H), 4.56 (ddd, J = 11.0, 8.3, 7.2 Hz, 1H), 3.93 (s, 3H), 2.90 (d, J = 13.8 Hz, 1H), 2.40-2.25 (m, 2H), 1.80-1.51 (m, 5H), 1.50-1.34 (m, 5H), 1.30-1.11 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 0.88-0.79 (m, 1H) ¹³C NMR (CDCl₃) δ 171.93, 168.59, 155.27, 148.65, 140.96, 140.43, 130.45, 128.64, 128.30, 125.88, 109.37, 77.05, 56.01, 51.06, 45.86, 43.72, 41.49, 37.39, 33.15, 27.56, 27.27, 24.07, 21.91, 19.72, 18.47 78 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.15 (s, 1H), 8.47 (d, J = 3369, (m/z) 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.35-7.27 2939, [M]⁺ (m, 4H), 7.25-7.12 (m, 6H), 6.86 (d, J = 5.2 Hz, 1736, calcd for 1H), 5.0-4.89 (m, 1H), 4.63-4.52 (m, 1H), 1649, C₃₁H₃₆N₂O₅, 3.94 (s, 3H), 2.90-2.72 (m, 2H), 2.60-2.49 (m, 1529, 516.2624; 1H), 2.40-2.27 (m, 2H), 1.97-1.73 (m, 4H), 1451, found, 1.73-1.50 (m, 3H), 1.49 (d, J = 6.3 Hz, 3H), 1264 516.2640 1.33-1.21 (m, 1H), 0.91-0.79 (m, 1H) 79 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.12 (s, 1H), 8.47 (d, J = 3368, (m/z) 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.36-7.29 2938, [M]⁺ (m, 2H), 7.28-7.19 (m, 5H), 7.03-6.98 (m, 1736, calcd for 2H), 6.85 (d, J = 5.2 Hz, 1H), 5.01-4.90 (m, 1649, C₃₀H₃₃ClN₂O₅, 1H), 4.61-4.51 (m, 1H), 3.93 (s, 3H), 2.95 (dd, 1528, 536.2078; J = 15.6, 3.3 Hz, 1H), 2.92-2.84 (m, 1H), 2.74 1481, found, (dd, J = 15.6, 7.4 Hz, 1H), 2.40 (dd, J = 13.9, 1264 536.2079 11.7 Hz, 1H), 2.37-2.26 (m, 1H), 2.17-2.06 (m, 1H), 1.80-1.64 (m, 2H), 1.61-1.37 (m, 2H), 1.30 (d, J = 6.4 Hz, 3H), 1.27-1.18 (m, 1H), 0.91-0.79 (m, 1H) 80 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.15 (s, 1H), 8.48 (d, J = (m/z) 8.2 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.54 (d, J = [M + H]⁺ 8.0 Hz, 2H), 7.36-7.18 (m, 2H), 6.86 (d, J = 5.2 calcd for Hz, 1H), 4.78 (dq, J = 9.2, 6.4 Hz, 1H), 4.57 C₂₈H₃₆F₃N₂O₅, (ddd, J = 11.0, 8.3, 7.2 Hz, 1H), 3.93 (s, 3H), 537.2576; 3.01-2.85 (m, 1H), 2.41 (dd, J = 13.8, 10.9 Hz, found, 1H), 2.32 (dt, J = 13.5, 6.8 Hz, 1H), 1.81-1.48 537.2566 (m, 5H), 1.47-1.31 (m, 2H), 1.39 (d, J = 6.4 Hz, 3H), 1.31-1.18 (m, 1H), 1.13 (dd, J = 14.8, 10.1 Hz, 1H), 1.00 (d, J = 6.5 Hz, 3H), 0.97 (d, J = 6.5 Hz, 3H), 0.92-0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.26 81 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.14 (s, 1H), 8.48 (d, J = (m/z) 8.1 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.56-7.14 [M + H]⁺ (m, 9H), 6.85 (d, J = 5.3 Hz, 1H), 4.96 (dq, J = calcd for 9.7, 6.3 Hz, 1H), 4.57 (dt, J = 11.0, 7.6 Hz, 1H), C₃₁H₃₄F₃N₂O₅, 3.92 (s, 3H), 3.03-2.87 (m, 2H), 2.77 (dd, J = 571.2420; 15.6, 7.3 Hz, 1H), 2.48 (dd, J = 13.9, 11.7 Hz, found, 1H), 2.32 (dt, J = 13.5, 6.9 Hz, 1H), 2.20-2.07 571.2405 (m, 1H), 1.86-1.73 (m, 1H), 1.75-1.65 (m, 1H), 1.62-1.48 (m, 1H), 1.46-1.37 (m, 1H), 1.32 (d, J = 6.3 Hz, 3H), 1.31-1.17 (m, 2H) ¹⁹F NMR (CDCl₃) δ −62.25 82 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.14 (d, J = 0.6 Hz, 1H), 3368, (m/z) 8.51 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 2930, [M]⁺ 7.32-7.26 (m, 2H), 7.23-7.16 (m, 3H), 6.86 1735, calcd for (dd, J = 5.3, 0.6 Hz, 1H), 4.95-4.85 (m, 1H), 1649, C₂₆H₃₄N₂O₅, 4.54 (ddd, J = 11.0, 8.2, 7.1 Hz, 1H), 3.94 (s, 1496, 454.2468; 3H), 2.78 (dd, J = 15.5, 3.2 Hz, 1H), 2.56 (dd, J = 1449, found, 15.5, 7.9 Hz, 1H), 2.42-2.29 (m, 1H), 2.01- 1263 454.2476 1.89 (m, 1H), 1.88-1.72 (m, 1H), 1.66-1.57 (m, 2H), 1.48-1.27 (m, 5H), 1.21 (d, J = 6.4 Hz, 3H), 1.19-1.07 (m, 1H), 0.99-0.89 (m, 1H), 0.86 (t, J = 6.8 Hz, 3H) 83 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.16 (s, 1H), 8.51 (d, J = 3368, (m/z) 8.2 Hz, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.33-7.26 2947, [M]⁺ (m, 2H), 7.23-7.13 (m, 3H), 6.87 (dd, J = 5.1 1735, calcd for Hz, 1H), 4.97-4.86 (m, 1H), 4.61-4.51 (m, 1649, C₂₉H₄₀N₂O₅, 1H), 3.94 (s, 3H), 2.68 (ddd, J = 13.6, 11.5, 5.3 1450, 496.2937; Hz, 1H), 2.47 (ddd, J = 13.6, 11.4, 5.8 Hz, 1H), 1280 found, 2.42-2.29 (m, 1H), 1.90-1.65 (m, 3H), 1.64- 496.2946 1.31 (m, 6H), 1.44 (d, J = 6.3 Hz, 3H), 1.30- 1.02 (m, 4H), 0.98-0.93 (m, 1H), 0.93-0.84 (m, 6H) 84 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.14 (d, J = 0.6 Hz, 1H), (m/z) 8.51 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.38-7.19 (m, 2H), 7.19-7.04 (m, 2H), 6.86 (d, calcd for J = 5.2 Hz, 1H), 4.99 (dq, J = 8.5, 6.4 Hz, 1H), C₂₈H₃₆ClN₂O₅, 4.55 (ddd, J = 11.2, 8.1, 6.6 Hz, 1H), 3.94 (s, 515.2313; 3H), 2.83 (dd, J = 14.4, 3.8 Hz, 1H), 2.60 (dd, J = found, 14.3, 11.3 Hz, 1H), 2.26 (dt, J = 13.5, 6.8 Hz, 515.2306 1H), 2.09-1.78 (m, 3H), 1.78-1.44 (m, 9H), 1.41 (d, J = 6.4 Hz, 3H), 1.37-1.20 (m, 3H), 0.91-0.79 (m, 1H) ¹³C NMR (CDCl₃) δ 171.90, 168.63, 155.33, 148.70, 140.50, 139.42, 131.59, 130.50, 129.94, 128.44, 109.42, 74.83, 56.06, 51.59, 48.80, 42.56, 40.05, 38.83, 33.24, 29.55, 28.81, 27.65, 25.18, 24.45, 21.50, 19.52 85 — — ESIMS ¹H NMR (CDCl₃) δ 12.15 (s, 1H), 8.51 (d, J = m/z 545 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.31-7.24 [M + H]⁺ (m, 4H), 7.23-7.14 (m, 4H), 7.09 (d, J = 6.9 Hz, 2H), 6.86 (d, J = 5.2 Hz, 1H), 4.90 (dq, J = 12.6, 6.2 Hz, 1H), 4.54 (dt, J = 10.8, 7.5 Hz, 1H), 3.93 (s, 3H), 2.71-2.50 (m, 3H), 2.48-2.39 (m, 1H), 2.33 (dd, J = 13.1, 6.0 Hz, 1H), 1.99-1.19 (m, 12 H), 1.43 (d, J = 6.3 Hz, 3H), 0.95 (dd, J = 15.4, 6.9 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.06, 168.66, 155.35, 148.73, 142.31, 142.21, 140.51, 130.51, 128.48, 128.36, 128.34, 128.20, 125.97, 125.78, 109.45, 75.62, 56.08, 51.17, 45.65, 40.09, 35.94, 33.08, 32.41, 32.11, 30.91, 29.14, 27.96, 19.78, 18.35 86 — — ESIMS ¹H NMR (CDCl₃) δ 12.10 (s, 1H), 8.47 (d, J = m/z 589 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.52 (d, J = [M + H]⁺ 8.0 Hz, 2H), 7.25-7.14 (m, 4H), 7.03 (at, J = 8.7 Hz, 2H), 6.86 (d, J = 5.2 Hz, 1H), 4.95 (dq, J = 9.7, 6.4 Hz, 1H), 4.57 (dt, J = 11.0, 7.3 Hz, 1H), 3.93 (s, 3H), 2.93 (d, J = 15.2 Hz, 2H), 2.74 (dd, J = 15.7, 7.5 Hz, 1H), 2.50 (dd, J = 13.7, 11.9 Hz, 1H), 2.32 (dt, J = 13.4, 6.8 Hz, 1H), 2.15-2.05 (m, 1H), 1.96-1.36 (m, 5H), 1.30 (d, J = 6.4 Hz, 3H), 0.87 (dd, J = 14.9, 7.5 Hz, 1H) ¹³C NMR (CDCl₃) δ 171.80, 168.66, 161.46 (d, J = 243 Hz), 155.35, 148.72, 144.66, 140.52, 135.79 (d, J = 3 Hz), 130.41, 130.14 (d, J = 7 Hz), 128.9, 128.48 (q, J = 32 Hz), 125.35 (q, J = 3 Hz), 124.23 (q, J = 270 Hz), 115.50, (d, J = 21 Hz), 109.47, 75.87, 56.07, 51.09 46.97, 43.82, 37.73, 36.51, 33.01, 27.36, 20.73, 18.7 ¹⁹F NMR (CDCl₃) δ −62.35, −116.54 87 — — ESIMS ¹H NMR (CDCl₃) δ 12.17 (s, 1H), 8.54 (d, J = m/z 461 8.1 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 6.86 (d, J = [M + H]⁺ 5.2 Hz, 1H), 4.98 (p, J = 6.4 Hz, 1H), 4.53 (m, 1H), 3.94 (s, 3H), 2.33 (m, 1H), 1.91 (m, 2H), 1.77 (m, 1H), 1.71-1.06 (m, 18H), 1.36 (d, J = 6.4 Hz, 3H), 0.89 (dd, J = 6.6, 2.3 Hz, 6H) ¹³C NMR (CDCl₃) δ 172.00, 168.61, 155.31, 148.69, 140.47, 130.57, 109.39, 75.09, 56.05, 51.72, 49.91, 42.56, 38.42, 37.21, 33.44, 31.41, 30.09, 28.45, 27.75, 25.06, 24.35, 22.95, 22.49, 21.50, 19.07 88 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.16 (d, J = 0.6 Hz, 1H), (m/z) 8.46 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.32-7.25 (m, 2H), 7.23-7.12 (m, 3H), 6.85 calcd for (dd, J = 5.3, 0.7 Hz, 1H), 4.84 (dq, J = 9.8, 6.3 C₂₈H₃₉N₂O₅, Hz, 1H), 4.56 (ddd, J = 11.0, 8.2, 7.2 Hz, 1H), 483.2859; 3.93 (s, 3H), 2.93-2.80 (m, 1H), 2.41-2.25 (m, found, 2H), 1.82 (tt, J = 10.8, 3.4 Hz, 1H), 1.74-1.42 483.2865 (m, 7H), 1.37 (d, J = 6.3 Hz, 3H), 1.35-1.02 (m, 3H), 0.93 (d, J = 6.6 Hz, 6H), 0.84-0.71 (m, 1H) ¹³C NMR (CDCl₃) δ 171.93, 168.63, 155.31, 148.70, 141.09, 140.47, 130.49, 128.71, 128.36, 125.90, 109.41, 75.52, 56.05, 51.08, 45.32, 42.31, 37.93, 34.48, 33.11, 28.86, 27.47, 27.18, 22.73, 22.45, 19.68, 18.54 89 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.13 (d, J = 0.6 Hz, 1H), (m/z) 8.51 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.19-7.08 (m, 2H), 7.06-6.94 (m, 2H), 6.86 (d, calcd for J = 5.4 Hz, 1H), 4.88 (dq, J = 9.6, 6.4 Hz, 1H), C₂₆H₃₄FN₂O₅, 4.54 (ddd, J = 11.0, 8.2, 7.1 Hz, 1H), 3.94 (s, 473.2452; 3H), 2.80-2.67 (m, 1H), 2.54 (dd, J = 15.5, 7.9 found, Hz, 1H), 2.42-2.30 (m, 1H), 1.95-1.74 (m, 473.2451 2H), 1.65-1.57 (m, 2H), 1.51-1.30 (m, 5H), 1.20 (d, J = 6.3 Hz, 3H), 1.13 (ddd, J = 12.8, 10.0, 5.5 Hz, 1H), 0.99-0.91 (m, 1H), 0.86 (t, J = 7.1 Hz, 3H) ¹⁹F NMR (CDCl₃) δ −117.29 90 — — ESIMS ¹H NMR (CDCl₃) δ 12.14 (s, 1H), 8.49 (d, J = m/z 489 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.36 (at, J = [M + H]⁺ 7.4 Hz, 2H), 7.32-7.15 (m, 5H), 7.12 (at, J = 7.3 Hz, 1H), 6.90 (d, J = 6.9 Hz, 2H), 6.86 (d, J = 5.2 Hz, 1H), 5.28-5.17 (m, 1H), 4.71-4.60 (m, 1H), 3.94 (s, 3H), 2.79 (t, J = 9.9 Hz, 1H), 2.54 (d, J = 12.6 Hz, 1H), 2.38 (dt, J = 13.0, 6.5 Hz, 1H), 2.26 (t, J = 12.0 Hz, 1H), 2.16 (m, 1H), 1.77 (td, J = 13.7, 12.8, 5.5 Hz, 1H), 1.70-1.51 (m, 2H), 1.34 (q, J = 11.4 Hz, 1H), 1.11 (m, 1H), 0.98 (d, J = 6.4 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.09, 168.68, 155.35, 148.73, 142.08, 140.73, 140.51, 130.47, 128.80, 128.59, 128.20, 127.07, 125.83, 109.46, 75.66, 56.07, 55.18, 51.08, 46.73, 37.55, 33.25, 27.21, 20.64, 18.17 91 — — ESIMS ¹H NMR (CDCl₃) δ 12.16 (s, 1H), 8.54 (d, J = m/z 441 8.1 Hz, 1H), 8.01 (d, J = 5.2 Hz, 1H), 7.30 (at, J = [M + H]⁺ 7.3 Hz, 2H), 7.26-7.19 (m, 1H), 7.15-7.09 (m, 2H), 6.87 (d, J = 5.2 Hz, 1H), 5.19 (m, 1H), 4.63 (dt, J = 10.8, 7.6 Hz, 1H), 3.94 (s, 3H), 2.62 (t, J = 9.9 Hz, 1H), 2.41 (dt, J = 13.4, 6.7 Hz, 1H), 1.99-1.79 (m, 2H), 1.76-1.54 (m, 2H), 1.43 (q, J = 11.9, 11.4 Hz, 1H), 1.37-0.94 (m, 5H), 0.92 (d, J = 6.4 Hz, 3H), 0.69 (t, J = 7.2 Hz, 3H) ¹³C NMR (CDCl₃) δ 172.21, 168.67, 155.34, 148.72, 142.48, 140.51, 130.50, 129.01, 128.50, 126.71, 109.45, 75.90, 56.07, 55.51, 51.17, 43.42, 33.48, 33.22, 27.93, 20.55, 20.05, 18.10, 14.00 92 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.16 (s, 1H), 8.51 (d, J = (m/z) 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.39-7.21 [M + H]⁺ (m, 2H), 7.22-7.10 (m, 3H), 6.85 (d, J = 5.2 Hz, calcd for 1H), 4.73 (dq, J = 9.6, 6.4 Hz, 1H), 4.52 (ddd, J = C₂₉H₄₁N₂O₅, 10.9, 8.2, 7.1 Hz, 1H), 3.92 (s, 3H), 2.76-2.49 497.3015; (m, 2H), 2.43-2.25 (m, 1H), 1.83-1.68 (m, found, 2H), 1.66-1.36 (m, 6H), 1.32 (d, J = 6.5 Hz, 497.3019 3H), 1.29-1.12 (m, 4H), 0.91-0.80 (m, 8H) ¹³C NMR (CDCl₃) δ 172.07, 168.63, 155.31, 148.70, 142.37, 140.49, 130.51, 128.39, 128.27, 125.73, 109.42, 77.30, 56.05, 51.18, 44.12, 43.21, 41.38, 35.93, 33.16, 30.42, 29.25, 27.84, 27.41, 24.01, 21.85, 19.75, 18.33 93 49-53 — ESIMS ¹H NMR (CDCl₃) δ 12.14 (d, J = 0.6 Hz, 1H), m/z 615 8.51 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.32-7.24 (m, 2H), 7.22-7.11 (m, 7H), 6.85 (d, J = 5.2 Hz, 1H), 4.88 (dq, J = 9.5, 6.3 Hz, 1H), 4.53 (dt, J = 10.9, 7.6 Hz, 1H), 2.69 (dd, J = 15.5, 3.5 Hz, 1H), 2.63-2.46 (m, 3H), 2.40-2.30 (m, 1H), 1.97-1.67 (m, 3H), 1.65-1.49 (m, 2H), 1.48-1.15 (m, 10H), 1.02-0.82 (m, 2H) ¹³C NMR (CDCl₃) δ 171.85, 168.58, 155.26, 148.64, 147.43, 142.18, 140.44, 139.46, 130.39, 129.95, 128.25, 125.74, 124.63- 116.27 (m), 120.88, 109.38, 75.96, 55.98, 51.13, 47.45, 41.71, 36.65, 35.95, 32.99, 31.12, 29.23, 27.73, 20.69, 18.43 ¹⁹F NMR (CDCl₃) δ −57.88 94 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.15 (d, J = 0.6 Hz, 1H), (m/z) 8.52 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.33-7.24 (m, 2H), 7.23-7.11 (m, 3H), 6.86 calcd for (dd, J = 5.3, 0.7 Hz, 1H), 4.91 (dq, J = 9.7, 6.4 C₂₇H₃₅N₂O₅, Hz, 1H), 4.55 (ddd, J = 10.9, 8.2, 7.1 Hz, 1H), 467.2546; 3.94 (s, 3H), 2.72 (dd, J = 15.4, 3.3 Hz, 1H), 2.54 found, (dd, J = 15.5, 7.8 Hz, 1H), 2.44-2.31 (m, 1H), 467.2545 2.09-1.86 (m, 2H), 1.72-1.61 (m, 2H), 1.59- 1.45 (m, 2H), 1.46-1.32 (m, 1H), 1.21 (d, J = 6.3 Hz, 3H), 1.11-0.96 (m, 2H), 0.74-0.59 (m, 1H), 0.54-0.40 (m, 1H), 0.41-0.27 (m, 1H), 0.09-0.00 (m, 1H), −0.07-−0.20 (m, 1H) ¹³C NMR (CDCl₃) δ 171.94, 168.62, 155.32, 148.70, 140.78, 140.49, 130.52, 128.80, 128.42, 126.04, 109.42, 76.48, 56.06, 51.22, 46.80, 42.68, 37.33, 36.61, 33.26, 28.33, 20.75, 18.90, 9.18, 5.68, 3.75 95 — — HRMS-FAB ¹H NMR (CDCl₃) δ 12.12 (d, J = 0.6 Hz, 1H), (m/z) 8.46 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), [M + H]⁺ 7.33-7.15 (m, 5H), 7.14-7.06 (m, 2H), 7.06- calcd for 6.96 (m, 2H), 6.85 (d, J = 5.2 Hz, 1H), 4.94 (dq, C₃₀H₃₄FN₂O₅, J = 9.6, 6.4 Hz, 1H), 4.56 (ddd, J = 11.0, 8.2, 7.1 521.2452; Hz, 1H), 3.93 (s, 3H), 3.05-2.84 (m, 2H), 2.71 found, (dd, J = 15.7, 7.6 Hz, 1H), 2.44 (dd, J = 13.8, 521.2452 11.6 Hz, 1H), 2.38-2.25 (m, 1H), 2.08 (tdd, J = 9.8, 7.5, 3.1 Hz, 1H), 1.83-1.65 (m, 2H), 1.59 (dt, J = 13.0, 7.9 Hz, 1H), 1.48 (dddd, J = 15.0, 10.0, 8.4, 4.4 Hz, 1H), 1.32-1.17 (m, 4H), 0.92- 0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −116.85 96 76-78 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.09 (s, 1H), 8.46 (d, J = 3371, (m/z) 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.55-7.49 2941, [M]⁺ (m, 2H), 7.32-7.26 (m, 2H), 7.22-7.15 (m, 1739, calcd for 4H), 6.86 (d, J = 5.1 Hz, 1H), 5.02-4.90 (m, 1650, C₃₂H₃₂F₆N₂O₆, 1H), 4.62-4.51 (m, 1H), 3.94 (s, 3H), 3.01- 1529, 654.2165; 2.89 (m, 2H), 2.77 (dd, J = 15.7, 7.5 Hz, 1H), 1325, found, 2.52 (dd, J = 13.9, 11.6 Hz, 1H), 2.38-2.27 (m, 1260 654.2171 1H), 2.19-2.07 (m, 1H), 1.85-1.66 (m, 2H), 1.64-1.50 (m, 1H), 1.50-1.35 (m, 1H), 1.31- 1.19 (m, 1H), 1.29 (d, J = 6.4 Hz, 3H), 0.94- 0.82 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.95, −62.37 97 76-78 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.11 (s, 1H), 8.46 (d, J = 3363, (m/z) 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.31-7.24 2937, [M]⁺ (m, 4H), 7.22-7.16 (m, 3H), 7.12-7.06 (m, 1738, calcd for 2H), 6.86 (d, J = 5.3 Hz, 1H), 5.02-4.89 (m, 1650, C₃₁H₃₃F₃N₂O₆, 1H), 4.62-4.51 (m, 1H), 3.94 (s, 3H), 3.05- 1529, 586.2291; 2.88 (m, 2H), 2.74 (dd, J = 15.8, 7.7 Hz, 1H), 1450, found, 2.46 (dd, J = 13.8, 11.5 Hz, 1H), 2.38-2.26 (m, 1261 586.2296 1H), 2.18-2.05 (m, 1H), 1.85-1.39 (m, 4H), 1.31-1.20 (m, 1H), 1.27 (d, J = 6.3 Hz, 3H), 0.93-0.80 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.93 98 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 12.13 (s, 1H), 8.50 (d, J = 3371, (m/z) 8.2 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.32-7.24 2935, [M]⁺ (m, 4H), 7.23-7.12 (m, 6H), 6.86 (d, J = 5.2 Hz, 1735, calcd for 1H), 4.96-4.84 (m, 1H), 4.59-4.46 (m, 1H), 1649, C₃₂H₃₈N₂O₅, 3.94 (s, 3H), 2.74 (dd, J = 15.5, 3.4 Hz, 1H), 2.63- 1528, 530.2781; 2.45 (m, 3H), 2.40-2.27 (m, 1H), 2.00-1.88 1451, found, (m, 1H), 1.87-1.24 (m, 9H), 1.23 (d, J = 6.4 Hz, 1264 530.2787 3H), 1.00-0.90 (m, 1H) 99 — — ESIMS ¹H NMR (CD₃OD) δ 7.33-7.06 (m, 5H), 4.87 m/z 318 (m, 1H), 3.89 (dd, J = 11.0, 7.3 Hz, 1H), 2.91- [M + H]⁺ 2.80 (m, 1H), 2.34 (dd, J = 13.7, 11.2 Hz, 1H), 2.29-2.15 (m, 1H), 1.85-1.74 (m, 1H), 1.71- 1.16 (m, 11H), 1.39 (d, J = 6.3 Hz, 1H), 0.96 (t, J = 7.2 Hz, 3H), 0.80-0.62 (m, 1H) ¹³C NMR (CD₃OD) δ 171.18, 142.28, 129.81, 129.48, 127.06, 77.92, 52.65, 46.69, 43.98, 38.91, 31.67, 30.32, 29.03, 28.62, 24.50, 20.00, 19.11, 14.41 100 — — ESIMS ¹H NMR (CD₃OD) δ 7.65-7.55 (m, 2H), 7.38 m/z 386 (d, J = 8.0 Hz, 2H), 4.91-4.84 (m, 1H), 3.88 [M + H]⁺ (dd, J = 11.0, 7.4 Hz, 1H), 2.96 (d, J = 13.5 Hz, 1H), 2.48 (dd, J = 13.9, 11.3 Hz, 1H), 2.21 (dt, J = 13.3, 6.7 Hz, 1H), 1.97-1.80 (m, 1H), 1.77- 1.54 (m, 5H), 1.54-1.15 (m, 6H), 1.41 (d, J = 6.3 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 0.79 (dd, J = 15.6, 8.0 Hz, 1H) ¹⁹F NMR (CD₃OD) δ −59.91 101 — — ESIMS ¹H NMR (CD₃OD) δ 7.34-7.14 (m, 5H), 4.93- m/z 332 4.86 (m, 1H), 3.95-3.83 (m, 1H), 2.68 (qd, J = [M + H]⁺ 15.3, 5.5 Hz, 2H), 2.28 (ddt, J = 13.9, 7.4, 3.0 Hz, 1H), 2.00-1.79 (m, 2H), 1.63 (dq, J = 9.6, 4.5 Hz, 2H), 1.51-1.35 (m, 4H), 1.36-1.26 (m, 2H), 1.24 (d, J = 6.3 Hz, 3H), 1.03 (ddt, J = 12.9, 10.3, 5.0 Hz, 1H), 0.94-0.88 (m, 1H), 0.85 (dd, J = 6.5, 1.1 Hz, 6H) ¹³C NMR (CD₃OD) δ 171.16, 142.20, 130.01, 129.53, 127.18, 78.63, 52.83, 48.95, 43.42, 38.34, 37.91, 31.69, 30.57, 29.48, 28.89, 23.47, 22.76, 21.12, 19.22 102 — — ESIMS ¹H NMR (CD₃OD) δ 7.37-7.04 (m, 10H), 4.96 m/z 352 (dq, J = 9.8, 6.4 Hz, 1H), 3.89 (dd, J = 11.1, 7.2 [M + H]⁺ Hz, 1H), 3.05-2.89 (m, 2H), 2.79 (dd, J = 15.5, 7.5 Hz, 1H), 2.42 (dd, J = 13.8, 11.6 Hz, 1H), 2.21 (dt, J = 13.5, 6.8 Hz, 1H), 2.13 (tdd, J = 9.9, 7.4, 3.4 Hz, 1H), 1.88-1.55 (m, 3H), 1.53-1.39 (m, 1H), 1.34-1.25 (m, 1H), 1.30 (d, J = 6.4 Hz, 3H), 0.84-0.69 (m, 1H) ¹³C NMR (CD₃OD) δ 171.10, 142.01, 130.10, 129.81, 129.62, 129.39, 127.30, 127.05, 78.61, 52.70, 48.20, 45.28, 38.80, 37.93, 31.65, 28.50, 21.05, 19.27 103 — — ESIMS — m/z 330 [M + H]⁺ 104 — — — — 105 221-224 — ESIMS ¹H NMR (CD₃OD) δ 7.31-7.22 (m, 2H), 7.21- m/z 318 7.12 (m, 3H), 4.80 (dq, J = 9.1, 6.4 Hz, 1H), 3.90 [M + H]⁺ (dd, J = 11.0, 7.4 Hz, 1H), 2.97-2.86 (m, 1H), 2.33 (dd, J = 13.8, 11.0 Hz, 1H), 2.24 (dt, J = 13.6, 6.7 Hz, 1H), 1.83-1.52 (m, 5H), 1.50- 1.36 (m, 5H), 1.35-1.24 (m, 1H), 1.24-1.15 (m, 1H), 1.02-0.97 (m, 6H), 0.78 (dd, J = 15.6, 7.7 Hz, 1H) ¹³C NMR (CD₃OD) δ 171.14, 142.12, 129.73, 129.41, 127.02, 79.32, 52.63, 47.06, 45.01, 42.26, 38.45, 31.69, 28.81, 28.38, 24.32, 22.34, 20.06, 19.04 106 — — ESIMS ¹H NMR (CD₃OD) δ 7.61-7.36 (m, 4H), 4.85- m/z 386 4.79 (m, 1H), 3.90 (dd, J = 11.0, 7.4 Hz, 1H), [M + H]⁺ 2.99 (d, J = 13.8 Hz, 1H), 2.52-2.40 (m, 1H), 2.26-2.17 (m, 1H), 1.83-1.55 (m, 5H), 1.52- 1.16 (m, 4H), 1.42 (d, J = 6.4 Hz, 1H), 1.00 (t, J = 6.8 Hz, 6H), 0.82 (dd, J = 15.3, 7.9 Hz, 1H) ¹⁹F NMR (CD₃OD) δ −63.84 107 — — ESIMS ¹H NMR (CD₃OD) δ 7.71-7.06 (m, 9H), 4.98 m/z 420 (dq, J = 9.7, 6.4 Hz, 1H), 3.98-3.82 (m, 1H), [M + H]⁺ 2.99 (dt, J = 15.7, 3.6 Hz, 2H), 2.83 (dd, J = 15.5, 7.3 Hz, 1H), 2.53 (dd, J = 13.9, 11.7 Hz, 1H), 2.27-2.11 (m, 2H), 1.87 (ddt, J = 12.3, 8.4, 3.9 Hz, 1H), 1.81-1.70 (m, 1H), 1.61 (dq, J = 14.6, 8.1, 7.7 Hz, 1H), 1.48-1.24 (m, 2H), 1.32 (d, J = 6.3 Hz, 1H), 0.82 (dd, J = 15.6, 8.0 Hz, 1H) ¹⁹F NMR (CD₃OD) δ −63.86 108 — — ESIMS ¹H NMR (CD₃OD) δ 7.31-7.24 (m, 2H), 7.24- m/z 365 7.18 (m, 2H), 5.14-4.99 (m, 1H), 3.89 (dd, J = [M + H]⁺ 11.2, 6.8 Hz, 1H), 2.86 (dd, J = 14.2, 4.1 Hz, 1H), 2.65 (dd, J = 14.3, 11.2 Hz, 1H), 2.24-1.99 (m, 3H), 1.94-1.80 (m, 1H), 1.80-1.47 (m, 9H), 1.44 (d, J = 6.4 Hz, 3H), 1.43-1.22 (m, 3H), 0.86 (dd, J = 14.3, 6.9 Hz, 1H) 109 — — ESIMS ¹H NMR (CD₃OD) δ 7.34-7.26 (m, 4H), 7.26- m/z 366.3 7.15 (m, 6H), 5.04-4.95 (m, 1H), 3.89 (dd, J = [M + H]⁺ 11.0, 7.4 Hz, 1H), 2.92-2.75 (m, 2H), 2.65- 2.54 (m, 1H), 2.34 (dd, J = 13.8, 11.1 Hz, 1H), 2.28-2.17 (m, 1H), 2.0-1.74 (m, 4H), 1.74- 1.50 (m, 3H), 1.53 (d, J = 6.3 Hz, 3H), 1.39- 1.25 (m, 1H), 0.88-0.76 (m, 1H) 110 — — ESIMS ¹H NMR (CD₃OD) δ 7.38-7.30 (m, 4H), 7.29- m/z 386.3 7.20 (m, 3H), 7.16-7.10 (m, 2H), 5.05-4.93 [M + H]⁺ (m, 1H), 3.88 (dd, J = 11.1, 7.3 Hz, 1H), 2.99 (dd, J = 15.5, 3.7 Hz, 1H), 2.94 (dd, J = 14.0, 2.6 Hz, 1H), 2.82 (dd, J = 15.5, 7.4 Hz, 1H), 2.48- 2.40 (m, 1H), 2.26-2.10 (m, 2H), 1.87-1.55 (m, 3H), 1.53-1.39 (m, 1H), 1.37-1.25 (m, 1H), 1.33 (d, J = 6.3 Hz, 3H), 0.88-0.76 (m, 1H) 111 — — ESIMS ¹H NMR (CDCl₃) δ 8.74 (bs, 3H), 7.31-7.26 m/z 346.3 (m, 2H), 7.21-7.16 (m, 1H), 7.15-7.09 (m, [M + H]⁺ 2H), 4.96-4.81 (m, 1H), 4.07-3.94 (m, 1H), 2.70-2.49 (m, 2H), 2.49-2.36 (m, 1H), 1.91- 1.61 (m, 3H), 1.61-1.31 (m, 6H), 1.44 (d, J = 6.2 Hz, 3H), 1.27-0.99 (m, 4H), 0.93-0.86 (m, 1H), 0.87 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H) 112 — — ESIMS ¹H NMR (CDCl₃) δ 8.70 (bs, 3H), 7.31-7.23 m/z 304.3 (m, 2H), 7.22-7.12 (m, 3H), 4.91-4.78 (m, [M + H]⁺ 1H), 4.0-3.88 (m, 1H), 2.74 (dd, J = 15.6, 2.3 Hz, 1H), 2.57-2.44 (m, 2H), 1.93-1.46 (m, 7H), 1.44-1.22 (m, 3H), 1.17 (d, J = 6.4 Hz, 3H), 1.16-1.05 (m, 1H), 0.84 (t, J = 6.8 Hz, 3H) 113 — — ESIMS ¹H NMR (DMSO-d₆) δ 8.38 (bs, 3H), 7.33-7.23 m/z 394 (m, 4H), 7.22-7.14 (m, 4H), 7.13-7.08 (m, [M + H]⁺ 2H), 4.81 (dq, J = 12.4, 6.2 Hz, 1H), 3.85 (t, J = 8.3 Hz, 1H), 2.68-2.52 (m, 3H), 2.40 (td, J = 12.7, 5.3 Hz, 1H), 2.18-2.08 (m, 1H), 1.85- 1.21 (m, HH), 1.38 (d, J = 6.3 Hz, 3H), 1.10 (m, 1H), 0.73 (dd, J = 14.3, 8.0 Hz, 1H) 114 — — ESIMS ¹H NMR (DMSO-d₆) δ 8.03 (s, 3H), 7.63 (d, J = m/z 438 8.0 Hz, 2H), 7.38 (m, J = 4H), 7.16 (t, J = 8.8 Hz, [M + H]⁺ 2H), 4.85 (m, 1H), 3.84 (dd, J = 11.4, 7.8 Hz, 1H), 2.98-2.85 (m, 2H), 2.79 (dd, J = 15.4, 6.7 Hz, 1H), 2.49 (m, 1H, obscured by DMSO solvent peak), 2.06 (m, 2H), 1.75 (m, 1H), 1.66- 1.44 (m, 2H), 1.44-1.15 (m, 2H), 1.20 (d, J = 6.4 Hz, 3H), 0.64 (dd, J = 15.5, 5.9 Hz, 1H) ¹⁹F NMR (DMSO-d₆) δ −60.70, −117.22 115 — — ¹H NMR (DMSO-d₆) δ 8.36 (s, 3H), 4.85 (ap, J = 6.3 Hz, 1H), 3.87 (dd, J = 11.0, 6.9 Hz, 1H), 2.13 (dt, J = 11.9, 6.6 Hz, 1H), 1.86 (m, 2H), 1.72 (dt, J = 10.8, 6.1 Hz, 1H), 1.65-1.03 (m, 17 H), 1.33 (d, J = 6.4 Hz, 3H), 0.86 (dd, J = 6.6, 2.2 Hz, 6H), 0.70 (dd, J = 14.5, 5.2 Hz, 1H) ¹³C NMR (DMSO-d₆) δ 170.05, 74.74, 51.20, 49.15, 41.89, 37.49, 36.49, 30.83, 30.35, 29.63, 27.83, 27.60, 27.23, 24.60, 23.89, 22.77, 22.30, 21.17, 18.08 116 — — ESIMS ¹H NMR (CD₃OD) δ 7.31-7.24 (m, 2H), 7.17 m/z 332 (dd, J = 7.6, 5.7 Hz, 3H), 4.86-4.80 (m, 1H), [M + H]⁺ 3.88 (dd, J = 11.0, 7.4 Hz, 1H), 2.92-2.82 (m, 1H), 2.36 (dd, J = 13.7, 11.1 Hz, 1H), 2.26-2.15 (m, 1H), 1.88-1.76 (m, 1H), 1.75-1.45 (m, 7H), 1.40 (d, J = 6.3 Hz, 3H), 1.36-1.23 (m, 2H), 1.16 (ddt, J = 13.5, 11.9, 5.5 Hz, 1H), 0.95 (dd, J = 6.6, 1.2 Hz, 6H), 0.75 (dd, J = 15.5, 7.4 Hz, 1H) 117 — — ESIMS ¹H NMR (CD₃OD) δ 7.30-7.18 (m, 2H), 7.09- m/z 322 6.96 (m, 2H), 4.95-4.89 (m, 1H), 3.87 (dd, J = [M + H]⁺ 11.0, 7.3 Hz, 1H), 2.78-2.58 (m, 2H), 2.33- 2.17 (m, 1H), 1.96-1.79 (m, 2H), 1.69-1.61 (m, 2H), 1.51-1.32 (m, 5H), 1.23 (d, J = 6.4 Hz, 3H), 1.20-1.10 (m, 1H), 0.92-0.83 (m, 1H), 0.87 (t, J = 7.1 Hz, 3H) 118 — — ESIMS ¹H NMR (DMSO-d₆) δ 8.30 (bs, 3H), 7.49-7.35 m/z 338 (m, 4H), 7.30 (dt, J = 8.4, 4.2 Hz, 1H), 7.20 (t, J = [M + H]⁺ 7.3 Hz, 2H), 7.12 (t, J = 7.3 Hz, 1H), 6.87 (d, J = 7.0 Hz, 2H), 5.24 (dd, J = 9.5, 6.4 Hz, 1H), 4.04-3.86 (m, 1H), 2.80 (t, J = 9.7 Hz, 1H), 2.32 (d, J = 11.2 Hz, 1H), 2.28-2.11 (m, 3H), 1.60 (m, 2H), 1.44 (m, 1H), 1.31 (m, 1H), 0.95- 0.88 (m, 1H), 0.89 (d, J = 6.3 Hz, 3H) 119 — — ESIMS ¹H NMR (DMSO-d₆) δ 8.38 (bs, 3H), 7.37-7.28 m/z 290 (m, 2H), 7.28-7.17 (m, 3H), 5.18 (m, 1H), 3.92 [M + H]⁺ (dd, J = 10.6, 7.4 Hz, 1H), 2.60 (t, J = 9.8 Hz, 1H), 2.19 (m, 1H), 1.90-1.76 (m, 2H), 1.55 (m, 2H), 01.45-0.87 (m, 6H), 0.84 (d, J = 6.3 Hz, 3H), 0.63 (t, J = 7.1 Hz, 3H) 120 — — ESIMS ¹H NMR (CDCl₃) δ 8.62 (s, 3H), 7.34-7.10 (m, m/z 346 5H), 4.83-4.50 (m, 1H), 4.16-3.88 (m, 1H), [M + H]⁺ 2.71-2.41 (m, 3H), 1.86-1.61 (m, 3H), 1.60- 1.24 (m, 9H), 1.22-1.09 (m, 3H), 0.95-0.70 (m, 8H) ¹³C NMR (CDCl₃) δ 170.15, 142.26, 128.39, 128.29, 125.74, 78.06, 52.12, 43.96, 43.06, 41.31, 35.83, 30.88, 30.29, 29.07, 27.74, 27.35, 24.01, 21.81, 19.70, 17.92 121 — — ESIMS ¹H NMR (CD₃OD) δ 7.52-7.40 (m, 2H), 7.41- m/z 316 7.33 (m, 3H), 5.17-5.07 (m, 1H), 4.05 (dd, J = [M + H]⁺ 11.1, 7.3 Hz, 1H), 2.90 (dd, J = 15.4, 3.8 Hz, 1H), 2.80 (dd, J = 15.4, 7.4 Hz, 1H), 2.52-2.38 (m, 1H), 2.30-2.18 (m, 1H), 2.15-2.01 (m, 1H), 1.97-1.80 (m, 2H), 1.80-1.56 (m, 3H), 1.42 (d, J = 6.4 Hz, 3H), 1.23 (dd, J = 11.5, 8.2 Hz, 1H), 1.14 (dd, J = 15.3, 7.6 Hz, 1H), 0.94- 0.78 (m, 1H), 0.69-0.59 (m, 1H), 0.59-0.47 (m, 1H), 0.28-0.17 (m, 1H), 0.07 (tt, J = 8.5, 4.4 Hz, 1H) 122 — — ESIMS ¹H NMR (CD₃OD) δ 7.54-7.48 (m, 2H), 7.46- m/z 370 7.38 (m, 2H), 7.39-7.28 (m, 3H), 7.28-7.20 [M + H]⁺ (m, 2H), 5.23-5.10 (m, 1H), 4.14-4.01 (m, 1H), 3.18-3.08 (m, 2H), 2.97 (dd, J = 15.7, 7.5 Hz, 1H), 2.71-2.55 (m, 1H), 2.39 (dt, J = 13.6, 6.9 Hz, 1H), 2.34-2.20 (m, 1H), 2.04-1.74 (m, 3H), 1.66 (dtd, J = 14.4, 9.3, 4.4 Hz, 1H), 1.55- 1.41 (m, 4H), 0.97 (dd, J = 15.6, 7.7 Hz, 1H) 123 227-232 — ESIMS ¹H NMR (CD₃OD) δ 7.29-7.06 (m, 9H), 4.93- m/z 464 4.82 (m, 1H), 3.86 (dd, J = 10.9, 7.2 Hz, 1H), [M + H]⁺ 2.72-2.42 (m, 4H), 2.31-2.17 (m, 1H), 1.98- 1.65 (m, 3H), 1.63-1.51 (m, 2H), 1.50-1.16 (m, 8H), 0.96-0.81 (m, 1H) ¹⁹F NMR (CD₃OD) δ −55.55 124 215-217 — ESIMS ¹H NMR (CDCl₃) δ 8.69 (bs, 3H), 7.53-7.45 m/z 504.4 (m, 2H), 7.25-7.08 (m, 6H), 4.93-4.81 (m, [M + H]⁺ 1H), 3.98-3.84 (m, 1H), 2.96-2.84 (m, 2H), 2.70 (dd, J = 15.8, 7.4 Hz, 1H), 2.50-2.37 (m, 2H), 2.09-1.97 (m, 1H), 1.80-1.31 (m, 5H), 1.22 (d, J = 6.1 Hz, 3H), 0.83-0.69 (m, 1H) 125 196-198 — ESIMS ¹H NMR (CDCl₃) δ 8.64 (bs, 3H), 7.32-7.12 m/z 436.4 (m, 7H), 7.07-6.99 (m, 2H), 4.92-4.79 (m, [M + H]⁺ 1H), 3.97-3.85 (m, 1H), 2.97-2.81 (m, 2H), 2.66 (dd, J = 15.7, 7.6 Hz, 1H), 2.52-2.31 (m, 2H), 2.08-1.94 (m, 1H), 1.81-1.39 (m, 5H), 1.19 (d, J = 6.5 Hz, 3H), 0.79-0.66 (m, 1H) 126 — — ESIMS ¹H NMR (CDCl₃) δ 8.69 (bs, 3H), 7.31-7.22 m/z 380.4 (m, 4H), 7.22-7.04 (m, 6H), 4.95-4.74 (m, [M + H]⁺ 1H), 3.99-3.80 (m, 1H), 2.75-2.64 (m, 1H), 2.62-2.38 (m, 4H), 1.95-1.22 (m, 10H), 1.18 (d, J = 5.7 Hz, 3H), 0.91-0.78 (m, 1H) 127 — — ESIMS ¹H NMR (CDCl₃) δ 7.36-7.06 (m, 5H), 5.07 (d, m/z 418 J = 8.3 Hz, 1H), 4.78 (dq, J = 12.4, 6.1 Hz, 1H), [M + H]⁺ 4.15 (dt, J = 10.8, 7.7 Hz, 1H), 2.92-2.75 (m, 1H), 2.30 (dd, J = 13.7, 11.3 Hz, 1H), 2.17 (dt, J = 13.3, 6.5 Hz, 1H), 1.83-1.69 (m, 1H), 1.68- 1.12 (m, 10H), 1.43 (s, 9H), 1.34 (d, J = 6.3 Hz, 3H), 1.10-0.97 (m, 1H), 0.93 (t, J = 7.2 Hz, 3H), 0.76-0.67 (m, 1H) ¹³C NMR (CDCl₃) δ 173.10, 154.96, 141.16, 128.70, 128.31, 125.85, 79.62, 75.19, 52.48, 45.31, 42.53, 37.88, 33.75, 29.35, 28.34, 27.81, 27.48, 23.50, 19.71, 18.48, 14.04 128 — — ESIMS ¹H NMR (CDCl₃) δ 7.53 (d, J = 8.0 Hz, 2H), m/z 486 7.24 (d, J = 8.0 Hz, 2H), 5.06 (d, J = 8.3 Hz, 1H), [M + H]⁺ 4.79 (dq, J = 9.9, 6.3 Hz, 1H), 4.16 (dt, J = 10.9, 7.7 Hz, 1H), 2.97-2.76 (m, 1H), 2.39 (dd, J = 13.8, 11.3 Hz, 1H), 2.19 (dt, J = 13.5, 6.8 Hz, 1H), 1.85-1.73 (m, 1H), 1.70-1.14 (m, 10H), 1.43 (s, 9H), 1.35 (d, J = 6.3 Hz, 3H), 1.03 (q, J = 11.8 Hz, 1H), 0.94 (t, J = 7.1 Hz, 3H), 0.81- 0.68 (m, 1H) ¹⁹F NMR (CDCl₃) δ −62.31 129 — — ESIMS ¹H NMR (CDCl₃) δ 7.34-7.14 (m, 5H), 5.10 (d, m/z 454 J = 8.3 Hz, 1H), 4.83 (dq, J = 9.6, 6.4 Hz, 1H), [M + Na]⁺ 4.19-4.08 (m, 1H), 2.74 (dd, J = 15.4, 3.2 Hz, 1H), 2.55 (dd, J = 15.5, 7.7 Hz, 1H), 2.29-2.16 (m, 1H), 1.97-1.87 (m, 1H), 1.80-1.69 (m, 1H), 1.55-1.38 (m, 4H), 1.43 (s, 9H), 1.37- 1.21 (m, 3H), 1.19 (d, J = 6.4 Hz, 3H), 1.17- 1.08 (m, 1H), 1.06-0.96 (m, 1H), 0.91-0.85 (m, 1H), 0.84 (d, 6H) ¹³C NMR (CDCl₃) δ 173.10, 154.94, 140.96, 128.82, 128.39, 125.97, 79.66, 76.05, 52.62, 47.51, 42.18, 37.47, 36.75, 33.78, 29.29, 28.35, 28.23, 23.04, 22.31, 20.79, 18.48 130 — — ESIMS ¹H NMR (CDCl₃) δ 7.37-7.01 (m, 10H), 5.06 m/z 474 (d, J = 8.3 Hz, 1H), 4.89 (dq, J = 9.6, 6.4 Hz, [M + Na]⁺ 1H), 4.15 (dt, J = 11.8, 7.9 Hz, 1H), 3.01-2.87 (m, 2H), 2.70 (dd, J = 15.6, 7.5 Hz, 1H), 2.39 (dd, J = 13.8, 11.6 Hz, 1H), 2.18 (dt, J = 13.5, 6.8 Hz, 1H), 2.08 (tdd, J = 9.9, 7.4, 3.1 Hz, 1H), 1.73 (dtd, J = 14.7, 7.1, 3.3 Hz, 1H), 1.67-1.47 (m, 2H), 1.42 (s, 9H), 1.41-1.33 (m, 1H), 1.26 (d, J = 6.3 Hz, 3H), 1.02 (q, J = 11.9 Hz, 1H), 0.75 (ddd, J = 16.1, 8.9, 2.9 Hz, 1H) ¹³C NMR (CDCl₃) δ 173.01, 154.96, 140.78, 140.54, 128.90, 128.71, 128.57, 128.32, 126.24, 125.94, 79.70, 75.84, 52.55, 46.86, 44.13, 37.84, 37.27, 33.78, 28.37, 27.48, 20.79, 18.66 131 — — ESIMS ¹H NMR (CDCl₃) δ 7.31-7.12 (m, 5H), 5.12 (d, m/z 452 J = 8.2 Hz, 1H), 4.91 (dq, J = 8.8, 6.3 Hz, 1H), [M + Na]⁺ 4.14 (ddd, J = 11.1, 8.3, 6.6 Hz, 1H), 2.83 (dd, J = 14.2, 3.6 Hz, 1H), 2.57 (dd, J = 14.2, 11.2 Hz, 1H), 2.18-1.93 (m, 3H), 1.84-1.47 (m, 10H), 1.43 (s, 9H), 1.38 (d, J = 6.4 Hz, 3H), 1.34-1.25 (m, 2H), 1.12-1.00 (m, 1H), 0.81-0.72 (m, 1H) ¹³C NMR (CDCl₃) δ 173.05, 154.97, 141.05, 128.61, 128.26, 125.87, 79.60, 74.50, 53.00, 48.49, 42.53, 40.09, 39.44, 33.82, 29.42, 28.65, 28.35, 27.77, 25.24, 24.43, 21.44, 19.52 132 — — ESIMS ¹H NMR (CDCl₃) δ 7.26-7.21 (m, 2H), 7.10- m/z 352 7.04 (m, 2H), 5.03 (d, J = 8.4 Hz, 1H), 4.80- [M − Boc]⁺ 4.64 (m, 1H), 4.14 (dt, J = 11.0, 7.7 Hz, 1H), 2.91-2.77 (m, 1H), 2.27 (dd, J = 13.9, 11.3 Hz, 1H), 2.23-2.07 (m, 1H), 1.79-1.64 (m, 1H), 1.58-1.47 (m, 3H), 1.43 (s, 9H), 1.39-1.25 (m, 2H), 1.35 (d, J = 6.4 Hz, 3H), 1.15-0.98 (m, 2H), 0.96 (t, J = 6.6 Hz, 6H), 0.91-0.69 (m, 2H) ¹³C NMR (CDCl₃) δ 173.07, 154.96, 139.52, 131.59, 129.99, 128.43, 79.73, 76.60, 52.46, 45.82, 43.72, 41.51, 36.80, 33.78, 28.34, 27.57, 27.31, 24.07, 21.97, 19.75, 18.42 133 — — ESIMS ¹H NMR (CDCl₃) δ 7.59-7.47 (m, 2H), 7.26- m/z 508 7.17 (m, 2H), 5.03 (d, J = 8.4 Hz, 1H), 4.79- [M + Na]⁺ 4.65 (m, 1H), 4.15 (dt, J = 11.0, 7.8 Hz, 1H), 2.91 (d, J = 13.7 Hz, 1H), 2.37 (dd, J = 13.8, 10.9 Hz, 1H), 2.22-2.14 (m, 1H), 1.81-1.64 (m, 1H), 1.57-1.48 (m, 3H), 1.43 (s, 9H), 1.41- 1.24 (m, 3H), 1.37 (d, J = 6.4 Hz, 3H), 1.17- 1.00 (m, 2H), 0.97 (t, J = 6.6 Hz, 6H), 0.77 (dd, J = 15.6, 7.9 Hz, 1H) ¹⁹F NMR (CDCl₃) δ −62.30 134 — — ESIMS ¹H NMR (CDCl₃) δ 7.53-7.10 (m, 9H), 5.03 (d, m/z 420 J = 8.3 Hz, 1H), 4.90 (dt, J = 12.5, 6.4 Hz, 1H), [M − Boc]⁺ 4.16 (dt, J = 11.1, 7.7 Hz, 1H), 3.00-2.88 (m, 2H), 2.76 (dd, J = 15.6, 7.3 Hz, 1H), 2.52-2.39 (m, 1H), 2.14-2.04 (m, 1H), 1.81-1.70 (m, 1H), 1.66-1.50 (m, 2H), 1.43 (s, 9H), 1.41- 1.23 (m, 2H), 1.30 (d, J = 6.3 Hz, 1H), 1.08- 0.97 (m, 1H), 0.77 (dd, J = 15.3, 7.9 Hz, 1H) ¹⁹F NMR (CDCl₃) δ −62.33 135 — (Neat) ESIMS ¹H NMR (CDCl₃) δ 7.34-7.24 (m, 4H), 7.23- 3382, m/z 488.4 7.10 (m, 6H), 5.05 (d, J = 8.4 Hz, 1H), 4.94- 2938, [M + Na]⁺ 4.84 (m, 1H), 4.23-4.12 (m, 1H), 2.88-2.69 1713, (m, 2H), 2.57-2.46 (m, 1H), 2.32 (dd, J = 13.8, 1496, 11.1 Hz, 1H), 2.25-2.13 (m, 1H), 1.93-1.67 1367, (m, 4H), 1.63-1.42 (m, 3H), 1.46 (d, J = 6.5 Hz, 1170 3H), 1.44 (s, 9H), 1.13-0.97 (m, 1H), 0.83- 0.71 (m, 1H) 136 — (Neat) ESIMS ¹H NMR (CDCl₃) δ 7.35-7.28 (m, 2H), 7.27- 3436, m/z 508.3 7.17 (m, 5H), 7.02-6.96 (m, 2H), 5.04 (d, J = 2936, [M + Na]⁺ 8.3 Hz, 1H), 4.95-4.83 (m, 1H), 4.21-4.08 (m, 1710, 1H), 2.93 (dd, J = 15.6, 3.3 Hz, 1H), 2.90-2.81 1493, (m, 1H), 2.72 (dd, J = 15.6, 7.4 Hz, 1H), 2.36 1367, (dd, J = 13.9, 11.7 Hz, 1H), 2.24-2.13 (m, 1H), 1164 2.12-2.01 (m, 1H), 1.75-1.32 (m, 4H), 1.43 (s, 9H), 1.28 (d, J = 6.4 Hz, 3H), 1.09-0.96 (m, 1H), 0.82-0.70 (m, 1H) 137 — — ESIMS ¹H NMR (CDCl₃) δ 7.31-7.24 (m, 2H), 7.22- m/z 440 7.11 (m, 3H), 5.04 (d, J = 8.4 Hz, 1H), 4.78- [M + Na]⁺ 4.66 (m, 1H), 4.15 (dt, J = 10.9, 7.7 Hz, 1H), 2.88 (d, J = 13.7 Hz, 1H), 2.29 (dd, J = 13.8, 11.0 Hz, 1H), 2.18 (dt, J = 13.5, 6.7 Hz, 1H), 1.79- 1.67 (m, 1H), 1.62-1.47 (m, 4H), 1.43 (s, 9H), 1.40-1.31 (m, 5H), 1.13 (dd, J = 14.6, 9.9 Hz, 1H), 1.02-0.93 (m, 7H), 0.75 (dd, J = 15.4, 7.6 Hz, 1H) ¹³C NMR (CDCl₃) δ 173.07, 154.91, 141.05, 128.63, 128.25, 125.83, 86.59, 79.63, 76.65, 52.45, 45.84, 43.70, 41.48, 37.36, 33.79, 28.30, 27.56, 27.31, 24.07, 21.92, 19.74, 18.41 138 — — ESIMS ¹H NMR (CDCl₃) δ 7.26-7.21 (m, 2H), 7.16- m/z 465 7.06 (m, 2H), 5.07 (d, J = 8.2 Hz, 1H), 4.91 (dq, [M + H]⁺ J = 8.7, 6.3 Hz, 1H), 4.14 (dt, J = 11.1, 7.4 Hz, 1H), 2.89-2.73 (m, 1H), 2.56 (dd, J = 14.2, 11.2 Hz, 1H), 2.17 (s, 3H), 2.16-2.08 (m, 1H), 2.07- 1.98 (m, 1H), 1.99-1.87 (m, 1H), 1.79 (ddt, J = 10.0, 7.1, 3.9 Hz, 1H), 1.73-1.47 (m, 9H), 1.43 (s, 9H), 1.38 (d, J = 6.3 Hz, 3H), 1.35-1.23 (m, 2H), 1.06 (q, J = 11.7 Hz, 1H), 0.78 (dd, J = 14.5, 6.6 Hz, 1H) 139 — (Neat) ESIMS ¹H NMR (CDCl₃) δ 7.32-7.26 (m, 2H), 7.23- 3366, m/z 446.4 7.12 (m, 3H), 5.08 (d, J = 8.3 Hz, 1H), 4.91- 2949, [M + H]⁺ 4.79 (m, 1H), 4.20-4.09 (m, 1H), 2.72-2.60 1713, (m, 1H), 2.51-2.39 (m, 1H), 2.27-2.16 (m, 1497, 1H), 1.83-1.62 (m, 3H), 1.61-1.31 (m, 6H), 1366, 1.44 (s, 9H), 1.41 (d, J = 6.3 Hz, 3H), 1.30-1.00 1166 (m, 4H), 0.91-0.84 (m, 6H), 0.86-0.79 (m, 1H) 140 — (Neat) ESIMS ¹H NMR (CDCl₃) δ 7.32-7.25 (m, 2H), 7.22- 3440, m/z 404.4 7.16 (m, 3H), 5.07 (d, J = 8.2 Hz, 1H), 4.89- 2930, [M + H]⁺ 4.77 (m, 1H), 4.20-4.07 (m, 1H), 2.81-2.71 1711, (m, 1H), 2.54 (dd, J = 15.5, 7.8 Hz, 1H), 2.29- 1497, 2.17 (m, 1H), 1.96-1.84 (m, 1H), 1.81-1.68 1366, (m, 1H), 1.58-1.47 (m, 2H), 1.46-1.28 (m, 1162 5H), 1.43 (s, 9H), 1.18 (d, J = 6.4 Hz, 3H), 1.18- 1.06 (m, 2H), 0.84 (t, J = 7.0 Hz, 3H) 141 — — ESIMS ¹H NMR (CDCl₃) δ 7.27 (m, 4H), 7.17 (m, 4H), m/z 516 7.08 (ad, J = 7.0 Hz, 2H), 5.10 (d, J = 8.0 Hz, [M + Na]⁺ 1H), 4.84 (m, 1H), 4.14 (q, J = 8.0 Hz, 1H), 2.66- 2.50 (m, 3H), 2.46-2.34 (m, 1H), 2.20 (dd, J = 12.5, 6.1 Hz, 1H), 1.83-1.33 (m, 10H), 1.44 (s, 9H), 1.40 (d, J = 6.4 Hz, 3H), 1.26-1.03 (m, 2H), 0.86 (bd, J = 15.4 Hz, 1H) ¹³C NMR (CDCl₃) δ 173.21, 154.99, 142.34, 142.27, 128.48, 128.36, 128.34, 128.20, 125.95, 125.77, 79.72, 75.18, 52.58, 45.67, 40.04, 35.94, 33.75, 32.38, 32.14, 30.92, 29.14, 28.38, 28.02, 19.81, 18.32 142 — — ESIMS ¹H NMR (CDCl₃) δ 7.50 (d, J = 8.0 Hz, 2H), m/z 560 7.24-7.13 (m, 4H), 7.02 (t, J = 8.6 Hz, 2H), [M + Na]⁺ 5.03 (d, J = 8.2 Hz, 1H), 4.89 (dq, J = 12.7, 6.3 Hz, 1H), 4.20-4.10 (m, 1H), 2.91 (ad, J = 15.1 Hz, 2H), 2.72 (dd, J = 15.7, 7.4 Hz, 1H), 2.47 (dd, J = 13.7, 11.9 Hz, 1H), 2.19 (dt, J = 13.4, 6.9 Hz, 1H), 2.10-1.99 (m, 1H), 1.74 (bt, J = 9.8 Hz, 1H), 1.67-1.55 (m, 1H), 1.55-1.29 (m, 2H), 1.43 (s, 9H), 1.28 (d, J = 6.4 Hz, 3H) 1.03 (q, J = 12.2 Hz, 1H), 0.78 (dd, J = 13.4, 5.8 Hz, 1H) ¹³C NMR (CDCl₃) δ 172.93, 161.44 (d, J = 243 Hz), 154.93, 144.75, 135.82 (d, J = 4 Hz), 130.13 (d, J = 8 Hz), 128.9, 128.43 (q, J = 32 Hz), 125.30 (q, J = 3 Hz), 124.23 (q, J = 270 Hz), 115.46 (d, J = 21 Hz), 79.82, 75.46, 52.48, 46.92, 43.75, 37.69, 36.44, 33.64, 28.32, 27.39, 20.73, 18.62 ¹⁹F NMR (CDCl₃) δ −62.34, −116.61 143 — ESIMS ¹H NMR (CDCl₃) δ 5.11 (d, J = 8.0 Hz, 1H), m/z 410 5.00-4.89 (m, 1H), 4.12 (m, 1H), 2.19 (dt, J = [M + H]⁺ 12.7, 5.9 Hz, 1H), 1.95-1.01 (m, 20H), 1.44 (s, 9H), 1.33 (d, J = 6.4 Hz, 3H), 0.87 (dd, J = 6.6, 3.3 Hz, 6H), 0.85-0.69 (m, 1H) ¹³C NMR (CDCl₃) δ 173.12, 154.98, 79.63, 74.67, 53.10, 49.70, 42.51, 38.36, 37.16, 34.02, 31.41, 30.00, 28.43, 28.35, 28.27, 27.82, 25.07, 24.29, 22.94, 22.48, 21.45, 19.05 144 — — ESIMS ¹H NMR (CDCl₃) δ 7.35-7.04 (m, 5H), 5.03 (d, m/z 432 J = 8.4 Hz, 1H), 4.77 (dt, J = 9.6, 6.2 Hz, 1H), [M + H]⁺ 4.15 (dt, J = 11.1, 7.8 Hz, 1H), 2.93-2.72 (m, 1H), 2.31 (dd, J = 13.7, 11.3 Hz, 1H), 2.24-2.14 (m, 1H), 1.77 (td, J = 13.7, 10.9, 3.0 Hz, 1H), 1.70-1.38 (m, 7H), 1.43 (s, 9H), 1.34 (d, J = 6.3 Hz, 3H), 1.28 (ddd, J = 12.0, 7.2, 5.2 Hz, 1H), 1.19-0.97 (m, 2H), 0.92 (d, J = 6.6 Hz, 6H), 0.70 (dd, J = 14.7, 6.9 Hz, 1H) ¹³C NMR (CDCl₃) δ 173.10, 154.97, 141.18, 128.71, 128.32, 125.86, 79.68, 75.10, 52.47, 45.29, 42.31, 37.90, 34.47, 33.78, 28.85, 28.33, 27.49, 27.18, 22.73, 22.45, 19.70, 18.47 145 — — ESIMS ¹H NMR (CDCl₃) δ 7.18-7.09 (m, 2H), 7.04- m/z 422 6.89 (m, 2H), 5.07 (d, J = 8.3 Hz, 1H), 4.90- [M + H]⁺ 4.75 (m, 1H), 4.13 (dt, J = 11.0, 7.5 Hz, 1H), 2.77-2.66 (m, 1H), 2.52 (dd, J = 15.5, 7.8 Hz, 1H), 2.29-2.18 (m, 1H), 1.93-1.78 (m, 2H), 1.80-1.63 (m, 2H), 1.55-1.26 (m, 4H), 1.43 (s, 9H), 1.17 (d, J = 6.4 Hz, 3H), 1.12 (dd, J = 13.5, 7.5 Hz, 2H), 0.88-0.81 (m, 1H), 0.85 (t, J = 7.1 Hz, 3H) ¹⁹F NMR (CDCl₃) δ −117.37 146 — — ESIMS ¹H NMR (CDCl₃) δ 7.35 (at, J = 7.4 Hz, 2H), m/z 460 7.26 (at, J = 7.3 Hz, 1H), 7.23-7.14 (m, 4H), [M + Na]⁺ 7.11 (at, J = 7.2 Hz, 1H), 6.91-6.84 (m, 2H), 5.16 (dd, J = 9.6, 6.4 Hz, 1H), 5.07 (d, J = 8.2 Hz, 1H), 4.31-4.17 (m, 1H), 2.74 (t, J = 9.9 Hz, 1H), 2.51 (d, J = 12.7 Hz, 1H), 2.32-2.17 (m, 2H), 2.17-2.06 (m, 1H), 1.77-1.47 (m, 3H), 1.44 (s, 9H), 1.33-1.23 (m, 1H), 1.11 (q, J = 11.7 Hz, 1H), 0.96 (dd, J = 6.4, 5.0 Hz, 3H) ¹³C NMR (CDCl₃) δ 173.26, 154.98, 142.22, 140.81, 128.76, 128.58, 128.16, 127.00, 125.78, 79.77, 75.25, 55.16, 52.48, 46.73, 37.54, 33.88, 28.35, 27.23, 20.66, 18.11 147 — — ESIMS ¹H NMR (CDCl₃) δ 7.34-7.24 (m, 2H), 7.21 m/z 412 (ddd, J = 7.3, 5.1, 1.2 Hz, 1H), 7.13-7.07 (m, [M + Na]⁺ 2H), 5.18-5.06 (m, 2H), 4.22 (m, 1H), 2.57 (t, J = 9.9 Hz, 1H), 2.28 (dt, J = 13.5, 6.7 Hz, 1H), 1.82 (m, 2H), 1.67-1.49 (m, 2H), 1.45 (s, 9H), 1.38-0.83 (m, 6H), 0.89 (d, J = 6.4 Hz, 3H), 0.67 (t, J = 7.2 Hz, 3H) ¹³C NMR (CDCl₃) δ 173.37, 154.98, 142.62, 128.94, 128.47, 126.65, 79.73, 75.49, 55.51, 52.56, 43.40, 33.89, 33.46, 28.35, 27.96, 20.57, 20.04, 18.04, 13.99 148 — — ESIMS ¹H NMR (CDCl₃) δ 7.31-7.23 (m, 2H), 7.16 (td, m/z 468 J = 6.4, 1.7 Hz, 3H), 5.10 (d, J = 8.3 Hz, 1H), [M + Na]⁺ 4.66 (dq, J = 9.5, 6.4 Hz, 1H), 4.11 (dt, J = 11.2, 7.5 Hz, 1H), 2.68-2.47 (m, 2H), 2.25-2.16 (m, 1H), 1.78-1.63 (m, 2H), 1.65-1.51 (m, 1H), 1.43 (s, 9H), 1.48-1.32 (m, 5H), 1.29 (d, J = 6.4 Hz, 3H), 1.22-1.06 (m, 4H), 0.90-0.78 (m, 8H) ¹³C NMR (CDCl₃) δ 173.19, 154.96, 142.39, 128.38, 128.26, 125.71, 79.62, 76.87, 52.58, 44.13, 43.16, 41.39, 35.93, 33.83, 30.41, 29.24, 28.36, 27.91, 27.40, 24.02, 21.87, 19.78, 18.29 149 — — ESIMS ¹H NMR (CDCl₃) δ 7.31-7.23 (m, 2H), 7.21- m/z 586 7.09 (m, 7H), 5.08 (d, J = 8.3 Hz, 1H), 4.82 (dq, [M + Na]⁺ J = 9.7, 6.4 Hz, 1H), 4.13 (dt, J = 10.9, 7.6 Hz, 1H), 2.67 (dd, J = 15.5, 3.5 Hz, 1H), 2.62-2.44 (m, 3H), 2.29-2.15 (m, 1H), 1.87 (ddq, J = 16.0, 8.3, 4.3, 3.4 Hz, 1H), 1.81-1.65 (m, 2H), 1.43 (s, 15H), 1.25-1.06 (m, 4H), 0.95-0.80 (m, 1H) ¹³C NMR (CDCl₃) δ 173.01, 154.89, 147.46 (q, J = 1.6 Hz), 142.24, 139.51, 129.98, 128.27, 125.77, 120.89, 120.46 (q, J = 256.9 Hz), 79.70, 75.57, 52.55, 47.47, 41.65, 36.65, 35.99, 33.70, 31.15, 29.25, 28.31, 27.84, 20.74, 18.42 ¹⁹F NMR (CDCl₃) δ −57.91 150 — — ESIMS ¹H NMR (CDCl₃) δ 7.28-7.21 (m, 2H), 7.19- m/z 438 7.09 (m, 3H), 5.11 (d, J = 8.2 Hz, 1H), 4.83 (dq, [M + Na]⁺ J = 9.8, 6.5 Hz, 1H), 4.12 (dt, J = 11.0, 7.7 Hz, 1H), 2.67 (dd, J = 15.6, 3.1 Hz, 1H), 2.49 (dd, J = 15.5, 7.7 Hz, 1H), 2.22 (ddd, J = 12.6, 9.9, 5.2 Hz, 1H), 2.00-1.80 (m, 2H), 1.61-1.43 (m, 4H), 1.41 (s, 9H), 1.16 (d, J = 6.4 Hz, 3H), 1.14- 1.08 (m, 1H), 1.05-0.95 (m, 1H), 0.94-0.86 (m, 1H), 0.62 (dtt, J = 9.9, 8.0, 4.9 Hz, 1H), 0.50- 0.37 (m, 1H), 0.31 (tt, J = 8.9, 4.5 Hz, 1H), 0.01 (td, J = 8.9, 8.4, 4.3 Hz, 1H), −0.16 (dq, J = 9.5, 4.9 Hz, 1H) ¹³C NMR (CDCl₃) δ 173.04, 154.94, 140.80, 128.80, 128.38, 125.99, 79.62, 76.00, 52.60, 46.78, 42.58, 37.28, 36.58, 33.88, 28.35, 20.76, 18.84, 9.17, 5.66, 3.72 151 — — ESIMS ¹H NMR (CDCl₃) δ 7.30-7.14 (m, 5H), 7.11- m/z 470 7.05 (m, 2H), 7.05-6.95 (m, 2H), 5.06 (d, J = [M + H]⁺ 8.3 Hz, 1H), 4.87 (dq, J = 9.5, 6.4 Hz, 1H), 4.15 (dt, J = 11.2, 7.8 Hz, 1H), 2.92 (ddd, J = 13.2, 5.9, 3.1 Hz, 2H), 2.68 (dd, J = 15.7, 7.5 Hz, 1H), 2.51-2.33 (m, 1H), 2.23-2.16 (m, 1H), 2.03 (tdd, J = 9.8, 7.5, 3.0 Hz, 1H), 1.79-1.66 (m, 1H), 1.66-1.47 (m, 2H), 1.45-1.36 (m, 1H), 1.42 (s, 9H), 1.25 (d, J = 6.4 Hz, 3H), 1.02 (q, J = 11.8 Hz, 1H), 0.84-0.68 (m, 1H) ¹⁹F NMR (CDCl₃) δ −116.84 152 65-67 (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 7.55-7.47 (m, 2H), 7.29- 3442, (m/z) 7.25 (m, 2H), 7.21-7.13 (m, 4H), 5.02 (d, J = 2939, [M]⁺ 8.4 Hz, 1H), 4.95-4.85 (m, 1H), 4.22-4.11 (m, 1711, calcd for 1H), 2.99-2.86 (m, 2H), 2.75 (dd, J = 15.8, 7.5 1509, C₃₀H₃₅F₆NO₅, Hz, 1H), 2.49 (dd, J = 13.9, 11.6 Hz, 1H), 2.26- 1326, 603.2419; 2.14 (m, 1H), 2.14-2.03 (m, 1H), 1.80-1.69 1259 found, (m, 2H), 1.68-1.56 (m, 1H), 1.56-1.30 (m, 603.2425 2H), 1.43 (s, 9H), 1.27 (d, J = 6.4 Hz, 2H), 1.11- 0.97 (m, 1H), 0.85-0.72 (m, 1H) 153 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 7.30-7.22 (m, 4H), 7.22- 3441, (m/z) 7.14 (m, 3H), 7.10-7.03 (m, 2H), 5.02 (d, J = 2953, [M]⁺ 8.2 Hz, 1H), 4.94-4.83 (m, 1H), 4.21-4.09 (m, 1713, calcd for 1H), 3.01-2.86 (m, 2H), 2.71 (dd, J = 15.8, 7.6 1509, C₂₉H₃₆F₃NO₅, Hz, 1H), 2.42 (dd, J = 13.8, 11.6 Hz, 1H), 2.25- 1367, 535.2546; 2.14 (m, 1H), 2.13-2.01 (m, 1H), 1.78-1.67 1259 found, (m, 1H), 1.66-1.36 (m, 3H), 1.43 (s, 9H), 1.25 535.2542 (d, J = 7.3 Hz, 3H), 1.10-0.97 (m, 1H), 0.83- 0.71 (m, 1H) ¹⁹F NMR (CDCl₃) δ −57.93 154 — (Neat) HRMS-ESI ¹H NMR (CDCl₃) δ 7.31-7.23 (m, 4H), 7.22- 3350, (m/z) 7.10 (m, 6H), 5.06 (d, J = 8.2 Hz, 1H), 4.90- 2932, [M]⁺ 4.76 (m, 1H), 4.19-4.03 (m, 1H), 2.71 (dd, J = 1712, calcd for 15.4, 3.3 Hz, 1H), 2.63-2.42 (m, 3H), 2.30- 1496, C₃₀H₄₁NO₄, 2.12 (m, 1H), 1.97-1.82 (m, 1H), 1.82-1.61 1366, 479.3036; (m, 2H), 1.59-1.25 (m, 6H), 1.43 (s, 9H), 1.20 1169 found, (d, J = 6.4 Hz, 3H), 1.19-1.04 (m, 1H), 0.92- 479.3037 0.79 (m, 1H) *Cmpd. No.—Compound Number *¹H NMR were run at 400 MHz unless noted otherwise. *¹³C NMR were run at 101 MHz unless noted otherwise. *¹⁹F NMR were run at 376 MHz unless noted otherwise.

TABLE 3 Biological Testing Rating Scale Rating Table for Fungal Pathogens % Control Rating  >70 A ≦70 B Not Tested C

TABLE 4 Biological Activity - PUCCRT and SEPTTR Disease Control in High and Low Volume Applications Low Volume activity High Volume activity at 121.5 g/H at 100 ppm Cmpd. PUCCRT SEPTTR PUCCRT SEPTTR No. 1DP* 3DC* 1DP* 3DC* 1DP* 3DC* 1DP* 3DC* 1 A B A A A A A A 2 A B A A A A A A 3 A B A A C C C C 4 A B A A C C C C 5 A A A A C C C C 6 A A A A C C C C 7 A A A A C C C C 8 A B A A C C C C 9 A B A A C C C C 10 A A A A C C C C 12 A B A A C C C C 13 A B A A C C C C 14 A B A A C C C C 15 A B A A C C C C 16 A A A A C C C C 17 A B A A C C C C 18 B B A A C C C C 19 A B A A C C C C 20 A A A B C C C C 21 A B A B C C C C 22 A B A B C C C C 23 A B A B C C C C 24 B B A B C C C C 25 B B B B C C C C 26 A B A B C C C C 27 A B A B C C C C 28 A B A A C C C C 29 A B A A C C C C 30 B B A A C C C C 31 A B A A C C C C 32 A B A B C C C C 33 B B A B C C C C 34 A B A A C C C C 35 A B A A C C C C 36 A B A A C C C C 37 A A A A C C C C 38 A A A A C C C C 39 B B A A C C C C 40 B B A B C C C C 41 B B B B C C C C 42 A B A A C C C C 43 A B A A C C C C 44 A B A A C C C C 45 A B A A C C C C 46 A A A A C C C C 47 A B A A C C C C 48 A A A A C C C C 49 B B A A C C C C 50 A B A A C C C C 51 A B A A C C C C 52 A B A A C C C C 53 A B A A C C C C 54 A A A A C C C C 55 A A A A C C C C 56 A B A B C C C C 57 B B B B C C C C 58 B B B B C C C C 59 A B A B C C C C 60 A A A A C C C C 61 A A A A C C C C 62 A B A A C C C C 63 A B A A C C C C 64 A B A A C C C C 65 B B B B C C C C 66 B B B B C C C C 67 B B B B C C C C 68 B B B B C C C C 69 B B A B C C C C 70 A B A A C C C C 71 C C C C A A A B 72 C C C C A B A B 73 C C C C A B A A 74 C C C C A A A A 75 C C C C A B A A 76 C C C C A B A A 77 C C C C C C C C 78 C C C C A B A A 79 C C C C A B A B 80 C C C C A B A B 81 C C C C A B A B 82 C C C C A A B A 83 C C C C A B A B 84 C C C C A B A A 85 C C C C A B A B 86 C C C C A B B B 87 C C C C A B A B 88 C C C C A B B A 89 C C C C C C C C 90 C C C C A A A A 91 C C C C A B A A 92 C C C C A B A B 93 C C C C B B B B 94 A B A A C C C C 95 A B A A C C C C 96 C C C C B B B B 97 C C C C A B A B 98 C C C C A B A A *Cmpd. No.—Compound Number *PUCCRT—Wheat Brown Rust (Puccinia triticina) *SEPTTR—Wheat Leaf Blotch (Septoria tritici) *1DP—1 Day Protectant *3DC—3 Day Curative *g/H—Grams Per Hectare *ppm—Parts Per Million

TABLE 5 Biological Activity - Disease Control at 100 ppm *Cmpd. ALTESO* CERCBE* COLLLA* ERYSCI* ERYSGH* No. 1DP* 3 A B A A A *Cmpd. No. - Compound Number *ALTESO - Tomato Early Blight (Alternaria solani) *CERCBE - Leaf Spot of Sugar Beets (Cercospora beticola) *COLLLA - Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotricum lagenarium) *ERYSCI - Powdery Mildew of Cucumber (Erysiphe cichoracearum) *ERYSGH - Barley Powdery Mildew (Blumeria graminis f.sp. hordei; Synonym: Erysiphe graminis f.sp. hordei) 1DP - 1 Day Protectant

TABLE 6 Biological Activity - Disease Control at 100 ppm *Cmpd. LEPTNO* RHYNSE* UNCINE* VENTIN* No. 1DP 3 A B A A *Cmpd. No. - Compound Number *LEPTNO - Wheat Glume Blotch (Leptosphaeria nodorum) *RHYNSE - Barley Scald (Rhyncosporium secalis) *UNCINE - Grape Powdery Mildew (Uncinula necator) *VENTIN - Apple Scab (Venturia inaequalis) *1DP - 1 Day Protectant

TABLE 7 Biological Activity - Disease Control at 25 ppm *Cmpd. PHAKPA* No. 1DP* 3DC* 3 B B *Cmpd. No. - Compound Number *PHAKPA - Asian Soybean Rust (Phakopsora pachyrhizi) *1DP - 1 Day Protectant *3DC - 3 Day Curative 

What is claimed is:
 1. A compound of Formula I

wherein X is hydrogen or C(O)R₃; Y is hydrogen, C(O)R₃, or Q; Q is

R₁ and R₂ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, and aryl, each optionally substituted with 0, 1 or multiple R₆; R₃ alkoxy or benzyloxy, each optionally substituted with 0, 1, or multiple R₆; R₄ is hydrogen, —C(O)R₅, or —CH₂OC(O)R₅; R₅ is alkyl, alkoxy, or aryl, each optionally substituted with 0, 1, or multiple R₆; R₆ is hydrogen, alkyl, aryl, halo, acyloxy, alkenyl, alkoxy, heteroaryl, heterocyclyl, or thioalkyl, each optionally substituted with 0, 1, or multiple R₇; and R₇ is hydrogen, alkyl, aryl, or halo.
 2. A compound according to claim 1, wherein X and Y are hydrogen.
 3. A compound according to claim 2, wherein R₁ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 4. A compound according to claim 2, wherein R₂ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 5. A compound according to claim 1, wherein X is C(O)R₃ and Y is hydrogen.
 6. A compound according to claim 5, wherein R₁ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 7. A compound according to claim 5, wherein R₂ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 8. A compound according to claim 1, wherein X is hydrogen and Y is Q.
 9. A compound according to claim 8, wherein R₁ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 10. A compound according to claim 8, wherein R₂ is chosen from alkyl or aryl, each optionally substituted with 0, 1 or multiple R₆.
 11. A compound according to claim 9, wherein R₄ is hydrogen.
 12. A compound according to claim 9, wherein R₄ is —C(O)R₅ or —CH₂OC(O)R₅.
 13. A compound according to claim 12, wherein R₅ is chosen from alkyl or alkoxy, each optionally substituted with 0, 1, or multiple R₆.
 14. A compound according to claim 13, wherein R₅ is chosen from —CH₃, —CH(CH₃)₂, —CH₂OCH₂CH₃, or —CH₂CH₂OCH₃.
 15. A composition for the control of a fungal pathogen including at least one of the compounds of claim 1 and a phytologically acceptable carrier material.
 16. A composition for the control of a fungal pathogen including mixtures of at least one of the compounds of claim 1 with other pesticides including fungicides, insecticides, nematocides, miticides, arthropodicides, bactericides, and combinations thereof.
 17. The composition according to claim 16, further comprising an azole fungicide selected from the group consisting of epoxiconazole, tebuconazole, fluquinconazole, flutriafol, metconazole, myclobutanil, cycproconazole, prothioconazole, and propiconazole.
 18. The composition according to claim 16, further comprising a strobilurin fungicide selected from the group consisting of trifloxystrobin, pyraclostrobin, orysastrobin, fluoxastrobin, and azoxystrobin.
 19. The composition according to claim 16, further comprising a succinate dehydrogenase inhibiting (SDHI) fungicide selected from the group consisting of fluxapyroxad, boscalid, penthiopyrad, benzovindiflupyr, bixafen, flupyram, and isopyrazam.
 20. The compositions according to claim 15 wherein the fungal pathogen is one of Leaf Blotch of Wheat (Mycosphaerella graminicola; anamorph: Septoria tritici), Wheat Brown Rust (Puccinia triticina), Stripe Rust (Puccinia striiformis), Scab of Apple (Venturia inaequalis), Blister Smut of Maize (Ustilago maydis), Powdery Mildew of Grapevine (Uncinula necator), Barley Scald (Rhynchosporium secalis), Blast of Rice (Magnaporthe grisea), Rust of Soybean (Phakopsora pachyrhizi), Glume Blotch of Wheat (Leptosphaeria nodorum), Powdery Mildew of Wheat (Blumeria graminis f. sp. tritici), Powdery Mildew of Barley (Blumeria graminis f. sp. hordei), Powdery Mildew of Cucurbits (Erysiphe cichoracearum), Anthracnose of Cucurbits (Glomerella lagenarium), Leaf Spot of Beet (Cercospora beticola), Early Blight of Tomato (Alternaria solani), and Net Blotch of Barley (Pyrenophora teres).
 21. The composition according to claim 20 wherein the fungal pathogen is one of Leaf Blotch of Wheat (Septoria tritici), Wheat Brown Rust (Puccinia triticina), and Rust of Soybean (Phakopsora pachyrhizi).
 22. A method for the control and prevention of fungal attack on a plant, the method including the step of: Applying a fungicidally effective amount of at least one of the compounds of claim 1 to at least one of the plant, an area adjacent to the plant, soil adapted to support growth of the plant, a root of the plant, and foliage of the plant.
 23. A method for the control and prevention of fungal attack on a plant, the method including the step of: Applying a fungicidally effective amount of at least one of the compositions according to claim 15 to at least one of the plant, an area adjacent to the plant, soil adapted to support growth of the plant, a root of the plant, and foliage of the plant. 